
<html lang="en"     class="pb-page"  data-request-id="0f7b3ec8-46ab-453a-9916-a7000b90e396"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;article:article:10.1021/acs.jmedchem.0c00936;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R" /></meta><meta name="dc.Creator" content="Barbara  Czako" /></meta><meta name="dc.Creator" content="Joseph. R.  Marszalek" /></meta><meta name="dc.Creator" content="Jason P.  Burke" /></meta><meta name="dc.Creator" content="Pijus  Mandal" /></meta><meta name="dc.Creator" content="Paul G.  Leonard" /></meta><meta name="dc.Creator" content="Jason B.  Cross" /></meta><meta name="dc.Creator" content="Faika  Mseeh" /></meta><meta name="dc.Creator" content="Yongying  Jiang" /></meta><meta name="dc.Creator" content="Edward Q.  Chang" /></meta><meta name="dc.Creator" content="Erika  Suzuki" /></meta><meta name="dc.Creator" content="Jeffrey J.  Kovacs" /></meta><meta name="dc.Creator" content="Ningping  Feng" /></meta><meta name="dc.Creator" content="Sonal  Gera" /></meta><meta name="dc.Creator" content="Angela L.  Harris" /></meta><meta name="dc.Creator" content="Zhen  Liu" /></meta><meta name="dc.Creator" content="Robert A.  Mullinax" /></meta><meta name="dc.Creator" content="Jihai  Pang" /></meta><meta name="dc.Creator" content="Connor A.  Parker" /></meta><meta name="dc.Creator" content="Nakia D.  Spencer" /></meta><meta name="dc.Creator" content="Simon S.  Yu" /></meta><meta name="dc.Creator" content="Qi  Wu" /></meta><meta name="dc.Creator" content="Martin R.  Tremblay" /></meta><meta name="dc.Creator" content="Keith  Mikule" /></meta><meta name="dc.Creator" content="Keith  Wilcoxen" /></meta><meta name="dc.Creator" content="Timothy P.  Heffernan" /></meta><meta name="dc.Creator" content="Giulio F.  Draetta" /></meta><meta name="dc.Creator" content="Philip  Jones" /></meta><meta name="dc.Description" content="Tumor-associated macrophages (TAMs) have a significant presence in the tumor stroma across multiple human malignancies and are believed to be beneficial to tumor growth. Targeting CSF1R has been pr..." /></meta><meta name="Description" content="Tumor-associated macrophages (TAMs) have a significant presence in the tumor stroma across multiple human malignancies and are believed to be beneficial to tumor growth. Targeting CSF1R has been pr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 29, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00936" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00936" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00936" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00936" /></link>
        
    
    

<title>Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00936" /></meta><meta property="og:title" content="Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0023.jpeg" /></meta><meta property="og:description" content="Tumor-associated macrophages (TAMs) have a significant presence in the tumor stroma across multiple human malignancies and are believed to be beneficial to tumor growth. Targeting CSF1R has been proposed as a potential therapy to reduce TAMs, especially the protumor, immune-suppressive M2 TAMs. Additionally, the high expression of CSF1R on tumor cells has been associated with poor survival in certain cancers, suggesting tumor dependency and therefore a potential therapeutic target. The CSF1–CSF1R signaling pathway modulates the production, differentiation, and function of TAMs; however, the discovery of selective CSF1R inhibitors devoid of type III kinase activity has proven to be challenging. We discovered a potent, highly selective, and orally bioavailable CSF1R inhibitor, IACS-9439 (1). Treatment with 1 led to a dose-dependent reduction in macrophages, promoted macrophage polarization toward the M1 phenotype, and led to tumor growth inhibition in MC38 and PANC02 syngeneic tumor models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00936"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00936">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00936&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00936&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00936&amp;href=/doi/10.1021/acs.jmedchem.0c00936" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 9888-9911</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01039" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01017" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Barbara Czako</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Czako</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1b7978617a70745b565f5a757f7e696874753574697c"><span class="__cf_email__" data-cfemail="4c2e2f362d27230c01080d2228293e3f232262233e2b">[email protected]</span></a>. Tel: (001)-713-745-2050.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Czako">Barbara Czako</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3357-7514" title="Orcid link">http://orcid.org/0000-0002-3357-7514</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph. R. Marszalek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph. R. Marszalek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph.+R.++Marszalek">Joseph. R. Marszalek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason P. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason P. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+P.++Burke">Jason P. Burke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pijus Mandal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pijus Mandal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pijus++Mandal">Pijus Mandal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul G. Leonard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul G. Leonard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Leonard">Paul G. Leonard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason B. Cross</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason B. Cross</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+B.++Cross">Jason B. Cross</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Faika Mseeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Faika Mseeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Faika++Mseeh">Faika Mseeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongying Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongying Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongying++Jiang">Yongying Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward Q. Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward Q. Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward+Q.++Chang">Edward Q. Chang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erika Suzuki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erika Suzuki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erika++Suzuki">Erika Suzuki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey J. Kovacs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey J. Kovacs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+J.++Kovacs">Jeffrey J. Kovacs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ningping Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ningping Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ningping++Feng">Ningping Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sonal Gera</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sonal Gera</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sonal++Gera">Sonal Gera</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela L. Harris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela L. Harris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela+L.++Harris">Angela L. Harris</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Liu">Zhen Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert A. Mullinax</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert A. Mullinax</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Mullinax">Robert A. Mullinax</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jihai Pang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jihai Pang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jihai++Pang">Jihai Pang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Connor A. Parker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Connor A. Parker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Connor+A.++Parker">Connor A. Parker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nakia D. Spencer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nakia D. Spencer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nakia+D.++Spencer">Nakia D. Spencer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon S. Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon S. Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+S.++Yu">Simon S. Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qi Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qi Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Wu">Qi Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin R. Tremblay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin R. Tremblay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+R.++Tremblay">Martin R. Tremblay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Mikule</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Mikule</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Mikule">Keith Mikule</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Wilcoxen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Wilcoxen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Wilcoxen">Keith Wilcoxen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy P. Heffernan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy P. Heffernan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in Oncology), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffernan">Timothy P. Heffernan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giulio F. Draetta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giulio F. Draetta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giulio+F.++Draetta">Giulio F. Draetta</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Philip Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute of Applied Cancer Science), University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Jones">Philip Jones</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00936&amp;href=/doi/10.1021%2Facs.jmedchem.0c00936" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 9888–9911</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 29, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 June 2020</li><li><span class="item_label"><b>Published</b> online</span>29 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00936" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00936</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9888%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBarbara%2BCzako%252C%2BJoseph.%2BR.%2BMarszalek%252C%2BJason%2BP.%2BBurke%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.0c00936%26title%3DDiscovery%2Bof%2BIACS-9439%252C%2Ba%2BPotent%252C%2BExquisitely%2BSelective%252C%2Band%2BOrally%2BBioavailable%2BInhibitor%2Bof%2BCSF1R%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9911%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00936"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2029</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00936" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Czako&quot;},{&quot;first_name&quot;:&quot;Joseph.&quot;,&quot;last_name&quot;:&quot;R. Marszalek&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;P. Burke&quot;},{&quot;first_name&quot;:&quot;Pijus&quot;,&quot;last_name&quot;:&quot;Mandal&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Leonard&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;B. Cross&quot;},{&quot;first_name&quot;:&quot;Faika&quot;,&quot;last_name&quot;:&quot;Mseeh&quot;},{&quot;first_name&quot;:&quot;Yongying&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Q. Chang&quot;},{&quot;first_name&quot;:&quot;Erika&quot;,&quot;last_name&quot;:&quot;Suzuki&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;J. Kovacs&quot;},{&quot;first_name&quot;:&quot;Ningping&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Sonal&quot;,&quot;last_name&quot;:&quot;Gera&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;L. Harris&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Mullinax&quot;},{&quot;first_name&quot;:&quot;Jihai&quot;,&quot;last_name&quot;:&quot;Pang&quot;},{&quot;first_name&quot;:&quot;Connor&quot;,&quot;last_name&quot;:&quot;A. Parker&quot;},{&quot;first_name&quot;:&quot;Nakia&quot;,&quot;last_name&quot;:&quot;D. Spencer&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;S. Yu&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;R. Tremblay&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Mikule&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Wilcoxen&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffernan&quot;},{&quot;first_name&quot;:&quot;Giulio&quot;,&quot;last_name&quot;:&quot;F. Draetta&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Jones&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;9888-9911&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00936&quot;},&quot;abstract&quot;:&quot;Tumor-associated macrophages (TAMs) have a significant presence in the tumor stroma across multiple human malignancies and are believed to be beneficial to tumor growth. Targeting CSF1R has been proposed as a potential therapy to reduce TAMs, especially the protumor, immune-suppressive M2 TAMs. Additionally, the high expression of CSF1R on tumor cells has been associated with poor survival in certain cancers, suggesting tumor dependency and therefore a potential therapeutic target. The CSF1–CSF1R signaling pathway modulates the production, differentiation, and function of TAMs; however, the discovery of selective CSF1R inhibitors devoid of type III kinase activity has proven to be challenging. We discovered a potent, highly selective, and orally bioavailable CSF1R inhibitor, IACS-9439 (1). Treatment with 1 led to a dose-dependent reduction in macrophages, promoted macrophage polarization toward the M1 phenotype, and led to tumor growth inhibition in MC38 and PANC02 syngeneic tumor models.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00936&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00936" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00936&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00936" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00936&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00936" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00936&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00936&amp;href=/doi/10.1021/acs.jmedchem.0c00936" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00936" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00936" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00936%26sid%3Dliteratum%253Aachs%26pmid%3D32787110%26genre%3Darticle%26aulast%3DCzako%26date%3D2020%26atitle%3DDiscovery%2Bof%2BIACS-9439%252C%2Ba%2BPotent%252C%2BExquisitely%2BSelective%252C%2Band%2BOrally%2BBioavailable%2BInhibitor%2Bof%2BCSF1R%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D9888%26epage%3D9911%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tumor-associated macrophages (TAMs) have a significant presence in the tumor stroma across multiple human malignancies and are believed to be beneficial to tumor growth. Targeting CSF1R has been proposed as a potential therapy to reduce TAMs, especially the protumor, immune-suppressive M2 TAMs. Additionally, the high expression of CSF1R on tumor cells has been associated with poor survival in certain cancers, suggesting tumor dependency and therefore a potential therapeutic target. The CSF1–CSF1R signaling pathway modulates the production, differentiation, and function of TAMs; however, the discovery of selective CSF1R inhibitors devoid of type III kinase activity has proven to be challenging. We discovered a potent, highly selective, and orally bioavailable CSF1R inhibitor, IACS-9439 (<b>1</b>). Treatment with <b>1</b> led to a dose-dependent reduction in macrophages, promoted macrophage polarization toward the M1 phenotype, and led to tumor growth inhibition in MC38 and PANC02 syngeneic tumor models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Strategies to enhance antitumor immunity by reactivating the adaptive and innate immune compartments through checkpoint inhibitors against programmed cell death 1 (PD-1), PD-1 ligand (PDL1), and cytotoxic T lymphocyte antigen 4 (CTLA4), have shown favorable clinical responses, yet, only a fraction of patients show durable responses. While tumor-intrinsic resistance mechanisms may exist, clinical and preclinical evidence highlights the abundance of tumor-associated macrophages (TAMs) as critical regulatory immune cells that promote tumor progression. Macrophages exist primarily in two main polarization states with the alternatively activated M2 TAM responsible for promoting tumor progression by secreting anti-inflammatory cytokines, such as IL-10 and TGFβ, whereas the classically activated M1 promotes immune-mediated tumor killing through the production of proinflammatory cytokines, such as IL-1β, IL-6, and tumor necrosis factor α (TNF-α).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> To overcome the immunosuppressive and protumoral functions of TAMs, therapeutic strategies have focused on TAM depletion in the tumor microenvironment as well as TAM reprogramming to favor antitumoral functions (polarization from M2 to M1).<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">Colony-stimulating factor 1 receptor (also known as CSF1R or macrophage colony-stimulating factor receptor, M-CSFR) is a membrane-associated tyrosine kinase. It acts as the receptor for colony-stimulating factor 1 (CSF1), a cytokine that controls the production, differentiation, and function of macrophages. Ligand binding activates CSF1R through a process of oligomerization within the membrane, transphosphorylation of the intracellular domain, and subsequent signaling.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">In several preclinical studies using murine breast cancer and glioblastoma models, it was demonstrated that CSF1–CSF1R signaling blockade slowed primary tumor growth, reduced metastatic potential, and improved the long-term survival of tumor-bearing mice.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Treatment with BLZ945, a potent CSF1R inhibitor, attenuated tumor growth, correlated with decreased TAM presence, and enriched CD8+ T-cells in tumor stroma in a murine K14-HPV-16 transgenic mouse model of cervical carcinogenesis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These findings have been translated into a first-in-human phase I/II study of BLZ945 alone or in combination with PDR001, a monoclonal antibody against PD-1 in advanced solid tumors (NCT02829723).<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Pexidartinib (PLX3397), an unselective CSF1R inhibitor that also inhibits cKIT, FLT3, PDGFRα, and PDGFRβ with low nanomolar activity, recently received FDA approval.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Pexidartinib demonstrated reduction of TAMs, efficient target engagement, and clinical efficacy as a monotherapy, with a 38% overall response rate in pigmented villonodular synovitis (PVNS), an orphan disease characterized by the overexpression of CSF1R.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">(12−16)</a> Additionally, emactuzumab (RG7155), a neutralizing antibody against CSF1R, not only reduced macrophage infiltration in mouse models but also demonstrated similar therapeutic effects against diffuse-type giant cell tumors in patients.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Two other neutralizing antibodies against CSF1R, AMG 820 (NCT01444404), and IMC-CS4 (NCT01346358) are also currently in phase I clinical trials for the treatment of advanced solid tumors.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> While there are several clinical opportunities for single-agent activity by suppressing CSF1R biology in dependent tumor cells, full clinical benefit is likely to come from combining CSF1R inhibition in macrophages with immune-modulating agents targeting T-cell biology, such as anti-CTLA4, anti-PD-1, and anti-PDL1 therapeutics. These combinations have the potential to promote tumor suppression through modulation of multiple arms of the immune system. These combinations currently are being explored in numerous clinical trials (i.e., NCT02777710, NCT04301778, and NCT03927105).<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a></div><div class="NLM_p">Several small-molecule CSF1R inhibitors have been described in the literature; however, only a few were reported to possess high levels of selectivity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31">(7−16,23−31)</a> BLZ945 was shown to inhibit CSF1R enzymatic activity with an IC<sub>50</sub> = 1 nM and was reported to have a >3200-fold selectivity for CSF1R over other related kinases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> GW2580 inhibited CSF1R enzymatic activity with an IC<sub>50</sub> = 30 nM, showing 22-fold and 75-fold selectivities toward TrkB and C, respectively, and over 150-fold selectivity against other kinases.<a onclick="showRef(event, 'ref29 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref32">(29,32)</a> GW2580 displayed an unfavorable <i>in vivo</i> PK profile with low exposures and rapid clearance and has not been further developed.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> A structurally related, highly selective inhibitor with an azetidine scaffold, JTE-952, was also reported in the literature. In a panel consisting of 51 kinases, JTE-952 was reported to have a 20-fold selectivity for CSF1R over TrkA; however, selectivity for TrkB and TrkC was not reported.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Analysis of the crystal structure of PLX3397 bound to CSF1R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H">4R7H</a>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and protein–ligand binding models of other CSF1R inhibitors (using PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO">3LCO</a>) suggested that these inhibitors bind in the ATP binding pocket in the inactive, DFG-out conformation of the kinase.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative examples of small-molecule CSF1R inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The objective of our program was to discover a highly selective small-molecule CSF1R inhibitor with excellent physicochemical and pharmacokinetic properties that potentially could be used in combination with other immuno-oncology therapies. Herein, we describe our efforts to identify a potent, orally bioavailable tool compound that we transformed into a highly selective and efficacious lead candidate.</div><div class="NLM_p">At the outset of our program, we performed a scaffold-hopping exercise using benzothiazole as a template, with the search directed toward finding novel combinations of hinge binding and linker groups (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A); BREED,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> as implemented in MOE,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was used for this purpose. A set of 1945 prealigned kinase–ligand complexes from the PDB were compared with those of the benzothiazole in a molecular model of BLZ945 bound to CSF1R, resulting in novel compounds that maintained both the position of the benzothiazole core and the interactions with the kinase hinge region. Examination of these results suggested that the kinase hinge residue, Cys666, could be engaged efficiently using two-atom linkers placed between the benzothiazole core and suitable hinge-binding moieties (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Schematic showing the scaffold-hopping template and kinase hinge target interactions. (B) Molecular model of 4-pyridyl hinge-binding motif with the −C–O– linker engaging the backbone NH of Cys666 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO">3LCO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test this hypothesis, a focused structure–activity relationship (SAR) study utilizing a variety of two-atom linkers was performed. This study revealed that the −C–O– linker was preferred when combined with a 4-pyridyl hinge-binding motif resulting in compound <b>3</b>, which exhibited an IC<sub>50</sub> of 303 nM in a CSF1R fluorescence resonance energy transfer (FRET)-based displacement binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). There was less preference among the two-atom linkers when combined with the 3-pyridyl hinge-binding moiety; none of these compounds matched the enzymatic activity of compound <b>3</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzymatic Activity of Compounds Containing a Two-Atom Linker between the Hinge-Binding Pyridine and the Benzothiazole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0015.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">In an effort to improve potency, an amine substituent was incorporated onto the pyridine of compound <b>3</b>, which was predicted to form a second hinge interaction with the backbone carbonyl of Cys666. Indeed, this modification led to a 6-fold improvement in enzymatic potency as demonstrated by compound <b>8</b>. Incorporating a chloro group at the 3-position of the pyridine led to similar improvement in potency as shown by compound <b>9</b>. Combining these two substituents had an additive effect with a 75-fold improvement in potency relative to compound <b>3</b>, with compound <b>10</b> exhibiting an IC<sub>50</sub> of 4 nM in the CSF1R FRET-based displacement binding assay. Compound <b>10</b> also inhibited the mCSF1-mediated proliferation of MNFS-60 myelogenous leukemia cells with an IC<sub>50</sub> of 228 nM, while it did not show significant activity against mCSF1-independent NS0 cell proliferation (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Studies in the Hinge Region and Deep Pocket Area of the 6-(Pyridin-4-ylmethoxy)benzo[<i>d</i>]thiazole Scaffold Lead to Significant Improvement in Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0017.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">Our molecular models predicted that the cyclohexyl ring extended into the deep pocket of the DFG-out conformation of CSF1R, a region that provided additional opportunities to improve potency and selectivity, given the modest differences in sequence among type III kinases in this area (i.e., Met637 is a Leu in cKIT, G795 is a Cys in other type III kinases). To engage the side chain of Glu633 in the deep pocket region, a hydroxyl substituent was incorporated on the cyclohexyl ring. To maximize the probability of engaging this interaction, we examined all four stereoisomers of the 2-aminocyclohexan-1-ol group. However, incorporating the hydroxyl group did not make a significant contribution to enzymatic or cellular potency.</div><div class="NLM_p">To evaluate whether incorporation of the hydroxyl group on the cyclohexane ring offered any selectivity advantage, and whether the orientation of the hydroxyl group affected selectivity, we evaluated these inhibitors in a binding assay against a representative set of type III kinases that are related to CSF1R including FLT3, cKIT, PDGFRα, and PDGFRβ. Overall, compound <b>12</b> exhibited a favorable selectivity profile. The cellular activity of compound <b>12</b> was measured by monitoring the inhibition of CSF1R autophosphorylation after CSF1 stimulation of THP-1 cells, a human monocytic cell line. To assess the compound’s selectivity against PDGFRβ, we measured agonist (PDGF-DD)-induced PDGFRβ autophosphorylation in a HEK293 cell line expressing human recombinant PDGFRβ (HEK293/PDGFRβ cells). BLZ945 was also tested in this assay as a competitor with reported selectivity against PDGFRβ. Our results confirmed that both BLZ945 and <b>12</b> exhibited minimal selectivity against PDGFRβ in a cellular setting, with <b>12</b> inhibiting CSF1-stimulated CSF1R autophosphorylation in THP-1 cells with an IC<sub>50</sub> of 183 nM, while inhibiting PDGFRβ autophosphorylation in HEK293/PDGFRβ cells with an IC<sub>50</sub> of 446 nM. BLZ945 displayed an IC<sub>50</sub> of 155 nM in the cellular phospho-CSF1R (THP) assay and IC<sub>50</sub> of 579 nM in the phospho-PDGFRβ (HEK293/PDGFRβ) assay.</div><div class="NLM_p">To assess broad kinase selectivity, compound <b>12</b> was evaluated against a panel of 468 kinases (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). It exhibited an acceptable selectivity profile, with significant activity against only a handful of related type III kinases at 1 μM, including cKIT, FLT3, PDGFRα, and PDGFRβ (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity profile of compound <b>12</b> against a panel of 468 kinases at a 1 μM test concentration. The larger the red circle, the greater the inhibition. Six kinases with the percent of control <10: CSF1R, cKIT, FLT3, AURB, PDGFRα, and PDGFRβ. See also <a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S1</a>, Supporting information.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>12</b> displayed low-to-moderate microsomal and hepatic clearances in <i>in vitro</i> microsomal and hepatocyte preparations and high plasma protein binding. It exhibited a suitable <i>in vivo</i> PK profile across species, with low clearance, reasonable half-life, and good oral bioavailability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Microsomal and Hepatic Stabilities, Plasma Protein Binding, and <i>In Vivo</i> PK Profile of Compound <b>12</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="/" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="."><i>in vitro</i> ADME properties of compound <b>12</b></th><th class="rowsep1 colsep0" colspan="5" align="center" char="/"><i>in vivo</i> pharmacokinetic data of compound <b>12</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">plasma protein binding (% bound)</th><th class="colsep0 rowsep0" align="center" char=".">hepatocytes CL<sub>int,scaled</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">microsomes CL<sub>int,scaled</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="/">dose IV/PO (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg) (IV)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h) (IV)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char="/">0.3/10</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">>90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char="/">0.3/3</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">155</td><td class="colsep0 rowsep0" align="char" char=".">293</td><td class="colsep0 rowsep0" align="char" char="/">0.3/3</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char="/">0.3/1</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char="/"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">Given its <i>in vitro</i> and <i>in vivo</i> profiles, compound <b>12</b> was used to probe the CSF1R biology, with BLZ945 being compared in these experiments. An immunohistochemistry (IHC) assay was used to measure the well-established macrophage marker F4/80 in PANC02 tumors from mice that had been treated with daily oral doses of 200 mg/kg compound <b>12</b> or BLZ945 for 7 days (<i>n</i> = 4 mice/group). Treatment with each compound resulted in a similar extent of reduction of F4/80 positive cells within the tumors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A–D), consistent with macrophage depletion. As an orthogonal measure of compound activity, CSF1R protein levels were measured by enzyme-linked immunosorbent assay (ELISA) in tumors from mice similarly treated and were found to be depleted to a similar extent by both compounds (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E) (<i>n</i> = 4 mice/group). Furthermore, as an additional measure of antimacrophage activity, mRNA transcripts of well-known macrophage-expressed genes were measured, and similar to the IHC and ELISA results, 200 mg/kg of compound <b>12</b> or BLZ945 (<i>n</i> = 3 mice/group) reduced the expression of the panel by 62–93% (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>F). Similar depletion of macrophages was observed for MC38 and EMT6 tumors treated with compound <b>12</b> or BLZ945 (data not shown). Taken together, the treatment of PANC02 tumors with compound <b>12</b> reduced tumor macrophages to a similar extent as that of BLZ945.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CSF1R inhibitors deplete tumor macrophages and reduce tumor growth. IHC for F4/80 for PANC02 tumors in mice that were treated daily for 7 days with (A) vehicle, (B) 200 mg/kg BLZ945, or (C) 200 mg/kg compound <b>12</b> (<i>n</i> = 4 mice/group). (D) Pathologist-scored quantification of the F4/80 IHC signal in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> (<i>n</i> = 4 mice/group). (E) Relative CSF1R protein expression in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> as measured using ELISA (<i>n</i> = 4 mice/group). (F) Relative mRNA expression of known macrophage genes in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> (<i>n</i> = 3 mice/group) as measured using a nanostring code set. (G) Growth of MC38 tumors implanted subcutaneously in mice and treated daily with vehicle or 200 mg/kg compound <b>12</b> (<i>n</i> = 10 mice/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Treatment of mice-bearing MC38 allograft tumors with 200 mg/kg compound <b>12</b> (<i>n</i> = 10 mice/group) resulted in a 62% reduction in tumor growth (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>G), consistent with the notion that the inhibition of CSF1R has therapeutic potential, possibly through macrophage depletion.</div><div class="NLM_p">While the antitumor impact of compound <b>12</b> was encouraging, we were not satisfied with the overall potency, physicochemical properties, and the level of selectivity that this inhibitor exhibited toward related type III RTKs, especially toward PDGFRβ. Therefore, we continued our quest to identify inhibitors with significantly improved potency, properties, and selectivity. To improve the selectivity profile of the benzothiazole scaffold, we used a combination of X-ray structures from the PDB and the patent literature. Sequence and structural comparison of the CSF1R active site with cKIT, FLT3, PDGFRα, and PDGFRβ<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> revealed that CSF1R is unique among these kinases; the CSF1R Gly795 residue aligns with a cysteine in the other related kinases (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). Substitution at the 4-position of the benzothiazole core would fill the space adjacent to Gly795 in CSF1R, while this substitution pattern would not be tolerated in cKIT, FLT3, PDGFRα, or PDGFβ as it would lead to a steric clash with the cysteine residue (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Furthermore, overlaying models of compound <b>12</b> and GW2580 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D), an inhibitor that showed high selectivity toward CSF1R over other related kinases, but not TrkA, led to the same conclusion.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Model of compound <b>12</b> bound to CSF1R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO">3LCO</a>). (B) Sequence alignment of class III receptor tyrosine kinases highlighting a key difference in the xDFG motif. (C) Overlay of cKIT Cys809 (orange; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HVS">4HVS</a>) with the model of compound <b>12</b> bound to CSF1R shows a small pocket that is present in CSF1R that is filled by a cysteine side chain in other class III RTKs. (D) Overlay of GW2580 (pink) with the model of compound <b>12</b> shows a methoxy group filling this pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test this hypothesis, we synthesized the 4-methoxy-substituted derivative of <b>12</b>, compound <b>15</b>. Indeed, this modification maintained a high affinity toward CSF1R in binding and cellular activity assays and led to a dramatic improvement in selectivity against related kinases cKIT, FLT3, PDGFRα, and PDGFRβ. The same high level of selectivity was observed in the cellular phospho-PDGFRβ target engagement assay (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Study of Substituted Benzothiazole Analogues Leads to Dramatic Improvement of Selectivity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0018.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound #</th><th class="colsep0 rowsep0" align="center">15</th><th class="colsep0 rowsep0" align="center">16</th><th class="colsep0 rowsep0" align="center">17</th><th class="colsep0 rowsep0" align="center">18</th><th class="colsep0 rowsep0" align="center">19</th><th class="colsep0 rowsep0" align="center">20</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">X</td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">–Cl</td><td class="colsep0 rowsep0" align="left">–F</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">–OMe</td><td class="colsep0 rowsep0" align="left">–OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">–Cl</td><td class="colsep0 rowsep0" align="left">–F</td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">–H</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF1R IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF1R Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3 Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">30 000 (>1875)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">590 (72)</td><td class="colsep0 rowsep0" align="left">1300 (520)</td><td class="colsep0 rowsep0" align="left">5.4 (1.58)</td><td class="colsep0 rowsep0" align="left">23 (17)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">30 000 (>1875)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>30 000 (>3703)</td><td class="colsep0 rowsep0" align="left">2100 (840)</td><td class="colsep0 rowsep0" align="left">530 (98)</td><td class="colsep0 rowsep0" align="left">790 (607)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">30 000 (>1875)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>30 000 (>3703)</td><td class="colsep0 rowsep0" align="left">370 (148)</td><td class="colsep0 rowsep0" align="left">12 (3.5)</td><td class="colsep0 rowsep0" align="left">32 (24)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">30 000 (>1875)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>30 000 (>3703)</td><td class="colsep0 rowsep0" align="left">230 (92)</td><td class="colsep0 rowsep0" align="left">4.1 (1.2)</td><td class="colsep0 rowsep0" align="left">6.7 (5.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNSF-60 IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">345</td><td class="colsep0 rowsep0" align="left">930</td><td class="colsep0 rowsep0" align="left">288</td><td class="colsep0 rowsep0" align="left">125</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">194</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phospho-CSF1R (THP-1) IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">243</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">191</td><td class="colsep0 rowsep0" align="left">127</td><td class="colsep0 rowsep0" align="left">176</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phospho-PDGFRβ (HEK293) IC<sub>50</sub> (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">>50 000 (>200)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">4114 (20)</td><td class="colsep0 rowsep0" align="left">1339 (10)</td><td class="colsep0 rowsep0" align="left">250 (1.4)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">4.32</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (% bound), (r/h)</td><td class="colsep0 rowsep0" align="left">>99/98.7</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>99/>99</td><td class="colsep0 rowsep0" align="left">>99/98.6</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>Lint,scaled</sub> (mL/min/kg) (r/h)</td><td class="colsep0 rowsep0" align="left">99/38</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">78/32</td><td class="colsep0 rowsep0" align="left">91/19</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div></div><div class="NLM_p">To understand whether introducing other substituents into the 4-position would lead to the same level of selectivity increase, we performed a focused SAR study. We found that the introduction of a trifluoromethoxy substituent into the 4-position (<b>16</b>) leads to decreased cellular potency. Incorporation of a fluoro- (<b>17</b>) or chloro (<b>18</b>) substituent was tolerated for potency; however, only a lower level of selectivity was achieved compared to that of the methoxy-substituted analogue <b>15</b>. Further structural analysis revealed that a hydrophobic pocket formed by the side chains of Thr663 and Met637 could potentially accommodate a substituent in the 7-position of the benzothiazole core and that filling this pocket could lead to a potency improvement. To test this hypothesis, the 7-chloro- (<b>19</b>) and 7-fluoro benzothiazole (<b>20</b>) analogues were prepared. These inhibitors revealed that while a substituent in the 7-position was indeed tolerated for potency, this modification was detrimental to selectivity.</div><div class="NLM_p">Introducing a substituent into the 4-position led to the desired selectivity improvement; however, these inhibitors possessed suboptimal <i>in vitro</i> DMPK properties, particularly unfavorable metabolic turnover in rat and human microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_p">Analyzing the correlation between liver microsomal intrinsic clearance and cLogP for nearly 100 analogues that were synthesized in the 6-methoxy benzothiazole series revealed that inhibitors with a cLogP > 3.5 tended to have high clearance in human liver microsomes (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Figure S1</a>). Based on this observation, we targeted the design and synthesis of inhibitors with a cLogP of less than 3.5 to improve metabolic stability while retaining favorable enzymatic and cellular potencies.</div><div class="NLM_p">To increase polarity and modulate physicochemical properties, we devised SAR studies in the hinge and deep pocket areas. Decreasing the cLogP by structural modifications in the hinge region quickly led to improved microsomal stability, while selectivity was preserved as demonstrated by compound <b>21</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Reversing the stereochemistry of the amino- and hydroxyl- substituents on the cyclohexyl ring led to improved potency while maintaining selectivity and favorable <i>in vitro</i> DMPK properties, as shown by compound <b>22</b>. Introduction of a 7-chloro substituent onto the benzothiazole core led to further improvement in potency, as exemplified by compound <b>23</b>, without a significant deleterious effect on selectivity or physicochemical properties.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Property Optimization of Benzothiazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0019.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">Since compounds <b>22</b> and <b>23</b> exhibited acceptable enzymatic and cellular potencies as well as a promising <i>in vitro</i> ADME profile, we decided to evaluate these inhibitors <i>in vivo</i>. Both inhibitors had a suitable <i>in vivo</i> PK profile across species with low-to-moderate clearance, reasonable half-life, and excellent oral bioavailability in rat and mouse and with moderate oral bioavailability in a dog (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S2</a>).</div><div class="NLM_p">These compounds exhibited excellent overall properties; however, we were not satisfied with the cellular potency of these inhibitors. SAR studies performed earlier on aminopyridine derivative <b>24</b> revealed that the introduction of an acetamide onto the aminopyridine moiety of <b>24</b> resulted in a significant boost in potency (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Potency Improvement by Introducing an Acetamide onto Compound <b>24</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0020.gif" alt="" id="fx7" /></img><div></div></div><div class="NLM_p">Although compound <b>25</b> possessed excellent potency, it suffered from significant non-NADPH-dependant microsomal metabolism; incubation with human and mouse liver microsomes for 45 min led to 80 and 54% parents remaining, respectively, even in the absence of NADPH (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S4</a>). Metabolite identification studies in human and mouse liver microsomes confirmed that the major metabolite is the hydrolysis product of the amide of compound <b>25</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S5</a>).</div><div class="NLM_p">Based on this information, we hypothesized that we would be able to further boost the potency, while maintaining optimal properties, if we introduced a substituent onto the amino pyrimidine moiety of inhibitor <b>22</b>. However, instead of introducing a hydrolytically unstable amide, we decided to incorporate a urea, as well as a series of heterocyclic groups including pyrazole, triazole, and pyridine. Assessing the enzymatic and cellular potencies as well as microsomal stability of these inhibitors clearly indicated that the methylpyrazole analogue IACS-9439 (<b>1</b>) stands out. IACS-9439 (<b>1</b>) displayed the predicted potency boost, with single-digit nanomolar potency in the MNSF-60 cell phenotypical assay and possessed reasonable metabolic stability when incubated with human and rat microsomal preparations. To test whether we could further improve the potency, we also prepared the 7-chloro analogue of IACS-9439. While this analogue displayed excellent potency, it had a high metabolic turnover in rat and human microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR Studies to Improve Potency of Selective Benzothiazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0021.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0022.gif" alt="" id="fx9" /></img><div></div></div><div class="NLM_p">Based on the excellent potency and selectivity profile, we decided to further evaluate IACS-9439 (<b>1</b>). To assess the selectivity, the inhibitor was tested against a panel of kinases (ScanEdge, 97-member kinase panel, DiscoverX) at 1 μM (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Profiling revealed that IACS-9439 exhibits a high level of selectivity for CSF1R with no significant inhibition of other kinases; the outcome was also in agreement with the results of binding affinity determination that confirmed the high selectivity of IACS-9439 for CSF1R vs FLT3 (9500-fold), cKIT (>17 000-fold), PDGFRα (1900-fold), and PDGFRβ (450-fold). Notably, IACS-9439 (<b>1</b>) displayed superior selectivity when compared to BLZ945 in the above kinase panel. These results were also confirmed in a cellular context, where IACS-9439 not only showed improved potency in the pCSF1R cellular target engagement assay in comparison with BLZ945 (IC<sub>50</sub> of 17 nM vs 155 nm) but also showed significantly higher selectivity for CSF1R against PDGFRβ (150-fold vs 3.7-fold) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Selectivity profile of IACS-9439 (<b>1</b>) against a panel of 97 kinases (DiscoverX) at a 1 μM test concentration. The larger the red circle, the greater the inhibition. One kinase with the percent of control <10: CSF1R. See also <a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S3</a>, Supporting information.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Selectivity Profile of IACS-9439 (<b>1</b>) and BLZ945 in Binding Affinity Assays against Type III Kinases CSF1R, FLT3, cKIT, PDGFRα, and PDGFRβ and in Cellular pCSFR1 and pPDGFRβ Target Engagement Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound #</th><th class="colsep0 rowsep0" align="center">BLZ945</th><th class="colsep0 rowsep0" align="center">IACS-9439 (1)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF1R Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3 Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">8700 (2552)</td><td class="colsep0 rowsep0" align="left">9500 (9500)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKIT Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">3000 (882)</td><td class="colsep0 rowsep0" align="left">17 000 (17 000)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">210 (61)</td><td class="colsep0 rowsep0" align="left">1900 (1900)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ Kd (nM) (fold X)</td><td class="colsep0 rowsep0" align="left">46 (13)</td><td class="colsep0 rowsep0" align="left">450 (450)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phospho-CSF1R IC<sub>50</sub> (nM) (THP-1)</td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phospho-PDGFRβ IC<sub>50</sub> (nM) (HEK293)</td><td class="colsep0 rowsep0" align="left">579 (3.7)</td><td class="colsep0 rowsep0" align="left">3560 (150)</td></tr></tbody></table></div></div><div class="NLM_p">IACS-9439 (<b>1</b>) had low-to-moderate microsomal stability in rat and human microsomes and high microsomal turnover in mouse, dog, and monkey microsomes. It had an acceptable free plasma concentration across species, with a free fraction (fu) of 6.5% in humans (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). IACS-9439 (<b>1</b>) possessed a suitable <i>in vivo</i> PK profile in rat and mouse, with moderate clearance, acceptable half-life, and excellent oral bioavailability. In the dog and monkey, the compound had higher clearance and shorter half-life, as well as lower oral bioavailability.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Microsomal and Hepatic Stabilities, Plasma Protein Binding, and <i>In Vivo</i> PK Profile of IACS-9439</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="/" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="."><i>in vitro</i> ADME properties of IACS-9439</th><th class="rowsep1 colsep0" colspan="5" align="center" char="/"><i>in vivo</i> pharmacokinetic data of IACS-9439</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">plasma protein binding (% bound)</th><th class="colsep0 rowsep0" align="center" char=".">hepatocytes CL<sub>int,scaled</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">microsomes CL<sub>int,scaled</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="/">dose IV/PO (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg) (IV)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h) (IV)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char="/">0.3/10</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">97.9</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char="/">0.3/3</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">95.2</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">293</td><td class="colsep0 rowsep0" align="char" char="/">0.3/3</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1.37</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">98.4</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">208</td><td class="colsep0 rowsep0" align="char" char="/">0.3/1</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">0.45</td><td class="colsep0 rowsep0" align="char" char=".">0.96</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">93.5</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char="/"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">To confirm the biological activity of IACS-9439 (<b>1</b>) and compare it to compound <b>12</b> and BLZ945, we performed a series of <i>in vivo</i> experiments utilizing PANC02 and MC38 syngeneic tumor models. MC38 tumor-bearing mice were treated with 20, 60, or 200 mg/kg BLZ945, compound <b>12</b>, or IACS-9439 (<b>1</b>) for 10 days (<i>n</i> = 3 mice/group), and similar dose-dependent reductions in macrophages were observed by IHC and mRNAs using nanostring (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) for each of the compounds.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. IACS-9439 (<b>1</b>) depletes tumor macrophages, promotes M1 macrophage, and inhibits tumor growth. (A) Heat map of nanostring and IHC measuring relative macrophage mRNAs or F4/80 protein levels from MC38 tumors treated daily for 10 days with vehicle or 20, 60, or 200 mg/kg of BLZ945, compound <b>12</b>, or IACS-9439 (<b>1</b>) (<i>n</i> = 3 mice/group). Note that 100 = no change (white) compared to vehicle-treated mice. (B) Relative EMR1 (F4/80) or (C) CD4 mRNA from PANC02 tumors treated daily for 10 days with 10, 25, 50, 100, or 200 mg/kg BLZ945 or IACS-9439 (<b>1</b>) (<i>n</i> = 4 mice/group). Tumor samples from CSF1Ri-treated mice were normalized to vehicle-treated mice and plotted in relation to the concentration of the compound in the plasma. Note that the vehicle was artificially set as 0.1 μM to enable curve fitting. (D) Flow cytometry depicting the percent of M1 (MHC II+) and M2 (CD206+) macrophages (CD45+, C11b+, F4/80+) in MC38 tumors from mice treated daily for 10 days with vehicle, 10, 50, or 200 mg/kg BLZ945, or IACS-9439 (<b>1</b>) (<i>n</i> = 10 mice/group). (E) Growth of MC38 tumors implanted subcutaneously in mice and treated daily with vehicle, BLZ945, or 200 mg/kg IACS-9439 (<b>1</b>) (<i>n</i> = 10 mice/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand the PK/PD relationship, mice-bearing PANC02 tumors were treated with 10, 25, 50, 100, or 200 mg/kg IACS-9439 (<b>1</b>) or BLZ945 for 5 days (<i>n</i> = 4 mice/group) before harvesting tumor and plasma to measure the changes in EMR1 (F4/80) mRNA, as a measure of macrophages, and CD4 mRNA, as a measure of CD4 T-cells and compare these to the concentration of IACS-9439 (<b>1</b>) or BLZ945 in the plasma. For both compounds and both mRNAs, there was a clear PK/PD relationship with IACS-9439 (<b>1</b>) working at lower plasma concentrations (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,C), a ∼3 μM IC<sub>50</sub> for IACS-9439 (<b>1</b>) compared to ∼18 μM IC<sub>50</sub> for BLZ945 for EMR1 mRNA and an ∼18 μM IC<sub>50</sub> for IACS-9439 (<b>1</b>) compared to an ∼56 μM IC<sub>50</sub> for BLZ945 for CD4 mRNA.</div><div class="NLM_p">CSF1R inhibitors have been reported to promote macrophage polarization toward the M1 phenotype.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Consistent with these reports, we found, using flow cytometry, that the treatment of mice-bearing MC38 tumors with 10, 50, or 200 mg/kg IACS-9439 (<b>1</b>) or BLZ945 for 10 days (<i>n</i> = 10 mice/group) resulted in a dose-dependent increase in the percentage of macrophages of the M1 class, with a concomitant dose-dependent decrease in the percentage of macrophages in the tumors that were of the M2 phenotype (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). This data is consistent with the treatment of tumors with IACS-9439 (<b>1</b>) and the other CSF1R inhibitors, shifting the tumor macrophage balance from a protumor M2 phenotype to an antitumor M1 phenotype.</div><div class="NLM_p last">The functional consequence of this shift in macrophage biology, reduction of M2 macrophages, while increasing the percentage of M1 macrophages, is highlighted by the observed identical decreases in the growth of MC38 tumors in mice treated with 200 mg/kg of IACS-9439 (<b>1</b>) or BLZ945 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E) (<i>n</i> = 10 mice/group). Taken together, the data indicate that IACS-9439 (<b>1</b>) is a potent selective inhibitor of CSF1R, which impacts macrophage biology and the growth of tumors in immune-competent environments.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20216" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20216" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>2</b>, <b>3</b>, and <b>8</b>–<b>20</b> were synthesized as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>2</b> was prepared starting from 2-bromo-6-methoxybenzo[<i>d</i>]thiazole <b>34</b>, which was reacted with cyclohexylamine in the presence of K<sub>2</sub>CO<sub>3</sub>. Subsequent demethylation with BBr<sub>3</sub> afforded intermediate <b>35</b>, which was alkylated with 3-(chloromethyl)pyridine to afford compound <b>2</b>. Compound <b>3</b> was prepared in a similar manner, utilizing 4-(chloromethyl)pyridine as the alkylating agent in the last step. Compound <b>8</b> was obtained following a similar route, by alkylating intermediate <b>35</b> with <i>tert</i>-butyl 4-(chloromethyl)pyridin-2-ylcarbamate, followed by removal of the Boc group by trifluoroacetic acid (TFA) to provide final compound <b>8</b>. Alkylation of intermediate <b>35</b> with 3-chloro-4-(chloromethyl)pyridine afforded compound <b>9</b>. To obtain compound <b>10</b>, intermediate <b>35</b> was reacted with 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine <b>44</b>, which was prepared in three steps from 2,3-dichloroisonicotinic acid <b>43</b>. Final deprotection with TFA provided the desired compound <b>10</b>. Compounds <b>11</b> and <b>12</b> were synthesized in a similar fashion. 2-Bromo-6-methoxybenzo[<i>d</i>]thiazole <b>34</b> was reacted with (1<i>S</i>,2<i>S</i>)-2-aminocyclohexan-1-ol or (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol, and the resulting product was demethylated using BBr<sub>3</sub> to provide intermediate <b>35</b>. Subsequent alkylation with 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine <b>44</b> and deprotection with TFA provided the final products <b>11</b> and <b>12</b>. To synthesize compounds <b>13</b> and <b>14</b>, 2-chloro-6-methoxybenzo[<i>d</i>]thiazole <b>34</b> was demethylated and alkylated with 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine <b>44</b>. S<sub>N</sub>Ar reaction with (1<i>R</i>,2<i>S</i>)-2-aminocyclohexan-1-ol or (1<i>S</i>,2<i>R</i>)-2-aminocyclohexan-1-ol and subsequent deprotection provided the desired products <b>13</b> and <b>14</b>. Compound <b>15</b> was synthesized starting from 4-fluoro-2-methoxy-1-nitrobenzene <b>38</b>, which was reacted with BnOH under S<sub>N</sub>Ar conditions and subsequently reduced to the corresponding aniline derivative <b>39</b>. The benzothiazole ring was formed by treating compound <b>39</b> with KSCN and CuSO<sub>4</sub> in MeOH. Subsequent reaction with <i>t</i>-BuONO and CuBr<sub>2</sub> led to intermediate <b>40</b>. S<sub>N</sub>Ar reaction of <b>40</b> with (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol followed by deprotection with TFA provided intermediate <b>35</b>. Alkylation of <b>35</b> with 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine <b>44</b> and subsequent deprotection led to analogue <b>15</b>. Compound <b>16</b> was synthesized in a slightly different manner. Thiazole derivative <b>42</b> was prepared by reacting 4-bromo-2-(trifluoromethoxy)aniline <b>41</b> with KSCN in the presence of Br<sub>2</sub> and AcOH and subsequent treatment of the product with <i>t</i>-BuONO and CuBr<sub>2</sub>. S<sub>N</sub>Ar reaction of <b>42</b> with (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol followed by introduction of the 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl functionality by Pd(dppf)Cl<sub>2</sub>-catalyzed coupling with B<sub>2</sub>Pin<sub>2</sub> and subsequent treatment with H<sub>2</sub>O<sub>2</sub> led to phenol intermediate <b>35</b>. Alkylation and subsequent deprotection provided the desired product <b>16</b>. Compounds <b>17</b>–<b>20</b> were prepared according to the sequence as it was described for compound <b>12</b>, utilizing the appropriately substituted 2-bromo-6-methoxybenzo[<i>d</i>]thiazole intermediates <b>34</b>, which in turn could be obtained from substituted anilines <b>37a</b>–<b>d</b> in two steps.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of Compounds <b>2</b>, <b>3</b>, and <b>8–20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnOH, NaH, 0 °C, dimethylformamide (DMF), 99%; (b) N<sub>2</sub>H<sub>4</sub>–H<sub>2</sub>O, Raney-Ni, rt, MeOH, 88%; (c) KSCN, CuSO<sub>4</sub>, 90 °C, MeOH, 37%; or KSCN, Br<sub>2</sub>, HOAc, 0 °C to rt, 4 h, AcOH, 12.5–78%; (d) <i>t</i>-BuONO, CuBr<sub>2</sub>, 0 °C to rt, MeCN, 30–53%; (e) amine, K<sub>2</sub>CO<sub>3</sub>, dimethyl sulfoxide (DMSO), 100 °C, 81%; or amine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, 110 °C, 78–100%; or amine, 110 °C, 79%; or amine, Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidinone (NMP), 125 °C, 66–70%; (f) TFA, 110 °C, 100%; (g) ArCH<sub>2</sub>Cl, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 42–88%; or ArCH<sub>2</sub>Cl, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 27–80%; (h) TFA, rt, quant.; (i) BBr<sub>3</sub>, 0 °C to rt, dichloromethane (DCM), 78–90%; (j) B<sub>2</sub>Pin<sub>2</sub>, KOAc, Pd(dppf)Cl<sub>2</sub>, 100 °C, 1,4-dioxane, quant.; (k) H<sub>2</sub>O<sub>2</sub>, rt, 1,4-dioxane, 60%; (l) BH<sub>3</sub>–tetrahydrofuran (THF); 60 °C, 45%; (m) 4-methoxybenzyl amine, 150 °C, 64%; and (n) SOCl<sub>2</sub>, rt, 2 h, DCM, 94%.</p></p></figure><div class="NLM_p">Compounds <b>4</b>–<b>7</b> were synthesized as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. 2-Bromobenzo[<i>d</i>]thiazole-6-carboxylate <b>45</b> was reduced with diisobutylaluminum hydride (DIBAL)-H and subsequently reacted with sodium thiomethoxide to provide intermediate <b>46</b>. Mesylate formation and reaction with pyridin-3-ylmethanol or pyridin-4-ylmethanol, respectively, led to intermediate <b>47</b>, which, upon oxidation with <i>m</i>-CPBA, and subsequent S<sub>N</sub>Ar reaction provided compounds <b>4</b> and <b>5</b>. To obtain compounds <b>6</b> and <b>7</b>, intermediate <b>46</b> was treated with diphenylphosphoryl azide (DPPA), and the resulting azide was reduced to the corresponding amine <b>48</b> using Lindlar’s catalyst. Amine <b>48</b> was reacted with 3-iodopyridine or 4-iodopyridine. Oxidation of intermediate <b>48</b> followed by S<sub>N</sub>Ar reaction led to compounds <b>6</b> and <b>7</b>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Chemical Synthesis of Compounds <b>4</b>–<b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIBAL-H, THF, 0 °C–rt 4 h, 98%; (b) MeSNa, DMF,12 h, 71%; (c) MsCl, DIPEA, DMF. DCM, 0 °C–rt, 12 h, quant.; (d) pyridin-3-ylmethanol or pyridin-4-ylmethanol, <i>t</i>-BuOK, dimethyl acetamide (DMA), 100 °C, 2 h, quant.; (e) <i>m</i>-CPBA, DCM, 2 h, quant.; (f) cyclohexanamine, DIPEA, DMA,120 °C 2 h, 18%; (g) DPPA, 1,8-diazabicycloundec-7-ene (DBU), THF, rt, 3 h, 92%; (h) Lindlar Cat., H<sub>2</sub>, EtOH, 2 h; and (i) 3-iodopyridine or 4-iodopyridine, Cu, CsOAc, DMSO, 90 °C, 2 h, 78%.</p></p></figure><div class="NLM_p">Compounds <b>21</b>–<b>23</b> were synthesized as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. 2-Chloro-4-methylpyrimidine <b>49</b> was treated with NCS in the presence of AIBN in CCl<sub>4</sub>. The resulting chloromethyl pyridine derivative <b>50</b> was reacted with benzothiazole derivative <b>51</b>. Subsequent S<sub>N</sub>Ar reaction with NH<sub>3</sub>–H<sub>2</sub>O provided the desired product <b>21</b>. To synthesize compound <b>22</b> in an efficient manner, a novel route was developed. 3-Methoxy-4-nitrophenol <b>52a</b> was reacted with 2-chloro-4-(chloromethyl)pyrimidine <b>50</b>, and the nitro group of the resulting product was reduced using Pt/C to afford intermediate <b>53a</b>. Reacting compound <b>53a</b> with di(1<i>H</i>-imidazol-1-yl)methanethione and subsequently with (1<i>S</i>,2<i>S</i>)-2-aminocyclohexanol led to intermediate <b>54a</b>, which upon treatment with BnMe<sub>3</sub>NBr<sub>3</sub> and BSTFA was cyclized to the desired benzothiazole. The final S<sub>N</sub>Ar reaction with NH<sub>3</sub> yielded compound <b>22</b>. Compound <b>23</b> was prepared in a similar manner starting out from 2-chloro-5-methoxy-4-nitrophenol <b>52b</b> that was synthesized starting from 3-methoxy-4-nitrophenol <b>52a</b> by treatment with NCS.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Chemical Synthesis of Compounds <b>21</b>–<b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>3</sub>, H<sub>2</sub>O 90 °C, 3 h, 49%; (b) AIBN, NCS, CCl<sub>4</sub>, 18 h, 67%; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, rt, 4 h, DMF, 8%; (d) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, rt, 20 h, DMF, 93%; (e) 10% Pt–C, rt, 2 h, THF–MeOH, (5:1), 97%; (f) di(1<i>H</i>-imidazol-1-yl)methanethione, (1<i>S</i>,2<i>S</i>)-2-aminocyclohexan-1-ol, rt, 4 h, DCM, 96%; (g) BnMe<sub>3</sub>NBr<sub>3</sub>, BSTFA, rt, 20 min, DCM, 95%; (h) NH<sub>3</sub> (7 M, in MeOH), 120 °C, 4 h, 64%; and (i) NCS, 50 °C, 2 h, DCM, quant.</p></p></figure><div class="NLM_p">Compounds <b>24</b> and <b>25</b> were synthesized as described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Intermediate <b>56</b> was alkylated with <i>tert</i>-butyl (4-(chloromethyl)pyridin-2-yl)carbamate and was subsequently deprotected to provide the desired product <b>24</b>. Compound <b>25</b> was prepared following a modified sequence, starting with intermediate <b>57</b> that was deprotected to afford benzothiazole derivative <b>58</b>. Mitsunobu reaction with <i>tert</i>-butyl (4-(hydroxymethyl)pyridin-2-yl)carbamate yielded intermediate <b>59</b>. Removal of the Boc group by TFA, followed by acylation with Ac<sub>2</sub>O in the presence of pyridine, and subsequent S<sub>N</sub>Ar reaction with (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol provided the desired product <b>25</b>.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Chemical Synthesis of Compounds <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (4-(chloromethyl)pyridin-2-yl)carbamate, Cs<sub>2</sub>CO<sub>3</sub>, 80 °C, 2 h, DMF, 17%; (b) TFA, rt, 16 h, 35%; (c) TFA, 65 °C, 24 h 40 h, 24%; (d) <i>tert</i>-butyl (4-(hydroxymethyl)pyridin-2-yl)carbamate, Ph<sub>3</sub>P, DtBAD, rt, 16 h, THF, 93%; (e) TFA, rt, 3 h, DCM, 60%; (f) Ac<sub>2</sub>O, pyr, 60 °C, 1 h, DMF, 88%; and (g) (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol DIPEA, DMA, 100 °C, 12 h, 38%.</p></p></figure><div class="NLM_p">Compounds <b>26</b>–<b>33</b> were prepared as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Compound <b>26</b> was prepared from intermediate <b>55a</b> in five steps. First, the secondary alcohol was protected with a TBS group. Subsequent S<sub>N</sub>Ar reaction with ammonia, followed by treatment with phenylchloroformate and methylamine, and final deprotection yielded compound <b>26</b>. Compounds <b>1</b> and <b>26</b>–<b>31</b> were prepared from intermediate <b>55a</b> in an S<sub>N</sub>Ar reaction with the appropriate aromatic amine. Compound <b>32</b> was prepared from intermediate <b>55b</b>, in a similar manner, via an S<sub>N</sub>Ar reaction with 1-methyl-1<i>H</i>-pyrazol-4-amine to provide the desired product.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Chemical Synthesis of Compounds <b>26</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBSCl, imid., DMF, 12 h, rt, 91%; (b) NH<sub>3</sub> in <i>i</i>PrOH (2 M), 120 °C, MW, 8 h, 72%; (c) phenylchloroformate, Py, DMAP (Cat.), 3 h, rt; (d) MeNH<sub>2</sub>, 12 h, rt, 51% for two steps; (e) tetra-<i>n</i>-butylammonium fluoride (TBAF), 12 h, rt, 40%; and (f) (i) 1-methyl-1<i>H</i>-pyrazol-4-amine DIPEA, 120 °C, 10 h, DMA, 46% (<b>1</b>); (ii) 1-methyl-1<i>H</i>-pyrazol-3-amine, DIPEA, 120 °C, 5 h, 2-propanol, MW, 15% (<b>27</b>); (iii) 1<i>H</i>-pyrazol-4-amine, TEA, 120 °C, 2 h, DMSO, MW, 44% (<b>28</b>); (iv) 1<i>H</i>-pyrazol-3-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 110 °C, 2 h, 14% (<b>29</b>); (v) 4-amino isoxazole hydrochloride, TEA, 120 °C, 2 h, DMSO, MW, 63% (<b>30</b>); (vi) 1-methyl-1<i>H</i>-1,2,3-triazol-4-amine, TsOH, dioxan, 110 °C, 12 h, 10% (<b>31</b>); and (vii) 1-methyl-1<i>H</i>-pyrazol-3-amine, DIPEA, 110 °C, 18 h, 5% (<b>32</b>).</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Rational design and iterative, hypothesis-driven potency and property optimization allowed us to develop a highly potent, exquisitely selective, and orally bioavailable CSF1R inhibitor, IACS-9439 (<b>1</b>). Deep analysis of the active site in the DGF-out conformation of kinases CSF1R, cKit, FLT3, PDGFRα, and PDGFRβ enabled us to rapidly design analogues of the initial lead, compound <b>12</b>, with drastically improved selectivity. A comprehensive evaluation of the selectivity of these inhibitors was enabled by utilizing a suite of assays including kinase binding as well as enzymatic assays for the above kinases. To evaluate selectivity in a cellular context, CSF1R and PDGFRβ cellular target engagement assays were implemented. Subsequent hypothesis-driven property optimization of the highly selective CSF1R inhibitor <b>15</b> led to analogues with improved DMPK properties. Finally, a significant boost in potency was achieved by introducing a substituent onto the hinge-binding motif, resulting in the identification of IACS-9439 (<b>1</b>). The excellent potency, exquisite CSF1R selectivity, and <i>in vivo</i> PK profile of IACS-9439 (<b>1</b>) allowed us to utilize it as an <i>in vivo</i> tool to probe CSF1R-mediated biology. We demonstrated that treatment with IACS-9439 (<b>1</b>) led to the dose-dependent reduction of macrophages and promoted macrophage polarization toward the M1 phenotype in the syngeneic tumor model and led to tumor growth inhibition in MC38 and PANC01 tumor models. We also developed a novel, highly efficient, and scalable synthetic route for the preparation of 4-methoxy-substituted benzothiazole analogues and IACS-9439 (<b>1</b>).</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthetic Methods</h3><div class="NLM_p">The inhibitors described were synthesized by employing standard chemical transformations. Starting materials and reagents were purchased from commercial suppliers, such as Sigma-Aldrich, Alfa Aesar, TCI, or Acros, and will be used without further purification unless otherwise indicated. Anhydrous solvents (e.g., THF, DMF, DMA, DMSO, MeOH, DCM, toluene) were purchased from Sigma-Aldrich and used directly. Purification of inhibitors was performed by column chromatography utilizing a Biotage system applying Biotage SNAP columns with a Biotage KP-Sil silica or Biotage Zip Si columns with a Biotage KP-Sil silica or a Teledyne ISCO system with RediSep Rf normal phase silica cartridges. Other inhibitors were purified by preparative high-pressure liquid chromatography (HPLC) using a Waters Autopurify system with a Waters Xbridge Prep C18 5 μm OBD, 19 mm × 150 mm or 50 mm × 100 mm column, and SQ detector mass spectrometer with electrospray ionization (ESI) ionization. The identity of all compounds with reported biological activity was confirmed by NMR spectroscopy and low-resolution mass spectrometry, and for selected analogues, high-resolution mass spectrometry. The purity of all compounds with reported biological activity was ≥95% and was determined by ultraperformance liquid chromatography (UPLC). NMR spectra were recorded on Bruker instruments operating at 300, 500, or 600 MHz. NMR spectra were obtained as CDCl<sub>3</sub>, CD<sub>3</sub>OD, D<sub>2</sub>O, (CD<sub>3</sub>)<sub>2</sub>SO, (CD<sub>3</sub>)<sub>2</sub>CO, C<sub>6</sub>D<sub>6</sub>, or CD<sub>3</sub>CN solutions (reported in ppm), using tetramethylsilane (0.00 ppm) or residual solvent (CDCl<sub>3</sub>, 7.26 ppm; CD<sub>3</sub>OD, 3.31 ppm; D<sub>2</sub>O, 4.79 ppm; (CD<sub>3</sub>)<sub>2</sub>SO, 2.50 ppm; (CD<sub>3</sub>)<sub>2</sub>CO, 2.05 ppm; C<sub>6</sub>D<sub>6</sub>, 7.16 ppm; CD<sub>3</sub>CN, 1.94 ppm) as the reference standard. Low-resolution mass spectral data were obtained on either a Waters H class UPLC with a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection between 200 and 400 nm, evaporating light scattering detection, and an SQ detector mass spectrometer with ESI ionization or a Water I-class UPLC with a Waters Acquity UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection at 254 and 290 nm, evaporating light scattering detection, and an SQ detector 2 mass spectrometer with ESI ionization. High-resolution mass spectra were obtained on a Waters Acquity I-Class UPLC coupled to an LTQ-Orbitrap Elite mass spectrometer. The injection volume was 5 μL. Chromatographic separation was performed on a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, at a flow rate of 0.5 mL/min. The mobile phases were 0.1% acetic acid in water (solvent A) and 0.1% acetic acid in acetonitrile (solvent B). The gradient had a total run time of 18 min and was as follows: 0–2 min 5% B; 2–12 min from 5 to 65% B; 12–14 min from 65 to 95% B; 14–16 min at 95% B; 16–16.1 min from 95 to 5% B; and 16.1–18 min at 5% B. The column temperature was kept at 40 °C. The samples were analyzed using the positive electrospray ionization (ESI) mode. The ESI source temperature was set at 375 °C, the capillary temperature was at 320 °C, and the electrospray voltage was at 4.1 kV. Sheath and auxiliary gases were 45 and 10 au, respectively.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Synthesis of <i>N</i>-Cyclohexyl-6-(pyridin-3-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine (<b>2</b>)</h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> Step 1: <i>N</i>-Cyclohexyl-6-methoxybenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 2-bromo-6-methoxybenzo[<i>d</i>]thiazole (2.0 g, 8.2 mmol), cyclohexanamine (1.1 g, 11 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.3 g, 16 mmol) in DMSO (15 mL) was heated at 100 °C for 22 h. The reaction mixture was cooled to rt, diluted with water (25 mL), and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by flash column chromatography (10–30% EtOAc in hexanes) to provide <i>N</i>-cyclohexyl-6-methoxybenzo[<i>d</i>]thiazol-2-amine (1.7 g, 81%) as a yellow solid. MS (ES+) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>OS requires 262, found: 263 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Step 2: 2-(Cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">To a solution of <i>N</i>-cyclohexyl-6-methoxybenzo[<i>d</i>]thiazol-2-amine (1.7 g, 6.7 mmol) in DCM (30 mL), at 0 °C, BBr<sub>3</sub> (4.2 g, 17 mmol) was added slowly, and the resulting mixture was stirred at rt for 3 h. The reaction mixture was slowly quenched with ice water. NaHCO<sub>3</sub> (4.2 g, 51 mmol) was added. The precipitate was filtered to afford 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (1.3 g, 78%) as a beige solid. MS (ES+) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>OS requires 248, found: 249 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Step 3: <i>N</i>-Cyclohexyl-6-(pyridin-3-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (75 mg, 0.30 mmol), 3-(chloromethyl)pyridine hydrochloride (59 mg, 0.36 mmol), and K<sub>2</sub>CO<sub>3</sub> (83 mg, 0.60 mmol) in DMF (1 mL) was heated to 80 °C and was stirred at this temperature for 16 h. The mixture was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN) to provide <i>N</i>-cyclohexyl-6-(pyridin-3-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine (89 mg, 88%) as a brown solid. MS (ES+) C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS requires 339, found: 340 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (s, 1H), 8.72 (d, <i>J</i> = 4.3 Hz, 1H), 8.63 (s, 1H), 8.22 (d, <i>J</i> = 7.7 Hz, 1H), 7.73 (dd, J = 7.3, 5.7 Hz, 1H), 7.50 (d, <i>J</i> = 1.9 Hz, 1H), 7.35 (d, <i>J</i> = 8.7 Hz, 1H), 7.01 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 5.23 (s, 2H), 3.73–3.60 (m, 1H), 2.02–1.93 (m, 2H), 1.77–1.68 (m, 2H), 1.62–1.54 (m, 1H), 1.39–1.17 (m, 5H).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of <i>N</i>-Cyclohexyl-6-(pyridin-4-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine (<b>3</b>)</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Step 1: <i>N</i>-Cyclohexyl-6-(pyridin-4-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (75 mg, 0.30 mmol), 4-(chloromethyl)pyridine hydrochloride (59 mg, 0.36 mmol), and K<sub>2</sub>CO<sub>3</sub> (83 mg, 0.60 mmol) in DMF was heated at 80 °C for 2 h. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN) to give <i>N</i>-cyclohexyl-6-(pyridin-4-ylmethoxy)benzo[<i>d</i>]thiazol-2-amine (79 mg, 78%) as a beige solid. MS (ES+) C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS requires 339, found: 340 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (s, 1H), 7.81 (d, <i>J</i> = 2.5 Hz, 2H), 7.44 (d, <i>J</i> = 2.6 Hz, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 6.97 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 5.34 (s, 2H), 3.70–3.61 (m, 1H), 2.02–1.93 (m, 2H), 1.77–1.68 (m, 2H), 1.62–1.55 (m, 1H), 1.38–1.18 (m, 5H).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Synthesis of 6-((2-Aminopyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (<b>8</b>)</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step 1: <i>tert</i>-Butyl 4-(chloromethyl)pyridin-2-ylcarbamate</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(hydroxymethyl)pyridin-2-ylcarbamate (67 mg, 0.30 mmol) in DCM (2 mL) was added SOCl<sub>2</sub> (10 drops). The reaction mixture was stirred at rt for 2 h. The mixture was concentrated to provide <i>tert</i>-butyl 4-(chloromethyl)pyridin-2-ylcarbamate as a yellow solid, which was used directly in the next step without further purification. MS (ES+) C<sub>11</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub> requires 242, found: 243 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step 2: 6-((2-Aminopyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (50 mg, 0.20 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (163 mg, 0.50 mmol) in DMF (2 mL) was stirred at rt for 2 h. <i>tert</i>-Butyl 4-(chloromethyl)pyridin-2-ylcarbamate (73 mg, 0.30 mmol) was added. The reaction mixture was stirred at 120 °C for 4 h. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide 6-((2-aminopyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (29 mg, 28%) as a beige solid. MS (ES+) C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>OS requires 354, found: 355 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>4</sub>-methanol) δ 7.88 (dd, <i>J</i> = 5.4, 0.7 Hz, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 7.24 (d, <i>J</i> = 2.5 Hz, 1H), 6.94 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.72–6.65 (m, 2H), 5.02 (s, 2H), 3.69–3.66 (m, 1H), 2.10–2.08 (m, 2H), 1.86–1.77 (m, 2H), 1.70–1.68 (m, 1H), 1.47–1.42 (m, 2H), 1.37–1.25 (m, 3H).</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Synthesis of 6-((3-Chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (<b>9</b>)</h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step 1: Synthesis of (3-Chloropyridin-4-yl)methanol</h5><div class="NLM_p last">To a solution of 3-chloroisonicotinaldehyde (660 mg, 4.66 mmol) in MeOH (20 mL) was added NaBH<sub>4</sub> (530 mg, 143 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched with NH<sub>4</sub>Cl (sat. aq), diluted with water (80 mL), and extracted with DCM/MeOH 20:1 (3 × 30 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to provide (3-chloropyridin-4-yl)methanol as a light yellow solid (520 mg, 78%), which was used in the next step without further purification. MS (ES+) C<sub>6</sub>H<sub>6</sub>ClNO requires 143, found: 144 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step 2: Synthesis of 3-Chloro-4-(chloromethyl)pyridine</h5><div class="NLM_p last">To a solution of (3-chloropyridin-4-yl)methanol (520 mg, 3.63 mmol) in DCM (4 mL) was added SOCl<sub>2</sub> (2.0 mL, 27 mmol). The reaction mixture was stirred at rt for 2 h and concentrated under reduced pressure to provide 3-chloro-4-(chloromethyl)pyridine as a tan solid, which was used in the next step without further purification. MS (ES+) C<sub>6</sub>H<sub>5</sub>Cl<sub>2</sub>N requires 161, found: 162 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Step 3: Synthesis of 6-((3-Chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (40 mg, 0.16 mmol) and K<sub>2</sub>CO<sub>3</sub> (110 mg, 0.797 mmol) in DMF (2 mL) was stirred at rt for 1 h. 3-Chloro-4-(chloromethyl)pyridine (78 mg, 0.48 mmol) was added. The reaction mixture was stirred at rt for 48 h, purified by prep-HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide 6-((3-chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (25 mg, 42%) as a yellow solid. MS (ES+) C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>OS requires 373, found: 374 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.59 (s, 1H), 8.51 (d, <i>J</i> = 5.0 Hz, 1H), 7.70 (d, <i>J</i> = 5.0 Hz, 1H), 7.34 (dd, <i>J</i> = 23.0, 5.7 Hz, 2H), 7.00 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 5.25 (s, 2H), 3.84–3.52 (m, 1H), 2.13–2.04 (m, 2H), 1.87–1.75 (m, 2H), 1.69 (dd, <i>J</i> = 9.3, 3.8 Hz, 1H), 1.53–1.22 (m, 5H).</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of 6-((2-Amino-3-chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (<b>10</b>)</h4><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 1: (2,3-Dichloropyridin-4-yl)methanol</h5><div class="NLM_p last">A mixture of 2,3-dichloroisonicotinic acid (960 mg, 5.00 mmol) and BH<sub>3</sub><sup>•</sup>THF (1.0 M, 25 mL, 25 equiv) was heated at 60 °C for 4 h. The reaction mixture was cooled to rt, MeOH (5 mL) was added, and the volatiles were removed under reduced pressure. The mixture was diluted with water (50 mL) and extracted with DCM (3 × 50 mL). The combined organic phases were washed with brine (1 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to provide (2,3-dichloropyridin-4-yl)methanol (400.5 mg, 45%) as a white solid. MS (ES+) C<sub>6</sub>H<sub>5</sub>Cl<sub>2</sub>NO requires 178, found: 179 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 2: (3-Chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methanol</h5><div class="NLM_p last">A mixture of (2,3-dichloropyridin-4-yl)methanol (200 mg, 1.12 mmol) and (4-methoxyphenyl)methanamine (1.0 mL, 7.6 mmol) was heated at 150 °C for 4 h. The residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–90%; 12 min; column: C18) to provide (3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methanol (201 mg, 64%) as a white solid. MS (ES+) C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub> requires 278, found: 279 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (d, <i>J</i> = 5.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.7 Hz, 2H), 6.91–6.72 (m, 3H), 4.52 (d, <i>J</i> = 12.7 Hz, 4H), 3.71 (s, 3H).</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 3: Synthesis of 3-Chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine</h5><div class="NLM_p last">A mixture of (3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methanol (50 mg, 0.18 mmol) and SOCl<sub>2</sub> (2.0 mL, 27 mmol) in DCM (2 mL) was stirred at rt for 2 h. The volatiles were removed under reduced pressure to provide 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (51 mg, 94%) as a yellow solid. MS (ES+) C<sub>14</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O requires 297, found: 298 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.96 (d, <i>J</i> = 5.5 Hz, 1H), 7.25 (t, <i>J</i> = 31.7 Hz, 2H), 6.86 (d, <i>J</i> = 8.7 Hz, 3H), 4.76 (s, 2H), 4.60 (d, <i>J</i> = 15.5 Hz, 2H), 3.77–3.68 (m, 3H).</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Step 4: 6-((3-Chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (51 mg, 0.17 mmol), 2-(cyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (42 mg, 0.17 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (110 mg, 0.338 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide 6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (31 mg, 35%) as a white solid. MS (ES+) C<sub>27</sub>H<sub>29</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 524, found: 525 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 5: 6-((2-Amino-3-chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A mixture of 6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (31 mg, 0.057 mmol) in TFA (2 mL) was stirred at rt for 8 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide 6-((2-amino-3-chloropyridin-4-yl)methoxy)-<i>N</i>-cyclohexylbenzo[<i>d</i>]thiazol-2-amine (7 mg, 18%) as a white solid. MS (ES+) C<sub>19</sub>H<sub>21</sub>ClN<sub>4</sub>OS requires 388, found: 389 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (s, 1H), 7.97 (d, <i>J</i> = 5.7 Hz, 1H), 7.49 (d, <i>J</i> = 2.5 Hz, 1H), 7.36 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 1H), 6.86 (d, <i>J</i> = 5.7 Hz, 1H), 5.18 (s, 2H), 3.68 (dt, <i>J</i> = 13.5, 8.7 Hz, 1H), 2.06–1.91 (m, 2H), 1.80–1.65 (m, 2H), 1.58 (dd, <i>J</i> = 16.3, 10.0 Hz, 1H), 1.29 (qd, <i>J</i> = 25.5, 12.8 Hz, 5H).</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>11</b>)</h4><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step 1: (1<i>S</i>,2<i>S</i>)-2-((6-Methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">To a solution of 2-bromo-6-methoxybenzo[<i>d</i>]thiazole (200 mg, 0.82 mmol) and (1<i>S</i>,2<i>S</i>)-2-aminocyclohexanol (145 mg, 1.23 mmol) in DMA (1 mL) was added DIPEA (0.28 mL, 1.64 mmol), and the resulting mixture was stirred at 100 °C for 12 h. The reaction mixture was diluted with EtOAc (15 mL) and washed with water (10 mL). The layers were separated, and the organic layer was washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (40–80% EtOAc in hexanes) to provide (1<i>S</i>,2<i>S</i>)-2-((6-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (180 mg, 0.647 mmol, 79% yield) as a white solid. MS (ES+) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S requires 278, found: 279 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step 2: 2-(((1<i>S</i>,2<i>S</i>)-2-Hydroxycyclohexyl)amino)benzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">To a solution of (1<i>S</i>,2<i>S</i>)-2-((6-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (150 mg, 0.54 mmol) in DCM (5 mL) at 0 °C was added BBr<sub>3</sub> (51 μL, 0.54 mmol) slowly. The resulting mixture was stirred at rt for 3 h. The reaction mixture was then quenched slowly with ice water (5 mL) followed by sat. NaHCO<sub>3</sub> (5 mL). The reaction mixture was diluted with EtOAc (20 mL). The layers were separated, and the organic layer was washed with NaHCO<sub>3</sub> (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give 2-(((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexyl)amino)benzo[<i>d</i>]thiazol-6-ol (120 mg, 84% yield) as a white powder. MS (ES+) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S requires 264, found: 265 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 3: (1<i>S</i>,2<i>S</i>)-2-(6-((3-Chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (50 mg, 0.17 mmol), 2-((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (45 mg, 0.17 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (110 mg, 0.34 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to give the title compound (30 mg, 34%) as a white solid. MS (ES+) C<sub>27</sub>H<sub>29</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 524, found: 525 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step 4: (1<i>S</i>,2<i>S</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>S</i>,2<i>S</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (30 mg, 0.06 mmol) in TFA (2 mL) was stirred at rt for 8 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide the title compound (17 mg, 73%) as a white solid. MS (ES+) C<sub>19</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>2</sub>S requires 404, found: 405 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (d, <i>J</i> = 5.0 Hz, 1H), 7.74 (d, <i>J</i> = 7.5 Hz, 1H), 7.37 (d, <i>J</i> = 2.6 Hz, 1H), 7.27 (d, <i>J</i> = 8.7 Hz, 1H), 6.88 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.72 (d, <i>J</i> = 5.0 Hz, 1H), 6.34 (s, 2H), 5.07 (s, 2H), 4.75 (d, <i>J</i> = 5.1 Hz, 1H), 3.56–3.47 (m, 1H), 3.41–3.35 (m, 1H), 2.07 (dd, <i>J</i> = 13.4, 7.7 Hz, 1H), 1.93–1.85 (m, 1H), 1.68–1.57 (m, 2H), 1.32–1.14 (m, 4H).</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>12</b>)</h4><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Step 1: (1<i>R</i>,2<i>R</i>)-2-((6-Methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p last">A mixture of 2-bromo-6-methoxybenzo[<i>d</i>]thiazole (3.00 g, 12.3 mmol) and (1<i>R</i>,2<i>R</i>)-2-aminocyclohexanol (4.25 g, 36.9 mmol) was heated at 110 °C for 6 h. The reaction was cooled to rt, diluted with water (30 mL), and extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to provide (1<i>R</i>,2<i>R</i>)-2-((6-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (3.01 g, 88%) as a brown solid. MS (ES+) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S requires 278, found: 279 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37 (d, <i>J</i> = 11 Hz, 1H), 7.03 (d, <i>J</i> = 3.5 Hz, 1H), 6.84 (dd, <i>J</i> = 11, 3.5 Hz, 1H), 6.27 (bs, 1H), 3.78 (s, 3H), 3.4–3.35 (m, 2H), 2.12–2.01 (m, 2H), 1.70–1.65 (m, 2H), 1.38–1.16 (m, 4H).</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Step 2: 2-(((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)amino)benzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">To a solution of 2-(6-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (3.00 g, 10.8 mmol) in DCM (30 mL) at 0 °C was added boron tribromide (5.4 g, 21 mmol) slowly. The resulting mixture was stirred at rt for 3 h. The reaction mixture was then diluted slowly with ice water (20 mL) followed by sat. NaHCO<sub>3</sub> (10 mL). The resulting precipitate was filtered and collected to provide 2-(((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexyl)amino)benzo[<i>d</i>]thiazol-6-ol (2.6 g, 90%) as a tan solid. MS (ES+) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S requires 264, found: 265 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 7.12 (d, <i>J</i> = 9 Hz, 1H), 6.89 (d, <i>J</i> = 2 Hz, 1H), 6.62 (dd, <i>J</i> = 9, 2 Hz, 1H), 3.50–3.41 (m, 1H), 3.31–3.36 (m, 1H), 2.10–2.03 (m, 1H), 1.98–1.93 (m, 1H), 1.70–1.59 (m, 2H), 1.36–1.17 (m, 4H).</div></div><div id="sec5_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Step 3: (1<i>R</i>,2<i>R</i>)-2-(6-((3-Chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy) benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (50 mg, 0.17 mmol), 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)benzo[<i>d</i>]thiazol-6-ol (45 mg, 0.17 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (110 mg, 0.34 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide (1<i>R</i>,2<i>R</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy) benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (30 mg, 34%) as a white solid. MS (ES+) C<sub>27</sub>H<sub>29</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 524, found: 525 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step 4: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>R</i>,2<i>R</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy) benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (30 mg, 0.06 mmol) in TFA (2 mL) was stirred at rt for 8 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to give (1<i>R</i>,2<i>R</i>)-2-(6-((2-amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (5 mg, 21%) as a white solid. HRMS (ES+) C<sub>19</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub>S<sup>+</sup> requires 405.1147, found: 405.1151 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (d, <i>J</i> = 5.0 Hz, 1H), 7.72 (d, <i>J</i> = 7.5 Hz, 1H), 7.36 (d, <i>J</i> = 2.5 Hz, 1H), 7.26 (d, <i>J</i> = 8.5 Hz, 1H), 6.88 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 6.72 (d, <i>J</i> = 5.0 Hz, 1H), 6.31 (s, 2H), 5.07 (s, 2H), 4.73 (d, <i>J</i> = 5.5 Hz, 1H), 3.52–3.48 (m, 1H), 3.36–3.31 (m, 1H), 2.06–2.04 (m, 1H), 1.89–1.86 (m, 1H), 1.64–1.60 (m, 2H), 1.29–1.17 (m, 4H). <sup>13</sup>C NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.00, 155.76, 152.61, 147.29, 145.97, 143.84, 131.20, 117.99, 113.45, 111.59, 111.18, 106.80, 71.38, 66.70, 59.48, 39.89, 39.75, 39.61, 39.47, 39.33, 39.19, 39.05, 33.98, 30.64, 23.95, 23.60.</div></div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of (1<i>R</i>,2<i>S</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (<b>13</b>)</h4><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Step 1: 2-Chlorobenzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">To a solution of 2-chloro-6-methoxybenzo[<i>d</i>]thiazole (150 g, 751 mmol, 1.0 equiv) in DCM (1.5 L) was added BBr<sub>3</sub> (470 g, 1.9 mol, 180 mL, 2.5 equiv) dropwise at −10–0 °C. During the addition, the solid was precipitated. After the addition, the reaction mixture was stirred at 25 °C for 16 h. Three additional batches of the same reaction were run. The four batches were combined, and the mixture was poured into cooled water (10 L) slowly, and then NaHCO<sub>3</sub> (sat.) solution (6 L) was added. The mixture was stirred at 0–5 °C for 0.5 h, filtered, and the filter cake was washed with water (∼10 L) until the pH of the filtrate was 7. The filter cake was washed with pet. ether (5 L) and dried under vacuum to afford 2-chlorobenzo[<i>d</i>]thiazol-6-ol (507 g, 2.59 mol, 86% yield) as a white solid. The product was used in the next step without further purification. MS (ES+) C<sub>7</sub>H<sub>4</sub>ClNOS requires 185, found: 186 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step 2: 3-Chloro-4-(((2-chlorobenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine</h5><div class="NLM_p last">To a solution of 2-chlorobenzo[<i>d</i>]thiazol-6-ol (143 g, 733 mmol) in DMF (800 mL) was added 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (220 g, 733 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (477 g, 1.47) at 15 °C. The mixture was stirred at 25 °C for 16 h. Water (1 L) was added dropwise, and the solid was precipitated. The suspension was stirred at 25 °C for 1 h. Three additional batches of the same reaction were run. The three batches were combined, filtered, washed with water (10 L), and the filter cake was collected. The cake was subpackaged slurried in pet ether/EtOAc = 5:1 (2 L, two times), filtered, collected, and dried under vacuum to provide 3-chloro-4-(((2-chlorobenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (800 g, 1.76 mol, 80%) as a light yellow solid. MS (ES+) C<sub>21</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S requires 445, found: 446 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Step 3: (1<i>R</i>,2<i>S</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">To a solution of 3-chloro-4-(((2-chlorobenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (2.0 g, 4.5 mmol) in NMP (20 mL) was added Na<sub>2</sub>CO<sub>3</sub> (2.4 g, 22 mmol) and (1<i>R</i>,2<i>S</i>)-2-aminocyclohexan-1-ol (0.81 mg, 5.4 mmol). The mixture was stirred at 125 °C for 16 h. The mixture was poured into water (100 mL), extracted with ethyl acetate (2 × 100 mL), and the residue was purified by pre-HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide the (1<i>R</i>,2<i>S</i>)-2-((6-((3-chloro-2-((4-methoxybenzyl)amino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (1.58 g, 2.98 mmol, 66% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.94 (d, <i>J</i> = 4.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 2.4 Hz, 1H), 7.23–7.28 (m, 3H), 7.09 (t, <i>J</i> = 6.4 Hz, 1H), 6.84–6.88 (m, 3H), 6.72 (d, <i>J</i> = 4.8 Hz, 1H), 5.08 (s, 2H), 4.65 (d, <i>J</i> = 4.0 Hz, 1H), 4.53 (d, <i>J</i> = 6.4 Hz, 2H), 3.92 (s, 1H), 3.79–3.84 (m, 1H), 3.71 (s, 3H),1.48–1.71 (m, 6H), 1.29–1.34 (m, 2H).</div></div><div id="sec5_1_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Step 4: (1<i>R</i>,2<i>S</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">A solution of (1<i>R</i>,2<i>S</i>)-2-((6-((3-chloro-2-((4-methoxybenzyl)amino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (1.0 g, 1.9 mmol) in TFA (10 mL) was stirred at 25 °C for 16 h. The mixture was quenched with water (100 mL), and the pH was adjusted to 9 with NH<sub>4</sub>OH (sat. aq). The solids were filtered and collected. The solid was purified by slurrying with EtOAc and petroleum ether 1:3 (40 mL). The mixture was filtered to collect the solids and provided the product (500 mg, 1.22 mmol, 64% yield) as a light brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.90 (d, <i>J</i> = 4.8 Hz, 1H), 7.61 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (d, <i>J</i> = 2.4 Hz, 1H), 7.27 (d, <i>J</i> = 8.8 Hz, 1H), 6.87 (dd, <i>J</i> = 2.4 Hz, 8.4 Hz, 1H), 6.72 (d, <i>J</i> = 5.2 Hz, 1H), 6.31 (s, 2H), 5.07 (s, 2H), 4.64 (d, <i>J</i> = 4.0 Hz, 1H), 3.92 (s, 1H), 3.79–3.84 (m, 1H), 1.48–1.71 (m, 6H), 1.29–1.34 (m, 2H).</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of (1<i>S</i>,2<i>R</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (<b>14</b>)</h4><div id="sec5_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step 1: Synthesis of (1<i>S</i>,2<i>R</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">To a solution of 3-chloro-4-(((2-chlorobenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (2.0 g, 3.8 mmol) in NMP (10 mL) were added (1<i>S</i>,2<i>R</i>)-2-aminocyclohexanol (685 mg, 4.52 mmol) and Na<sub>2</sub>CO<sub>3</sub> (2.0 g, 19 mmol). The reaction mixture was stirred at 120 °C for 16 h. Water was added (100 mL), and the mixture was extracted with EtOAc (3 × 100 mL). The organic phases were washed with brine (2 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide (1<i>S</i>,2<i>R</i>)-2-((6-((3-chloro-2-((4-methoxybenzyl)amino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (2.9 g, 5.3 mmol, 70% yield) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.94 (d, <i>J</i> = 5.2 Hz, 1H), 7.61 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (d, <i>J</i> = 2.8 Hz, 1H), 7.27–7.23 (m, 3H), 7.07 (t, <i>J</i> = 6.0 Hz, 1H), 6.87–6.83 (m, 3H), 6.71 (d, <i>J</i> = 5.2 Hz, 1H), 5.07 (s, 2H), 4.64 (d, <i>J</i> = 4.0 Hz, 1H), 4.53 (d, <i>J</i> = 6.0 Hz, 2H), 3.91 (s, 1H), 3.81 (t, <i>J</i> = 8.0 Hz, 1H), 3.70 (s, 3H), 1.70–1.44 (m, 6H), 1.33–1.28 (m, 2H).</div></div><div id="sec5_1_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step 2: (1<i>S</i>,2<i>R</i>)-2-((6-((2-Amino-3-chloropyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">(1<i>S</i>,2<i>R</i>)-2-((6-((3-Chloro-2-((4-methoxybenzyl)amino)pyridin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (2.3 g, 4.2 mmol) in TFA (23 mL) was stirred at rt for 16 h. Water (30 mL) was added, and the pH was adjusted to 9 with NH<sub>4</sub>OH (sat. aq). The solids were filtered and collected. The solid was purified by slurrying with EtOAc and petroleum ether 1:3 (40 mL). The mixture was filtered, and the solids were collected to provide the product (804 mg, 1.92 mmol, 45%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.89 (d, <i>J</i> = 5.2 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 2.8 Hz, 1H), 7.27 (d, <i>J</i> = 8.4 Hz, 1H), 6.87 (dd, <i>J</i> = 2.4, 8.8 Hz, 1H), 6.72 (d, <i>J</i> = 4.8 Hz, 1H), 6.31 (s, 2H), 5.06 (s, 2H), 4.64 (d, <i>J</i> = 4.0 Hz, 1H), 3.91 (s, 1H), 3.83–3.78 (m, 1H), 1.70–1.44 (m, 6H), 1.31–1.28 (m, 2H).</div></div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-({6-[(2-Amino-3-chloropyridin-4-yl)methoxy]-4-methoxy-1,3-benzothiazol-2-yl}amino)cyclohexan-1-ol (<b>15</b>)</h4><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step 1: 4-(Benzyloxy)-2-methoxy-1-nitrobenzene</h5><div class="NLM_p last">To a solution of phenylmethanol (41.0 g, 380 mmol) in DMF (500 mL) was added NaH (9.60 g, 399 mmol) at 0 °C. The reaction mixture was stirred for 0.5 h, and then 4-fluoro-2-methoxy-1-nitrobenzene (50.0 g, 292 mmol) was added. The mixture was stirred at rt for 1 h. The reaction was quenched with water (500 mL), filtered, and concentrated under reduced pressure to give 4-(benzyloxy)-2-methoxy-1-nitrobenzene (75 g, 99%) as a yellow solid. LC-MS (ES+) C<sub>14</sub>H<sub>13</sub>NO<sub>4</sub> requires 259, found: 260 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step 2: 4-(Benzyloxy)-2-methoxybenzenamine</h5><div class="NLM_p last">To a solution of 4-(benzyloxy)-2-methoxy-1-nitrobenzene (75.0 g, 290 mmol) in MeOH (800 mL) was added Raney-Ni (3.0 g) followed by the dropwise addition of N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (44.0 g, 870 mmol) at 0 °C. the mixture was stirred at rt for 16 h. The reaction mixture was quenched by sat. NH<sub>4</sub>OH (200 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were dried, filtered, and concentrated under reduced pressure to give 4-(benzyloxy)-2-methoxybenzenamine (56 g, 84%) as a yellow liquid. LC-MS (ES+) C<sub>14</sub>H<sub>15</sub>NO<sub>2</sub> requires 229, found: 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Step 3: 6-(Benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">To a solution of 4-(benzyloxy)-2-methoxybenzenamine (28.0 g, 0.122 mol) in methanol (600 mL) was added KSCN (59.3 g, 0.611 mol), followed by the addition of anhydrous CuSO<sub>4</sub> (195 g, 1.22 mol). The mixture was stirred for 16 h at 90 °C and concentrated under reduced pressure. The residue was dissolved in DCM (500 mL), the precipitate was filtered, and the filter cake was washed with dichloromethane (2 × 100 mL). The combined organic layer was washed with NH<sub>4</sub>OH (sat. aq, 500 mL). The aqueous layer was extracted with dichloromethane. The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel chromatography (50–100% EtOAc in petroleum ether) to give 6-(benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (13 g, 37%) as a black solid. LC-MS (ES+) C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S requires 286, found: 287 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Step 4: 6-(Benzyloxy)-2-bromo-4-methoxybenzo[<i>d</i>]thiazole</h5><div class="NLM_p last">To a suspension of 6-(benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (22.0 g, 0.077 mol) in MeCN (100 mL) was added <i>t</i>-BuONO (11.8 g, 0.110 mol) at 0 °C. The mixture was stirred for 30 min, and then CuBr<sub>2</sub> (10.3 g, 0.046 mol) was added. The reaction was stirred for an additional 2 h at room temperature. Water was added, the precipitate was filtered, and the filtrate was extracted with EtOAc. The combined organic layers were washed with water, diluted NH<sub>4</sub>OH (sat. aq), and brine and concentrated under reduced pressure. The residue was purified by silica gel chromatography (10% EtOAc in petroleum ether) to give 6-(benzyloxy)-2-bromo-4-methoxybenzo[<i>d</i>]thiazole (8.0 g, 30%) as a gray-white solid. LC-MS (ES+) C<sub>15</sub>H<sub>12</sub>BrNO<sub>2</sub>S requires 349, found: 350 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.51–7.29 (m, 5H), 6.88 (d, <i>J</i> = 2.2 Hz, 1H), 6.61 (d, <i>J</i> = 2.2 Hz, 1H), 5.09 (s, 2H), 3.98 (s, 3H).</div></div><div id="sec5_1_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Step 5: (1<i>R</i>,2<i>R</i>)-2-(6-(Benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 6-(benzyloxy)-2-bromo-4-methoxybenzo[<i>d</i>]thiazole (3.50 g, 10.0 mmol), (1<i>R</i>, 2<i>R</i>)-2-aminocyclohexanol (3.45 g, 30.0 mmol), and DIPEA (5.16 g, 40.0 mmol) in DMF (10 mmol) was heated at 110 °C for 48 h. The reaction was cooled to rt, diluted with water (30 mL), and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed by water (100 mL), brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give (1<i>R</i>,2<i>R</i>)-2-(6-(benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (3.8 g, 100%, crude) as a brown solid. MS (ES+) C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>S requires 384, found: 385 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Step 6: 2-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">A solution of (1<i>R</i>,2<i>R</i>)-2-(6-(benzyloxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (1152 mg, 3.0 mmol) in TFA (10 mL) was heated at 65 °C for 48 h. The solvent was removed, the reaction mixture was diluted slowly by sat. NaHCO<sub>3</sub>, and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol (882 mg, 100%, crude) as a brown solid. MS (ES+) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S requires 294, found: 295 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Step 7: 2-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">A mixture of 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (example 1, step 3; 202 mg, 0.68 mmol), 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol (200 mg, 0.68 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (443 mg, 1.36 mmol) in DMF (2 mL) was stirred at 80 °C for 3 h. The mixture was diluted by water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give (1<i>R</i>,2<i>R</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (300 mg, 79%, crude) as a brown solid. MS (ES+) C<sub>28</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>4</sub>S requires 554, found: 555 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Step 8: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>R</i>,2<i>R</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (300 mg, 0.54 mmol) in TFA (2 mL) was stirred at rt for 8 h. The volatiles were removed under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to give (1<i>R</i>,2<i>R</i>)-2-(6-((2-amino-3-chloropyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (19 mg, 8%) as a white solid. MS (ES+) C<sub>20</sub>H<sub>23</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 434, found: 435 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (s, 1H), 7.95 (d, <i>J</i> = 5.4 Hz, 1H), 7.04 (s, 1H), 6.85 (d, <i>J</i> = 5.5 Hz, 1H), 6.69 (s, 1H), 5.14 (s, 2H), 3.88 (s, 3H), 3.60 (d, <i>J</i> = 11.0 Hz, 1H), 3.32 (dd, <i>J</i> = 17.5, 11.8 Hz, 1H), 2.01 (d, <i>J</i> = 13.0 Hz, 1H), 1.89 (d, <i>J</i> = 8.9 Hz, 1H), 1.70–1.56 (m, 2H), 1.42–0.92 (m, 4H).</div></div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>16</b>)</h4><div id="sec5_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Step 1: 6-Bromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">To a solution of 4-bromo-2-(trifluoromethoxy)aniline (5.9 g, 23.1 mmol) in AcOH (100 mL) was added KSCN (8.97 g, 92.5 mmol). After stirring for 30 min at rt, the reaction mixture was cooled to 0 °C, and a solution of Br<sub>2</sub> (5.5 g, 34.6 mmol) in AcOH was added dropwise. The reaction mixture was stirred for 4 h at rt. Subsequently, the pH of the reaction mixture was adjusted to 7 with NH<sub>3</sub>–H<sub>2</sub>O. The mixture was extracted with EtOAc (3 × 80 mL), the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (PE/THF = 10:1) to give the title compound (0.9 g, 12.5%) MS (ES+) C<sub>8</sub>H<sub>4</sub>BrF<sub>3</sub>N<sub>2</sub>OS requires 312, found: 313 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step 2: 2,6-Dibromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazole</h5><div class="NLM_p last">A solution of 6-bromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-amine (900 mg, 3 mmol) in MeCN (20 mL) was cooled to −5 °C, and CuBr<sub>2</sub> (0.83 g, 3.6 mmol) and <i>t</i>-BuONO (0.37 mg, 3.6 mmol) were added dropwise. The reaction mixture was stirred at 0–5 °C for 30 min, and then it was heated to 40 °C and stirred for 6 h. The insoluble was filtered off, and the filtrate was washed with 1 N HCl solution, the resultant solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the product (0.6 g, 53%). MS (ESI+) C<sub>8</sub>H<sub>2</sub>Br<sub>2</sub>F<sub>3</sub>NOS requires 375, found: 376 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Step 3: (1<i>R</i>,2<i>R</i>)-2-(6-Bromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 2,6-dibromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazole (980 mg, 2.61 mmol), (1<i>R</i>,2<i>R</i>)-2-aminocyclohexanol (901 mg, 7.83 mmol), and DIPEA (1 g, 7.83 mmol) in DMA (10 mL) was heated to 100 °C for 16 h. Saturated NH<sub>4</sub>Cl solution (8 mL) was added, and the reaction mixture was extracted with EtOAc (3 × 5 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (25% EtOAc in petroleum ether) to give the product (836 mg, 78%) as a white solid. MS (ESI+) C<sub>14</sub>H<sub>14</sub>BrF<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S requires 410, found: 411 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step 4: (1<i>R</i>,2<i>R</i>)-2-(6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>R</i>,2<i>R</i>)-2-(6-bromo-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (600 mg, 1.463 mmol), B<sub>2</sub>Pin<sub>2</sub> (446 mg, 1.75 mmol), KOAc (286 mg, 2.92 mmol), and Pd(dppf)Cl<sub>2</sub> (107 mg, 0.15 mmol) in 1,4-dioxane (20 mL) was heated to 100 °C and stirred for 16 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to provide the residue that was used in the next step without further purification (671 mg, 100%). MS (ESI+) C<sub>20</sub>H<sub>26</sub>BF<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S requires 458, found: 459 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step 5: 2-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexylamino)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>)-2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (700 mg, 1.53 mmol) in dioxane (5 mL) was added H<sub>2</sub>O<sub>2</sub> (5 mL), and the reaction mixture was stirred for 2 h at rt. The solvent was evaporated, and the residue was taken up in EtOAc (5 mL)/water (4 mL). The crude product was extracted with EtOAc (3 × 5 mL), the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (25% EtOAc in petroleum ether) to provide the product (320 mg, 60%) as an oil. MS (ESI+) C<sub>14</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S requires 348, found: 349 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Step 6: (1<i>R</i>,2<i>R</i>)-2-(6-((3-Chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-6-ol (150 mg, 0.43 mmol), 3-chloro-4-(chloromethyl)-<i>N</i>-(4-methoxybenzyl)pyridin-2-amine (153 mg, 0.517 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (421 mg, 1.29 mmol) in DMF (3 mL) was stirred at 80 °C for 16 h. The volatiles were removed under reduced pressure, and the residue was purified by column chromatography (70% EtOAc in pet. ether) to provide the product (70 mg, 27%) as an oil. MS (ESI+) C<sub>28</sub>H<sub>28</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S requires 608, found: 609 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step 7: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>)-2-(6-((3-chloro-2-(4-methoxybenzylamino)pyridin-4-yl)methoxy)-4-(trifluoromethoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (70 mg, 0.115 mmol) in DCM (3 mL) was added TFA (3 mL), and then the reaction mixture was stirred at rt for 16 h. The solvent was evaporated, and 2 N NaOH was added until the pH was adjusted to >7. The mixture was stirred for 1 h, and the crude product was extracted with EtOAc (3 × 3 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (90% EtOAc in petroleum ether) to give the title compound (2.5 mg, 4.5%) as a white solid. MS (ES+) C<sub>20</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S requires 488, found: 489.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8 8.14 (d, <i>J</i> = 6.5 Hz, 1H), 7.91 (d, <i>J</i> = 5 Hz, 1H), 7.49 (d, <i>J</i> = 2.5 Hz, 1H), 6.94 (s, 1H), 6.74 (d, <i>J</i> = 4.5 Hz, 1H), 6.35 (s, 2H), 5.11 (s, 2H), 4.80 (d, <i>J</i> = 4.5 Hz, 1H), 3.34–3.40 (m, 1H), 2.04–2.06 (m, 1H), 1.87–1.90 (m, 1H), 1.62–1.64 (m, 2H), 1.24–1.30 (m, 4H).</div></div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-chlorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>17</b>)</h4><div id="sec5_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step 1: 4-Chloro-6-methoxybenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">To a solution of 2-chloro-4-methoxyaniline (1.6 g, 10 mmol) in AcOH (20 mL) were added KSCN (3.95 g, 40.76 mmol) and CuBr<sub>2</sub> (2.6, 11.9 mmol); the reaction mixture was cooled to 0 °C. Br<sub>2</sub> (1.95 g, 12.2 mmol) was added dropwise, and the reaction mixture was stirred for 4 h at rt. The pH of the mixture was adjusted to 7 with NH<sub>4</sub>OH (sat. aq) solution. The mixture was extracted with EtOAc (3 × 50 mL), the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc in petroleum ether) to provide 4-chloro-6-methoxybenzo[<i>d</i>]thiazol-2-amine (1.7 g, 78%). MS (ES+) C<sub>8</sub>H<sub>7</sub>ClN<sub>2</sub>OS requires 214, found: 215 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.596 (s, 2H), 7.311(s, 1H), 6.925 (s, 1H), 3.749 (s, 3H).</div></div><div id="sec5_1_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step 2: 2-Bromo-4-chloro-6-methoxybenzo[<i>d</i>]thiazole</h5><div class="NLM_p last">A solution of 4-chloro-6-methoxybenzo[<i>d</i>]thiazol-2-amine (2.1 g, 7.9 mmol) in MeCN (40 mL) was cooled to −5 °C, and <i>t</i>-BuONO (1.23 g, 11.9 mmol) was added dropwise. The mixture was stirred at 0 °C for 30 min and subsequently heated to 40 °C and stirred for 6 h. The mixture was filtered, and the filtrate was washed with 1 N HCl solution. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide the crude product (1.25 g, 46%) that was used in the next step without further purification. MS (ESI+) C<sub>8</sub>H<sub>5</sub>BrClNOS requires 277, found: 278 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Steps 3–7: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-chlorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">As described for compound <b>12</b>. (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-chlorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol. MS (ES+) C<sub>19</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S requires 438, found: 439 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06 (d, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 5 Hz, 1H), 7.40 (d, <i>J</i> = 2.5 Hz, 1H), 7.02 (d, <i>J</i> = 2.5 Hz, 1H), 6.72 (d, <i>J</i> = 5 Hz, 1H), 6.53 (s, 2H), 5.10 (s, 2H), 4.81 (d, <i>J</i> = 5 Hz, 1H), 3.36–3.52 (m, 1H), 1.99–2.02 (m, 1H), 1.87–1.89 (m, 1H), 1.62–1.64 (m, 2H), 1.15–1.31 (m, 4H).</div></div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-4-fluorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>18</b>)</h4><div class="NLM_p last">(1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl) methoxy)-4-fluorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol was prepared as described for compound <b>17</b>. MS (ES+) C<sub>19</sub>H<sub>20</sub>ClFN<sub>4</sub>O<sub>2</sub>S requires 422, found: 423 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.957 (d, <i>J</i> = 7.5 Hz, 1H), 7.910 (d, <i>J</i> = 5 Hz, 1H), 7.251 (d, <i>J</i> = 2 Hz, 1H), 7.864 (dd, <i>J</i><sub>1</sub> = 2 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1H), 6.725 (d, <i>J</i> = 4.5 Hz, 1H), 6.350 (s, 1H), 5.087 (s, 2H), 4.761 (d, J = 5 Hz, 1H), 3.514–3.526 (m, 1H), 2.041–2.065 (m, 1H), 1.874–1.897 (m, 1H), 1.616–1.657 (m, 2H), 1.182–1.309 (m, 4H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-7-chlorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>19</b>)</h4><div class="NLM_p last">(1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-7-chlorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol was prepared as described for compound <b>17</b>. MS (ES+) C<sub>19</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S requires 438, found: 439 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03 (d, <i>J</i> = 12.5 Hz, 1H), 7.93 (d, <i>J</i> = 5 Hz, 1H), 7.27 (d, <i>J</i> = 8.5 Hz, 1H), 7.07 (d, <i>J</i> = 8.5 Hz, 1H), 6.77 (d, <i>J</i> = 5 Hz, 1H), 6.37 (s, 2H), 5.18 (s, 2H), 4.77 (d, <i>J</i> = 5 Hz, 1H), 3.48–3.50 (m, 1H), 2.04–2.07 (m, 1H), 1.88–1.90 (m, 1H), 1.61–1.65 (m, 2H), 1.18–1.30 (m, 4H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-7-fluorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>20</b>)</h4><div class="NLM_p last">(1<i>R</i>,2<i>R</i>)-2-(6-((2-Amino-3-chloropyridin-4-yl)methoxy)-7-fluorobenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol was prepared as described for compound <b>17</b>. MS (ES+) C<sub>19</sub>H<sub>20</sub>ClFN<sub>4</sub>O<sub>2</sub>S requires 422, found: 423.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.07 (d, <i>J</i> = 7.5 Hz, 1H), 7.91 (d, <i>J</i> = 5 Hz, 1H), 7.06–7.14 (m, 2H), 6.73 (d, <i>J</i> = 5 Hz, 1H), 6.36 (s, 2H), 5.16 (s, 2H), 4.77 (d, <i>J</i> = 5 Hz, 1H), 3.49–3.51 (m, 1H), 2.05–2.07 (m, 1H), 1.88–1.90 (m, 1H), 1.61–1.65 (m, 2H), 1.18–1.30 (m, 4H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Synthesis of <i>N</i>-Cyclohexyl-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>4</b>)</h4><div id="sec5_1_16_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Step 1: (2-Bromobenzo[<i>d</i>]thiazol-6-yl)methanol</h5><div class="NLM_p last">To a solution of ethyl 2-bromobenzo[<i>d</i>]thiazole-6-carboxylate (1.2 g, 4.2 mmol) in THF (20 mL), at 0 °C, DIBAL-H (10.5 mL, 10.5 mmol, 1 M in toluene) was added slowly. The reaction mixture was stirred at rt for 4 h. The mixture was quenched with water (15 mL), filtered, and the filtrate was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure to provide (2-bromobenzo[<i>d</i>]thiazol-6-yl)methanol (1.0 g, 98%) as a yellow solid. MS (ES+) C<sub>8</sub>H<sub>6</sub>BrNOS requires 244, found: 244, 246 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Step 2: (2-(Methylthio)benzo[<i>d</i>]thiazol-6-yl)methanol</h5><div class="NLM_p last">A mixture of (2-bromobenzo[<i>d</i>]thiazol-6-yl)methanol (1.0 g, 4.0 mmol) and CH<sub>3</sub>SNa (560 mg, 8 mmol) in DMF (15 mL) was stirred at rt for 16 h. The reaction mixture was diluted with water and extracted with EtOAs (3 × 30 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EtOAc in PE 20–45%) to afford (2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methanol (598 mg, 71%) as a beige solid. MS (ES+) C<sub>9</sub>H<sub>9</sub>NOS<sub>2</sub> requires 211, found: 212 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Step 3: 6-(Chloromethyl)-2-(methylthio)benzo[<i>d</i>]thiazole</h5><div class="NLM_p last">MsCl (572 mg, 5 mmol) was added to a solution of (2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methanol (350 mg, 1.66 mmol) and DIPEA (642 mg, 5 mmol) in DCM (10 mL) at 0 °C. The mixture was treated with three drops of DMF and stirred at rt for 16 h. NaHCO<sub>3</sub> (sat. aq, 15 mL) was added, and the aqueous phase was extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to provide 6-(chloromethyl)-2-(methylthio)benzo[<i>d</i>]thiazole (380 mg, quant.) as a beige solid. MS (ES+) C<sub>9</sub>H<sub>8</sub>ClNS<sub>2</sub> requires 229, found: 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Step 4: 2-(Methylthio)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole</h5><div class="NLM_p last">A solution of pyridine 3-ol (123 mg, 1.29 mmol) in DMA (1 mL) was added to a mixture of <i>t</i>-BuOK (171 mg, 1.5 mmol) in DMA (2 mL). It was stirred at rt for 1 h and subsequently heated to 100 °C for 1 h. A solution of 6-(chloromethyl)-2-(methylthio)benzo[<i>d</i>]thiazole (229 mg, 1 mmol) in DMA (1 mL) was added. The mixture was stirred for 2 h. The reaction mixture was cooled to rt; it was diluted with water and extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to provide 2-(methylthio)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole (288 mg, quant.). The product was used in the next step without further purification. MS (ES+) C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>OS<sub>2</sub> requires 288, found: 289 [M + H]+.</div></div><div id="sec5_1_16_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Step 5: 2-(Methylsulfinyl)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole</h5><div class="NLM_p last">To a solution of 2-(methylthio)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole (288 mg, 1 mmol, crude) in DCM (3 mL) was added <i>m</i>-CPBA (202 mg, 1 mmol, 85%). The reaction mixture was stirred at rt for 2 h. The reaction was quenched with Na<sub>2</sub>CO<sub>3</sub> (sat. aq, 5 mL), extracted with DCM (3 × 15 mL), and the combined organic phases were dried over MgSO<sub>4</sub> and concentrated under reduced pressure to provide 2-(methylsulfinyl)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole (304 mg crude, 100%). MS (ES+) C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> requires 304, found: 305 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Step 6: <i>N</i>-Cyclohexyl-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p">A mixture of 2-(methylsulfinyl)-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazole (50 mg, 0.16 mmol) in cyclohexanamine (0.5 mL) was stirred at 100 °C for 2 h. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to provide the product (10 mg, 18%).</div><div class="NLM_p last">MS (ES+) C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS requires 339, found: 340 [M + H]<sup>+</sup>; MS (ES+) C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS requires 339, found: 340 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.32 (d, <i>J</i> = 2.9 Hz, 1H), 8.14 (dd, <i>J</i> = 4.7, 0.6 Hz, 1H), 7.70 (d, <i>J</i> = 1.0 Hz, 1H), 7.52 (ddd, <i>J</i> = 8.5, 2.7, 0.8 Hz, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.40–7.34 (m, 2H), 5.20 (s, 2H), 3.78–3.71 (m, 1H), 2.14–2.07 (m, 2H), 1.86–1.80 (m, 2H), 1.73–1.67 (m, 1H), 1.52–1.42 (m, 2H), 1.39–1.26 (m, 3H).</div></div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Synthesis of <i>N</i>-Cyclohexyl-6-((pyridin-4-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>5</b>)</h4><div class="NLM_p"><i>N</i>-Cyclohexyl-6-((pyridin-4-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine (5) was prepared as described for <i>N</i>-cyclohexyl-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine (4).</div><div class="NLM_p last">MS (ES+) C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>OS requires 339, found: 340 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.02 (d, <i>J</i> = 7.5 Hz, 1H), 7.79–7.71 (m, 2H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.19 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 6.11–6.04 (m, 2H), 5.02 (s, 2H), 3.71–3.66 (m, 1H), 1.99–1.91 (m, 2H), 1.75–1.67 (m, 2H), 1.61–1.53 (m, 1H), 1.36–1.15 (m, 5H).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Synthesis of <i>N</i>-Cyclohexyl-6-((pyridin-3-ylamino)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>6</b>)</h4><div id="sec5_1_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Step 1: 6-(Azidomethyl)-2-(methylthio)benzo[<i>d</i>]thiazole</h5><div class="NLM_p last">To a solution of (2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methanol (100 mg, 0.473 mmol) in THF (1578 μL) at 0 °C were added diphenyl phosphorazidate (122 μL, 0.568 mmol) and DBU (86 μL, 0.57 mmol), and the resulting mixture was stirred at rt for 3 h. The volatiles were removed under reduced pressure, and the residue was purified via silica gel chromatography (0–100% EtOAc in hexanes) to provide 6-(azidomethyl)-2-(methylthio)benzo[<i>d</i>]thiazole (103 mg, 92% yield) as a colorless liquid that solidified overnight. MS (ES+) C<sub>9</sub>H<sub>8</sub>N<sub>4</sub>S<sub>2</sub> requires 236, found: NA.</div></div><div id="sec5_1_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Step 2: (2-(Methylthio)benzo[<i>d</i>]thiazol-6-yl)methanamine</h5><div class="NLM_p last">A reaction vessel was charged with 6-(azidomethyl)-2-(methylthio)benzo[<i>d</i>]thiazole (73 mg, 0.309 mmol), Lindlar’s catalyst (66 mg, 0.031 mmol), and EtOH (3 mL) under an atmosphere of N<sub>2</sub>. The suspension was degassed with N<sub>2</sub> for 5 min and purged with H<sub>2</sub> for 5 min. The reaction mixture was stirred under an atmosphere of H<sub>2</sub> at 1 atm for 2 h. The reaction mixture was purged with N<sub>2</sub>, filtered through celite, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0–10% MeOH in DCM w/0.1% NH<sub>4</sub>OH) to provide (2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methanamine (70 mg, 81% yield) as a yellow liquid. MS (ES+) C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>S<sub>2</sub> requires 210, found: 211 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Step 3: <i>N</i>-((2-(Methylthio)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine</h5><div class="NLM_p last">To a suspension of 3-iodopyridine (49 mg, 0.24 mmol) and (2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methanamine (50 mg, 0.24 mmol) in DMSO-<i>d</i><sub>6</sub> (475 μL) were added Cu (1.5 mg, 0.024 mmol) and CsOAc (91 mg, 0.47 mmol), and the resulting mixture was stirred at 90 °C for 7 h. The reaction was diluted with MeOH (1 mL), and TFA was added. The mixture was filtered, the solvent was removed under reduced pressure, and the residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–90%; 12 min; column: C18) to provide <i>N</i>-((2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine (53 mg, 78% yield) as a brown amorphous material. MS (ES+) C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>S<sub>2</sub> requires 287, found: 288 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Step 4: <i>N</i>-((2-(Methylsulfinyl)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine</h5><div class="NLM_p last">To a suspension of <i>N</i>-((2-(methylthio)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine (50 mg, 0.17 mmol) in DCM (1.7 mL) at 0 °C was added <i>m</i>-CPBA (43 mg, 0.17 mmol) in DCM (0.5 mL) in portions, and the resulting mixture was stirred at 0 °C for 1 h. The solution was diluted with NaHCO<sub>3</sub> (sat. aq, 2 mL) and extracted with DCM (3 × 1 mL). The volatiles were removed under reduced pressure to provide <i>N</i>-((2-(methylsulfinyl)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine (53 mg, 100% yield) as a brown amorphous material. MS (ES+) C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>OS<sub>2</sub> requires 303, found: 304 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Step 5: <i>N</i>-Cyclohexyl-6-((pyridin-3-ylamino)methyl)benzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A microwave vial was charged with a solution of <i>N</i>-((2-(methylsulfinyl)benzo[<i>d</i>]thiazol-6-yl)methyl)pyridin-3-amine (21 mg, 0.069 mmol) in DMA (277 μL) and cyclohexanamine (23 μL, 0.21 mmol), and Hunig’s base (12 μL, 0.069 mmol) was added. The resulting mixture was stirred at 120 °C for 24 h. The mixture was diluted with MeOH, acidified with TFA, and the residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–90%; 12 min; column: C18) to provide <i>N</i>-cyclohexyl-6-((pyridin-3-ylamino)methyl)benzo[<i>d</i>]thiazol-2-amine (2 mg, 8.54% yield) as a pale yellow amorphous material. MS (ES+) C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>S requires 338, found: 339 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (brs, 1H), 8.06 (d, <i>J</i> = 5.0 Hz, 1H), 8.03 (d, <i>J</i> = 5.0 Hz, 1H), 7.92 (s, 1H), 7.70 (m, 3H), 7.37 (d, <i>J</i> = 10.0 Hz, 1H), 7.24 (d, <i>J</i> = 5.0 Hz, 1H), 4.4 (s, 2H), 3.7(m, 1H), 1.71–1.76 (m, 4H), 1.25–1.4 (m, 6H).</div></div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Synthesis of <i>N</i>-Cyclohexyl-6-((pyridin-4-ylamino)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>7</b>)</h4><div class="NLM_p"><i>N</i>-cyclohexyl-6-((pyridin-4-ylamino)methyl)benzo[<i>d</i>]thiazol-2-amine was prepared as described for <i>N</i>-cyclohexyl-6-((pyridin-3-yloxy)methyl)benzo[<i>d</i>]thiazol-2-amine (6).</div><div class="NLM_p last">MS (ES+) C<sub>19</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S, requires 401, found: 402 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.27 (d, <i>J</i> = 5.2 Hz, 1H), 6.86 (d, <i>J</i> = 5.1 Hz, 1H), 6.83 (d, <i>J</i> = 2.3 Hz, 1H), 6.63 (d, <i>J</i> = 2.2 Hz, 1H), 4.97 (s, 2H), 3.94 (s, 3H), 3.66–3.54 (m, 1H), 3.46–3.37 (m, 1H), 2.20–2.10 (m, 1H), 2.07–2.00 (m, 1H), 1.80–1.71 (m, 2H), 1.44–1.31 (m, 4H).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Aminopyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>21</b>)</h4><div id="sec5_1_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Step 1: 2-Chloro-4-(chloromethyl)pyrimidine</h5><div class="NLM_p last">To a solution of 2-chloro-4-methylpyrimidine (5.0 g, 39 mmol) in CCl<sub>4</sub> (100 mL) were added NCS (7.8 g, 58 mmol) and AIBN (0.64 g, 3.9 mmol), and the resulting mixture was heated at reflux for 18 h. The reaction mixture was allowed to cool to rt. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (10–40% EtOAc in hexanes) to give 2-chloro-4-(chloromethyl)pyrimidine (3.1 g, 49%) as a clear oil. MS (ES+) C<sub>5</sub>H<sub>4</sub>Cl<sub>2</sub>N<sub>2</sub> requires 162, found: 163 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Step 2: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol (40 mg, 0.14 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (116 mg, 0.36 mmol) in DMF (2 mL) was stirred at rt for 1 h. 2-Chloro-4-(chloromethyl)pyrimidine (30 mg, 0.19 mmol) was added, and the mixture was stirred at rt for 4 h. The mixture was diluted with water, extracted with EtOAc (3 × 30 mL), the combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to provide the product (38 mg, 67%) as a brown solid. MS (ES+) C<sub>19</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>3</sub>S, requires 421, found: 421, 423 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step 3: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Aminopyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>R</i>,2<i>R</i>)-2-(6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (38 mg, 0.095 mmol) in NH<sub>4</sub>OH (sat. aq) solution was stirred at 90 °C for 3 h in a sealed tube. The mixture was cooled to rt, concentrated, and purified by prep-HPLC (NH<sub>4</sub>HCO<sub>3</sub>) to provide the product (3 mg, 8%) as a beige solid. MS (ES+) C<sub>19</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S, requires 401, found: 402 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.27 (d, <i>J</i> = 5.2 Hz, 1H), 6.86 (d, <i>J</i> = 5.1 Hz, 1H), 6.83 (d, <i>J</i> = 2.3 Hz, 1H), 6.63 (d, <i>J</i> = 2.2 Hz, 1H), 4.97 (s, 2H), 3.94 (s, 3H), 3.66–3.54 (m, 1H), 3.46–3.37 (m, 1H), 2.20–2.10 (m, 1H), 2.07–2.00 (m, 1H), 1.80–1.71 (m, 2H), 1.44–1.31 (m, 4H).</div></div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((6-((2-Aminopyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>22</b>)</h4><div id="sec5_1_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> Step 1: 2-Chloro-4-((3-methoxy-4-nitrophenoxy)methyl)pyrimidine</h5><div class="NLM_p last">To a solution of 3-methoxy-4-nitrophenol (2.83 g, 16.7 mmol) and 2-chloro-4-(chloromethyl)pyrimidine (3.0 g, 18 mmol) in DMF (16 mL) was added K<sub>2</sub>CO<sub>3</sub> (2.8 g, 20 mmol), and the resulting mixture was stirred at rt for 20 h. Ice cold water (30 mL) was added, and the mixture was stirred for 10 min before filtering on a Buchner funnel. The solid was washed with cold water (10 mL) and dried under vacuum for 2 h to give 2-chloro-4-((3-methoxy-4-nitrophenoxy)methyl)pyrimidine (4.6 g, 93%) as a light brown solid. MS (ES+) C<sub>12</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>4</sub> requires 295, found: 296 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step 2: 4-((2-Chloropyrimidin-4-yl)methoxy)-2-methoxyaniline</h5><div class="NLM_p last">A reaction vessel was charged with 2-chloro-4-((3-methoxy-4-nitrophenoxy)methyl)pyrimidine (4.6 g, 16 mmol), 10% Pt–C (460 mg, 0.12 mmol), and THF–MeOH (5:1, 60 mL). The suspension was degassed with N<sub>2</sub> for 3 min and purged with H<sub>2</sub> for 3 min. The reaction mixture was stirred under an atmosphere of H<sub>2</sub> at 1 atm for 2 h. The reaction mixture was purged with N<sub>2</sub>, filtered through celite, and concentrated under reduced pressure to give 4-((2-chloropyrimidin-4-yl)methoxy)-2-methoxyaniline (4.0 g, 97%) as a light yellow powder. MS (ES+) C<sub>12</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub> requires 265, found: 266 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> Step 3: 1-(4-((2-Chloropyrimidin-4-yl)methoxy)-2-methoxyphenyl)-3-((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexyl)thiourea</h5><div class="NLM_p last">To a solution of 4-((2-chloropyrimidin-4-yl)methoxy)-2-methoxyaniline (4.0 g, 15 mmol) in DCM (200 mL) was added di(1<i>H</i>-imidazol-1-yl)methanethione (3.2 g, 18 mmol), and the resulting mixture was stirred at rt for 4 h. (1<i>S</i>,2<i>S</i>)-2-Aminocyclohexanol (3.5 g, 30 mmol) was added, and the resulting mixture was stirred at rt for 3 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (25–100% EtOAc in hexanes) to give 1-(4-((2-chloropyrimidin-4-yl)methoxy)-2-methoxyphenyl)-3-((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexyl)thiourea (6.1 g, 96%) as a white solid. MS (ES+) C<sub>19</sub>H<sub>23</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 422, found: 423 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> Step 4: (1<i>S</i>,2<i>S</i>)-2-((6-((2-Chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p last">To a solution of 1-(4-((2-chloropyrimidin-4-yl)methoxy)-2-methoxyphenyl)-3-((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexyl)thiourea (1.0 g, 2.3 mmol) in DCM (100 mL) was added BSTFA (1.3 mL, 4.7 mmol), and the resulting solution was stirred for 5 min. Solid benzyltrimethylammonium tribromide (0.92 g, 2.3 mmol) was added to the previous reaction mixture. After 20 min, sat. NaHCO<sub>3</sub> (30 mL) was added, and the reaction mixture was stirred for 5 min. The biphasic mixture was transferred to a separatory funnel with an additional 20 mL of DCM, and the layers were separated. The organic layers were washed with saturated aq NaHCO<sub>3</sub> (30 mL), followed by 10% aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1 × 20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was triturated with 1:2 ether/hexanes (30 mL), and the resulting solid was filtered through a Buchner funnel. After rinsing with 1:1 ether/hexanes (10 mL), (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol was collected as an off-white powder (945 mg, 95%). MS (ES+) C<sub>19</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>3</sub>S requires 420, found: 421 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Step 5: (1<i>S</i>,2<i>S</i>)-2-((6-((2-Aminopyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p last">A microwave vial was charged with (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (300 mg, 0.71 mmol) and NH<sub>3</sub> (7 M in MeOH, 2.0 mL). The vial was sealed, and the reaction mixture was heated to 120 °C in the microwave reactor for 4 h. The volatiles were removed under reduced pressure. The residue was purified by reverse phase preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–90%; 20 min; column: C18) to give (1<i>S</i>,2<i>S</i>)-2-((6-((2-aminopyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol as a TFA salt (182 mg, 64%) as an off-white powder. MS (ES+) C<sub>19</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S requires 401, found: 402 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 6.5 Hz, 1H), 6.86 (d, <i>J</i> = 5.2 Hz, 1H), 6.83 (d, <i>J</i> = 2.4 Hz, 1H), 6.62 (d, <i>J</i> = 2.0 Hz, 1H), 4.90 (s, 2H), 3.93 (s, 3H), 3.59 (m, 1H), 3.40 (m, 1H), 2.14 (m, 1H), 2.02 (m, 1H), 1.76 (m, 2H), 1.43–1.28 (m, 4H).</div></div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((6-((2-Aminopyrimidin-4-yl)methoxy)-7-chloro-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>23</b>)</h4><div id="sec5_1_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> Step 1: 2-Chloro-5-methoxy-4-nitrophenol</h5><div class="NLM_p last">To a solution of 3-methoxy-4-nitrophenol (1.0 g, 5.9 mmol) at 0 °C was added NCS (0.868 g, 6.50 mmol), and the resulting mixture was stirred at 50 °C for 2 h. The reaction mixture was diluted with EtOAc (20 mL) and washed with water (2 × 20 mL). The layers were separated, and the organic layer was washed with sat. NaCl (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide 2-chloro-5-methoxy-4-nitrophenol (1.2 g, ∼100%) as a yellow solid. MS (ES+) C<sub>7</sub>H<sub>6</sub>ClNO<sub>4</sub> requires 203, found: 204 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Steps 2–6: As Described for Compound 22</h5><div class="NLM_p last">MS (ES+) C<sub>19</sub>H<sub>22</sub>ClN<sub>5</sub>O<span class="strike">3</span>S requires 435, found: 436 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 5.0 Hz, 1H), 7.89 (d, <i>J</i> = 7.7 Hz, 1H), 6.79 (s, 1H), 6.74 (d, <i>J</i> = 4.9 Hz, 1H), 6.67 (s, 2H), 5.04 (s, 2H), 4.75 (d, <i>J</i> = 5.1 Hz, 1H), 3.85 (s, 3H), 3.53–3.46 (m, 1H), 3.36–3.32 (m, 1H), 2.09–1.99 (m, 1H), 1.92–1.84 (m, 1H), 1.69–1.56 (m, 2H), 1.31–1.16 (m, 4H).</div></div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Synthesis of (1<i>R</i>,2<i>R</i>)-2-(6-((2-Aminopyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>24</b>)</h4><div id="sec5_1_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> Step 1: <i>tert</i>-Butyl 4-((2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-yloxy)methyl)pyridin-2-ylcarbamate</h5><div class="NLM_p last">A solution of 2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol (100 mg, 0.34 mmol) <i>tert</i>-butyl 4-(chloromethyl)pyridin-2-ylcarbamate (83 mg, 0.34 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (333 mg, 1.02 mmol) in DMF (2 mL) was stirred at 80 °C for 2 h. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with water (10 mL) and brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide <i>tert</i>-butyl 4-((2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-yloxy)methyl)pyridin-2-ylcarbamate (30 mg, 17%) as a yellow solid. MS (ES+) C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>5</sub>S requires 500, found: 501 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> Step 2: (1<i>R</i>,2<i>R</i>)-2-(6-((2-Aminopyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl 4-((2-((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-yloxy)methyl)pyridin-2-ylcarbamate (30 mg, 0.06 mmol) in TFA (1 mL) was stirred at rt for 16 h. The volatiles were removed under reduced pressure, and the residue was purified by prep-HPLC to provide (1<i>R</i>,2<i>R</i>)-2-(6-((2-aminopyridin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (8.6 mg, 35%) as a white solid. MS (ES+) C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> requires 400, found: 401 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.87 (d, <i>J</i> = 5.2 Hz, 1H), 7.62 (d, <i>J</i> = 7.5 Hz, 1H), 6.90 (d, <i>J</i> = 2.3 Hz, 1H), 6.54–6.48 (m, 3H), 5.97 (s, 2H), 4.95 (s, 2H), 4.78 (d, <i>J</i> = 5.0 Hz, 1H), 3.82 (s, 3H), 3.55–3.47 (m, 1H), 2.07–2.01 (m, 1H), 1.91–1.84 (m, 1H), 1.63 (t, <i>J</i> = 13.1 Hz, 2H), 1.32–1.16 (m, 4H).</div></div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Synthesis of <i>N</i>-(4-(((2-(((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide (<b>25</b>)</h4><div id="sec5_1_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> Step 1: 2-Bromo-4-methoxybenzo[<i>d</i>]thiazol-6-ol</h5><div class="NLM_p last">A vial was charged with 6-(benzyloxy)-2-bromo-4-methoxybenzo[<i>d</i>]thiazole (0.80 g, 2.28 mmol) and TFA (1.76 mL, 22.8 mmol), and the suspension was stirred at 65 °C for 40 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0–100% EtOAc in hexanes); however, the product was contaminated with the starting material. The solid was triturated with DCM (2 × 5 mL), centrifuged, and the liquid was decanted. The remaining solid was dried to provide 2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-ol (142 mg, 0.546 mmol, 24% yield) as a white solid. MS (ES+) C<sub>8</sub>H<sub>6</sub>BrNO<sub>2</sub>S requires 259 found: 259.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> Step 2: <i>tert</i>-Butyl (4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)carbamate</h5><div class="NLM_p">To a suspension of <i>tert</i>-butyl (4-(hydroxymethyl)pyridin-2-yl)carbamate (133 mg, 0.592 mmol), 2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-ol (140 mg, 0.538 mmol), and Ph<sub>3</sub>P (198 mg, 0.754 mmol) in THF (2.6 mL) at 0 °C was added (<i>E</i>)-di-<i>tert</i>-butyl diazene-1,2-dicarboxylate (174 mg, 0.754 mmol), and the resulting mixture was stirred at rt for 16 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0–100% EtOAc in hexanes) to provide <i>tert</i>-butyl (4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)carbamate (233 mg, 0.350 mmol, 93% yield) as a pale yellow solid.</div><div class="NLM_p last">MS (ES+) C<sub>19</sub>H<sub>20</sub>BrN<sub>3</sub>O<sub>4</sub>S requires 465 found: 466 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> Step 3: <i>N</i>-(4-(((2-Bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide</h5><div class="NLM_p last">To a suspension of <i>tert</i>-butyl (4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)carbamate (233 mg, 0.50 mmol) in DCM (1 mL) at 0 °C was added TFA (962 μL, 12.5 mmol), and the resulting mixture was stirred at rt for 3 h. The residue was adsorbed onto celite and purified via flash chromatography (0–10% MeOH in DCM w/0.5% NH<sub>4</sub>OH) to provide 4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-amine (109 mg, 0.298 mmol, 60%) as a green amorphous material. MS (ES+) C<sub>14</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>2</sub>S requires 365 found: 366 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> Step 4: <i>N</i>-(4-(((2-Bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide</h5><div class="NLM_p">To a suspension of 4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-amine (69 mg, 0.19 mmol) and pyridine (76 μL, 0.942 mmol) in DMF (377 μL) was added Ac<sub>2</sub>O (89 μL, 0.94 mmol), and the resulting mixture was stirred at 60 °C for 1 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0–10% MeOH in DCM w/0.5% NH<sub>4</sub>OH) to provide <i>N</i>-(4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide (68 mg, 88%) as a green foam solid.</div><div class="NLM_p last">MS (ES+) C<sub>16</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>3</sub>S requires 407 found: 408 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> Step 5: <i>N</i>-(4-(((2-(((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide</h5><div class="NLM_p last">To a solution of <i>N</i>-(4-(((2-bromo-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide (68 mg, 0.17 mmol) and (1<i>R</i>,2<i>R</i>)-2-aminocyclohexanol (57 mg, 0.50 mmol) in DMA (555 μL) was added DIPEA (32 μL, 0.183 mmol), and the resulting mixture was stirred at 100 °C for 12 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0–10% MeOH in DCM w/0.5% NH<sub>4</sub>OH) to provide <i>N</i>-(4-(((2-(((1<i>R</i>,2<i>R</i>)-2-hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyridin-2-yl)acetamide (28 mg, 0.063 mmol, 38.0%) as an off-white solid. MS (ES+) C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O4<sub>S</sub> requires 442 found: 443 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (d, <i>J</i> = 6.0 Hz, 1H), 7.63 (s, 1H), 7.14 (d, <i>J</i> = 6.0 Hz, 1H), 6.94 (d, <i>J</i> = 6.0 Hz, 1H), 6.56 (s, 1H), 5.13 (s, 2H), 4.78 (s, 1H), 3.83 (s, 3H), 3.5 (m, 1H), 2.09 (s, 3H), 2.03 (m, 1H), 1.86 (m, 1H), 1.63 (m, 2H), 1.23 (m, 4H).</div></div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Synthesis of 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-Hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea (<b>26</b>)</h4><div id="sec5_1_25_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> Step 1: <i>N</i>-((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-Butyldimethylsilyl)oxy)cyclohexyl)-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">To a solution of (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (300 mg, 0.72 mmol) in DMF (2 mL) were added TBDMSCl (130 mg, 0.86 mmol) and imidazole (150 mg, 2.2 mmol), and the resulting mixture was stirred at rt for 12 h. The residue was purified via silica gel chromatography (10–50% EtOAc in hexanes) to provide <i>N</i>-((1S,2S)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (347 mg, 91% yield) as an off-white solid. MS (ES+) C<sub>25</sub>H<sub>35</sub>ClN<sub>4</sub>O<sub>3</sub>SSi requires 535, found: 536 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> Step 2: 6-((2-Aminopyrimidin-4-yl)methoxy)-<i>N</i>-((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)-4-methoxybenzo[<i>d</i>]thiazol-2-amine</h5><div class="NLM_p last">A microwave vial was charged with <i>N</i>-((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (300 mg, 0.56 mmol), and NH<sub>4</sub>OH (aq, 2 M) in 2-propanol (3 mL) was added. The vial was sealed, and the reaction mixture was heated to 120 °C in the microwave reactor for 8 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (20–70% EtOAc in hexanes) to provide 6-((2-aminopyrimidin-4-yl)methoxy)-<i>N</i>-((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (208 mg, 72%) as an off-white solid. MS (ES+) C<sub>25</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub>SSi requires 515, found: 516 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> Step 3: 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-Butyldimethylsilyl)oxy)cyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea</h5><div class="NLM_p last">To a solution of 6-((2-aminopyrimidin-4-yl)methoxy)-<i>N</i>-((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)-4-methoxybenzo[<i>d</i>]thiazol-2-amine (100 mg, 0.20 mmol) in DCM (5 mL) were added pyridine (33 μL, 0.39 mmol), DMAP (2 mg, 0.02 mmol), and phenylchloroformate (40 mg, 0.25 mmol). The resulting mixture was stirred at rt for 3 h. The reaction was quenched with MeNH<sub>2</sub> (0.2 mL, 1.4 mmol) (7 N in MeOH) and stirred for 16 h. The volatiles were removed under reduced pressure, and the residue was diluted with EtOAc (15 mL), and NaHCO<sub>3</sub> (aq 10 w/w%, 5 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (1 × 5 mL), the combined organic layers were washed with NaHCO<sub>3</sub> (aq 10 w/w%, 5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (20–80% EtOAc in hexane) to provide 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea (57 mg, 51%) as a yellow oil. MS (ES+) C<sub>27</sub>H<sub>40</sub>N<sub>6</sub>O<sub>4</sub>SSi requires 572, found: 573 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> Step 4: 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-Hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea</h5><div class="NLM_p last">To a solution of 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-((<i>tert</i>-butyldimethylsilyl)oxy)cyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea (50 mg, 0.087 mmol) in DCM (2 mL) was added TBAF (0.3 mL, 0.3 mmol), and the resulting mixture was stirred at rt for 12 h. The volatiles were removed under reduced pressure. The residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H2O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–50%; 20 min; column: C18) to provide 1-(4-(((2-(((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexyl)amino)-4-methoxybenzo[<i>d</i>]thiazol-6-yl)oxy)methyl)pyrimidin-2-yl)-3-methylurea (16 mg, 40%) as a white solid. MS (ES+) C<sub>21</sub>H<sub>26</sub>N<sub>6</sub>O<sub>4</sub>S requires 458.5, found: 459.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 8.64 (d, <i>J</i> = 5.4 Hz, 1H), 7.24 (d, <i>J</i> = 5.4 Hz, 1H), 7.18 (s, 1H), 7.1 (s, 1H),7.02 (m, 1H), 6.68 (s, 1H), 5.09 (s, 2H), 3.87 (s, 3H), 3.66 (s, 3H), 3.56 (m, 1H), 3.31–3.35 (m, 1H), 2.01 (m, 1H), 1.88 (m, 1H), 1.64 (m, 2H), 1.2–1.32 (m, 4H).</div></div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-(7-Chloro-4-methoxy-6-((2-(1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol IACS-9439 (<b>1</b>)</h4><div id="sec5_1_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> Step 1: (1<i>S</i>,2<i>S</i>)-2-((4-Methoxy-6-((2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p last">A microwave vial was charged with (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (550 mg, 1.31 mmol), 1-methyl-1<i>H</i>-pyrazol-4-amine (381 mg, 3.92 mmol), and DIPEA (456 μL, 2.61 mmol), and 2-propanol (5.2 mL) was added. The vial was sealed, and the reaction mixture was heated to 120 °C in the microwave reactor for 5 h. The volatiles were removed under reduced pressure. The residue was purified by reverse phase preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>OH/H<sub>2</sub>O, <i>B</i> = 0.1% NH<sub>4</sub>OH/MeCN; gradient: <i>B</i> = 10–90%; 20 min; column: C18) to provide the title compound (290 mg, 46%) as a light tan foam solid. HRMS (ES+) C<sub>23</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub>S<sup>+</sup> requires 482.1969, found: 482.1971 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (s, 1H), 8.41 (d, <i>J</i> = 3.6 Hz, 1H), 7.88 (s, 1H), 7.61 (d, <i>J</i> = 6.0 Hz, 2H), 7.47 (s, 1 H), 6.95 (s, 1H), 6.82–6.89 (d, <i>J</i> = 4.0, 1H), 6.59 (s, 1H), 5.0.5 (s, 2H), 4.76 (d, <i>J</i> = 4.0 Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.5 (m, 1H), 2.05 (m, 1H), 1.86 (m, 1H), 1.62 (m, 2H), 1.29–1.16 (m, 4H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.6,0 163.71, 159.18, 158.69, 153.44, 149.98, 136.38, 131.27, 129.77, 123.08, 120.45, 107,53, 98.11, 97.73, 71.49, 69.62, 59.26, 55.62, 39.92, 39.78, 39.64, 39.51, 39.37, 39.23, 39.09, 38.61, 30.59, 23.91, 23.51.</div></div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((4-Methoxy-6-((2-((1-methyl-1<i>H</i>-pyrazol-3-yl)amino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>27</b>)</h4><div id="sec5_1_27_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> Step 1: (1<i>S</i>,2<i>S</i>)-2-((4-Methoxy-6-((2-((1-methyl-1<i>H</i>-pyrazol-3-yl)amino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p last">A solution of (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (20 mg, 0.048 mmol), 1-methyl-1<i>H</i>-pyrazol-3-amine (46 mg, 0.47 mmol), and DIPEA (0.2 mL) in DMA (0.5 mL) was stirred at 110 °C for 18 h. The residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 10–50%; 20 min; column: C18) to provide (1<i>S</i>,2<i>S</i>)-2-((4-methoxy-6-((2-((1-methyl-1<i>H</i>-pyrazol-3-yl)amino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (3.5 mg, 15% yield) as a brown solid. MS (ES+) C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S requires 481, found: 482.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.4 (s, 1H), 7.48 (s, 1H), 7.02 (d, <i>J</i> = 5.4 Hz, 1H), 6.99 (s, 1H), 6.84 (s, 1H), 6.53 (s, 1H), 5.14 (s, 2H), 3.99 (s, 3H), 3.84 (s, 3H), 3.65 (m, 1H), 3.42–3.49 (m, 1H), 2.05–2.1 (m, 2H), 1.78 (m, 2H), 1.33–1.42 (m, 4H).</div></div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Synthesis of (1<i>S</i>,2<i>R</i>)-2-((6-((2-((1<i>H</i>-Pyrazol-4-yl)amino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (<b>28</b>)</h4><div id="sec5_1_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> Step 1: (1<i>S</i>,2<i>R</i>)-2-((6-((2-((1<i>H</i>-Pyrazol-4-yl)amino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">A microwave vial was charged with (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (25 mg, 0.06 mmol), 1<i>H</i>-pyrazol-4-amine (20 mg, 0.24 mmol), TEA (0.025 mL, 0.18 mmol), and DMSO-<i>d</i><sub>6</sub> (1.5 mL). The reaction mixture was heated to 120 °C in the microwave reactor for 2 h. The mixture was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 20–50%; 12 min; column: C18) to give (1<i>S</i>,2<i>R</i>)-2-((6-((2-((1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (12.2 mg, 0.026 mmol, 43.9% yield) as a gray solid. MS (ES+) C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S requires 467.5, found: 468.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.38 (brs, 1H), 8.15 (m, 2H), 7.0 (s, 1H), 6.92 (s, 1H), 6.86 (s, 1H), 5.13 (s, 2H), 3.99 (s, 3H), 3.60 (m, 1H), 3.47–3.50 (m, 1H), 2.05–2.09 (m, 2H), 1.79 (m, 2H), 1.32–1.48 (m, 4H).</div></div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (1<i>S</i>,2<i>S</i>)-2-(6-((2-(1<i>H</i>-Pyrazol-5-ylamino)pyrimidin-4-yl)methoxy)-4-methoxybenzo [<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>29</b>)</h4><div id="sec5_1_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> Step 1: (1<i>S</i>,2<i>S</i>)-2-(6-((2-(1<i>H</i>-Pyrazol-5-ylamino)pyrimidin-4-yl)methoxy)-4-methoxybenzo [d]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>S</i>,2<i>S</i>)-2-(6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (45 mg, 0.11 mmol), 1<i>H</i>-pyrazol-3-amine (11 mg, 0.13 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (10 mg, 0.011 mmol), Xantphos (6 mg, 0.011), and Cs<sub>2</sub>CO<sub>3</sub> (72 mg, 0.22 mmol) in dioxane (2 mL) was stirred at 110 °C for 2 h under a N<sub>2</sub> atmosphere. The solids were filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (NH<sub>4</sub>HCO<sub>3</sub>) to provide the title compound (6 mg, 14%) as a white solid. MS (ES+) C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S requires 467 found: 468 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.68 (d, <i>J</i> = 5 Hz, 1H), 8.41 (d, <i>J</i> = 3 Hz, 1H), 7.40 (d, <i>J</i> = 5 Hz, 1H), 6.90 (m, d, <i>J</i> = 2 Hz, 1H), 6.67 (d, <i>J</i> = 3 Hz, 1H), 6.00 (d, <i>J</i> = 2.5 Hz, 1H), 5.20 (s, 2H), 3.95 (s, 3H), 3.60–3.61 (m, 1H), 3.41–3.42 (m, 1H), 2.14–2.16 (m, 1H), 2.03–2.05 (m, 1H), 1.72–1.79 (m, 2H), 1.31–1.43 (m, 4H).</div></div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((6-((2-(Isoxazol-4-ylamino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>30</b>)</h4><div id="sec5_1_30_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> Step 1: (1<i>S</i>,2<i>S</i>)-2-((6-((2-(Isoxazol-4-ylamino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol</h5><div class="NLM_p">A vial was charged with (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (20 mg, 0.048 mmol), isoxazol-4-amine (18 mg, 0.14 mmol) (0.020 mL, 0.14 mmol), and MeOH (2 mL), and the reaction was heated for 3 h at 100 °C. The residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 20–50%; 12 min; column: C18) to provide (1<i>S</i>,2<i>S</i>)-2-((6-((2-(isoxazol-4-ylamino)pyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (14 mg, 0.030 mmol, 63%) as a light brown solid. MS (ES+) C<sub>22</sub>H<sub>24</sub>N<sub>6</sub>O<sub>4</sub>S requires 468.5, found: copy in <i>m</i>/<i>z</i> [M + H]<sup>+</sup>.</div><div class="NLM_p last"><sup>1</sup>H NMR (600 MHz, MeOD-<i>d</i><sub>4</sub>) δ 9.06 (s, 1H), 8.52 (s, 1H), 8.46 (d, <i>J</i> = 5.4 Hz, 1H), 6.99 (dd, <i>J</i> = 15.0 and 5.4 Hz, 2H), 6.87 (s, 1H), 5.16 (s, 2H), 3.99 (s, 3H), 3.60 (m, 1H), 3.47–3.51 (m, 1H), 2.05–2.1 (m, 2H), 1.78 (m, 2H), 1.34–1.44 (m, 4H).</div></div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (1<i>S</i>,2<i>S</i>)-2-(4-Methoxy-6-((2-(1-methyl-1<i>H</i>-1,2,3-triazol-4-ylamino)pyrimidin-4-yl) methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>31</b>)</h4><div id="sec5_1_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> Step 1: (1<i>S</i>,2<i>S</i>)-2-(4-Methoxy-6-((2-(1-methyl-1<i>H</i>-1,2,3-triazol-4-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>S</i>,2<i>S</i>)-2-(6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo [<i>d</i>]thiazol-2-ylamino)cyclohexanol (60 mg, 0.14 mmol), 1-methyl-1<i>H</i>-1,2,3-triazol-4-amine (17 mg, 0.17 mmol), and TsOH (12 mg, 0.07 mmol) in dioxane (2 mL) was stirred at 110 °C for 16 h. The mixture was diluted with EtOAc, washed with NaHCO<sub>3</sub> (sat. aq), and dried over Na<sub>2</sub>SO<sub>4</sub>. The combined organic layers were concentrated under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to give the title compound (7.0 mg, 10%) as a white solid. MS (ES+) C<sub>22</sub>H<sub>26</sub>N<sub>8</sub>O<sub>3</sub>S requires 482 found: 483 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 8.47 (d, <i>J</i> = 5 Hz, 1H), 8.13 (s, 1H), 7.61 (d, J = 7.5 Hz, 2H), 6.94–6.96 (m, 2 H), 6.60 (s, 1 H), 5.10 (s, 2H), 4.76 (d, <i>J</i> = 5 Hz, 1H), 4.00 (s, 3H), 3.83 (s, 3H), 2.02–2.05 (m, 1H), 1.86–1.88 (m, 1H), 1.60–1.65 (m, 2H), 1.18–1.30 (m, 4H).</div></div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((4-Methoxy-6-((2-(pyridin-3-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexan-1-ol (<b>32</b>)</h4><div id="sec5_1_32_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> Step 1: (1<i>S</i>,2<i>S</i>)-2-((4-Methoxy-6-((2-(pyridin-3-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol</h5><div class="NLM_p last">A microwave vial was charged with (1<i>S</i>,2<i>S</i>)-2-((6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (20 mg, 0.48 mmol), pyridin-3-amine (14 mg, 0.14 mmol), one drop of HCl (aq 36.5%), and MeOH (1.5 mL). The vial was sealed, and the reaction mixture was heated to 110 °C in the microwave reactor for 3 h. The residue was purified by mass-triggered preparative HPLC (mobile phase: <i>A</i> = 0.1% TFA/H<sub>2</sub>O, <i>B</i> = 0.1% TFA/MeCN; gradient: <i>B</i> = 20–50%; 12 min; column: C18) to give (1<i>S</i>,2<i>S</i>)-2-((4-methoxy-6-((2-(pyridin-3-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-yl)amino)cyclohexanol (11 mg, 48%) as an off-white solid. MS (ES+) C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub>S requires 478.6, found: 479.5 [M + H]. <sup>1</sup>H NMR (600 MHz, MeOD-<i>d</i><sub>4</sub>) δ 9.40 (s, 1H), 9.28 (m, 1H), 9.10 (d, <i>J</i> = 4.8 Hz, 1H), 8.02 (d, <i>J</i> = 4.8 Hz, 1H), 7.91 (m, 2H), 7.07 (d, <i>J</i> = 2.4 Hz, 1H), 6.93 (d, <i>J</i> = 1.8 Hz, 1H), 5.44 (s, 2H), 4.02 (s, 3H), 3.60 (m, 1H), 3.47–3.51 (m, 1H), 2.05–2.1 (m, 2H), 1.79 (m, 2H), 1.34–1.46 (m, 4H).</div></div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-(7-Chloro-4-methoxy-6-((2-(1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (<b>33</b>)</h4><div id="sec5_1_33_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> Step 1: (1<i>S</i>,2<i>S</i>)-2-(7-Chloro-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of 7-chloro-2-((1<i>S</i>,2<i>S</i>)-2-hydroxycyclohexylamino)-4-methoxybenzo[<i>d</i>]thiazol-6-ol (350 mg, 1.07 mmol), 2-chloro-4-(chloromethyl)pyrimidine (208 mg, 1.28 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (698 mg, 2.14 mmol) in DMF (8 mL) was stirred at 80 °C for 3 h. The volatiles were removed under reduced pressure to give the residue, which was purified by column chromatography (PE/EA = 1:9) to give (1<i>S</i>,2<i>S</i>)-2-(7-chloro-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (3) (185 mg, 35%) as a yellow solid. MS (ES+) C<sub>19</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub>S requires 454 found: 455 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> Step 2: (1<i>S</i>,2<i>S</i>)-2-(7-Chloro-4-methoxy-6-((2-(1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol</h5><div class="NLM_p last">A mixture of (1<i>S</i>,2<i>S</i>)-2-(7-chloro-6-((2-chloropyrimidin-4-yl)methoxy)-4-methoxybenzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (3) (60 mg, 0.13 mmol), 1-methyl-1<i>H</i>-pyrazol-4-amine (21 mg, 0.15 mmol), and TsOH (11 mg, 0.065 mmol) in dioxane (2 mL) was stirred at 110 °C overnight. The mixture was diluted with EtOAc, washed with NaHCO<sub>3</sub> (sat. aq), and dried over Na<sub>2</sub>SO<sub>4</sub>. The combined organic layers were concentrated under reduced pressure. The residue was purified by preparative HPLC (mobile phase: <i>A</i> = 0.1% NH<sub>4</sub>HCO<sub>3</sub>/H<sub>2</sub>O, <i>B</i> = MeCN; gradient: <i>B</i> = 5–95%; 12 min; column: C18) to give (1<i>S</i>,2<i>S</i>)-2-(7-chloro-4-methoxy-6-((2-(1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)methoxy)benzo[<i>d</i>]thiazol-2-ylamino)cyclohexanol (3.5 mg, 5%) as a white solid. MS (ES+) C<sub>23</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>3</sub>S requires 515 found: 516 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 1H), 8.44 (d, <i>J</i> = 4.5 Hz, 1H),7.89 (d, <i>J</i> = 9.5 Hz, 2H), 7.48 (s, 1 H), 6.83–6.89 (m, 2 H), 5.17 (s, 2H), 4.17 (d, <i>J</i> = 5.5 Hz, 1H), 3.77 (s, 3H), 3.49 (s, 3H), 2.02–2.08 (m, 1H), 1.86–1.89 (m, 1H), 1.60–1.65 (m, 2H), 1.19–1.30 (m, 4H).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i142"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00936" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00936?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00936</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay conditions, materials and methods, kinase profiling data for compound <b>12</b> (Table S1) and for IACS-9439 (<b>1</b>) (Table S3) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">CSF1R compound <b>3</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">CSF1R compound <b>12</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf">jm0c00936_si_001.pdf (312.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_002.pdb">jm0c00936_si_002.pdb (371.31 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_003.pdb">jm0c00936_si_003.pdb (371.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_004.csv">jm0c00936_si_004.csv (4.3 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00936" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Czako</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3357-7514" title="Orcid link">http://orcid.org/0000-0002-3357-7514</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ee8c8d948f8581aea3aaaf808a8b9c9d8180c0819c89"><span class="__cf_email__" data-cfemail="583a3b2239333718151c19363c3d2a2b373676372a3f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph. R. Marszalek</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason P. Burke</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pijus Mandal</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Leonard</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason B. Cross</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Faika Mseeh</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongying Jiang</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Q. Chang</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erika Suzuki</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey J. Kovacs</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ningping Feng</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonal Gera</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela L. Harris</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Liu</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Mullinax</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jihai Pang</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Connor A. Parker</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nakia D. Spencer</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon S. Yu</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Wu</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin R. Tremblay</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Mikule</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Wilcoxen</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffernan</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to AdvanCe Therapeutics and Innovation in
Oncology), University of Texas MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulio F. Draetta</span> - <span class="hlFld-Affiliation affiliation">Department
of Genomic Medicine, The University of Texas
MD Anderson Cancer Center, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Jones</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute of Applied Cancer Science), University
of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8972-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i144">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Tesaro Inc. and the University of Texas MD Anderson Cancer Center. The authors thank Richard Lewis, Michael Soth, and Edith Nagy for proofreading the manuscript and for their valuable feedback.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">°C</td><td class="NLM_def"><p class="first last">celsius</p></td></tr><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">can</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">BSTFA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl)trifluoroacetamide</p></td></tr><tr><td class="NLM_term">MeOD-<i>d</i><sub>4</sub></td><td class="NLM_def"><p class="first last">deuterated methanol</p></td></tr><tr><td class="NLM_term">DMSO-<i>d</i><sub>6</sub></td><td class="NLM_def"><p class="first last">deuterated dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicycloundec-7-ene</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIBAL</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethyl acetamide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">ES<sup>+</sup></td><td class="NLM_def"><p class="first last">electrospray positive ionization</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HI FBS</td><td class="NLM_def"><p class="first last">heat inactivated fetal bovine serum</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropanol</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">molar</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last">3-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last"><i>p</i>-methoxybenzyl</p></td></tr><tr><td class="NLM_term">qPCR</td><td class="NLM_def"><p class="first last">quantitative polymerase chain reaction</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">Selectfluor</td><td class="NLM_def"><p class="first last">1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)</p></td></tr><tr><td class="NLM_term"><i>t</i>-BuONO</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl nitrite</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i146">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savai, R.</span></span> <span> </span><span class="NLM_article-title">Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">48436</span>– <span class="NLM_lpage">48452</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.18632%2Foncotarget.17061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28467800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1crjs1Ciuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=48436-48452&author=X.+Zhengauthor=K.+Turkowskiauthor=J.+Moraauthor=B.+Bruneauthor=A.+Weigertauthor=W.+Seegerauthor=R.+Savai&title=Redirecting+tumor-associated+macrophages+to+become+tumoricidal+effectors+as+a+novel+strategy+for+cancer+therapy&doi=10.18632%2Foncotarget.17061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy</span></div><div class="casAuthors">Zheng Xiang; Turkowski Kati; Seeger Werner; Savai Rajkumar; Mora Javier; Brune Bernhard; Weigert Andreas; Seeger Werner; Savai Rajkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">48436-48452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer research in recent decades has highlighted the potential influence of the tumor microenvironment on the progression and metastasis of most known cancer types.  Within the established microenvironment, tumor-associated macrophages (TAMs) are one of the most abundant and crucial non-neoplastic cell types.  The polarization of macrophages into tumor-suppressive M1 or tumor-promoting M2 types is a fundamental event in the establishment of the tumor microenvironment.  Although ample evidence indicates that TAMs are primarily M2 polarized, the mechanisms responsible for the regulation and maintenance of M1 and M2 polarization imbalance remain unclear.  The manipulation of this critical axis through three main approaches may provide new strategies for cancer therapy - (I) specific interference with M2-like TAM survival or inhibiting their signaling cascades, (II) repression of macrophage recruitment to tumors, and (III) repolarization of tumor-promoting M2-like TAMs to a tumoricidal M1-like phenotype.  This review summarizes current strategies for cancer intervention via manipulation of macrophage polarization, with particular focus on composition of the tumor microenvironment and its influence on cancer progression and metastasis.  It is clear that additional fundamental and preclinical research is required to confirm the efficacy and practicality of this novel and promising strategy for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVn-pfX7PHl5Pq5LRczm8ffW6udTcc2eYVARicF108r7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjs1Ciuw%253D%253D&md5=31465e5ce142a49835f12d75963e02da</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17061%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTurkowski%26aufirst%3DK.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DBrune%26aufirst%3DB.%26aulast%3DWeigert%26aufirst%3DA.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DSavai%26aufirst%3DR.%26atitle%3DRedirecting%2520tumor-associated%2520macrophages%2520to%2520become%2520tumoricidal%2520effectors%2520as%2520a%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D48436%26epage%3D48452%26doi%3D10.18632%2Foncotarget.17061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: implications in cancer immunotherapy</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.2217%2Fimt-2016-0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28231720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=289-302&author=A.+J.+Pettyauthor=Y.+Yang&title=Tumor-associated+macrophages%3A+implications+in+cancer+immunotherapy&doi=10.2217%2Fimt-2016-0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated macrophages: implications in cancer immunotherapy</span></div><div class="casAuthors">Petty, Amy J.; Yang, Yiping</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-302</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-743X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment.  These anti-inflammatory and protumorigenic macrophages modulate the local microenvironment to facilitate tumor growth and metastasis.  In this review, we examine the origin of TAMs and the complex regulatory networks within the tumor microenvironment that facilitate the polarization of TAMs toward a protumoral phenotype.  More extensively, we evaluate the mechanisms by which TAMs mediate angiogenesis, metastasis, chemotherapeutic resistance and immune evasion.  Lastly, we will highlight novel interventional strategies targeting TAMs in preclin. studies and in early clin. trials that have significant potential in improving efficacy of current chemotherapeutic and/or immunotherapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp07UjzPBelvrVg90H21EOLACvtfcHk0lgiEUK_WRs_Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Gls7s%253D&md5=e873b29c2f3661a8e49db1f06277adac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0135%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DTumor-associated%2520macrophages%253A%2520implications%2520in%2520cancer%2520immunotherapy%26jtitle%3DImmunotherapy%26date%3D2017%26volume%3D9%26spage%3D289%26epage%3D302%26doi%3D10.2217%2Fimt-2016-0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baral, R.</span></span> <span> </span><span class="NLM_article-title">Tumor promoting role of anti-tumor macrophages in tumor microenvironment</span>. <i>Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.cellimm.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.cellimm.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28433198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2017&pages=1-10&author=K.+K.+Goswamiauthor=T.+Ghoshauthor=S.+Ghoshauthor=M.+Sarkarauthor=A.+Boseauthor=R.+Baral&title=Tumor+promoting+role+of+anti-tumor+macrophages+in+tumor+microenvironment&doi=10.1016%2Fj.cellimm.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor promoting role of anti-tumor macrophages in tumor microenvironment</span></div><div class="casAuthors">Goswami, Kuntal Kanti; Ghosh, Tithi; Ghosh, Sarbari; Sarkar, Madhurima; Bose, Anamika; Baral, Rathindranath</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CLIMB8</span>;
        ISSN:<span class="NLM_cas:issn">0008-8749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent advances in tumor biol. demand detailed anal. of the complex interaction of tumor cells with their adjacent microenvironment (tumor stroma) to understand the various mechanisms involved in tumor growth and metastasis.  Mononuclear phagocytes or macrophages, a type of innate immune cells, defend the organism against infection and injury.  On the other hand, tumor assocd. macrophages (TAMs) constitute a significant part of the tumor-infiltrating immune cells, have been linked to the growth, angiogenesis, and metastasis of a variety of cancers, most likely through polarization of TAMs to the M2 (alternative) phenotype.  Clin. and exptl. evidences have shown that cancer tissues with high infiltration of TAMs are assocd. with poor patient prognosis and resistance to therapies, thus, targeting of TAMs in tumors is considered as a promising immunotherapeutic strategy.  Depletion of M2 TAMs or 're-education' of them as anti-tumor effectors might contribute significantly to the search of new modalities in anti-cancer treatments.  Basic questions on the factors responsible for homing of macrophages in tumors, mechanism of conversion of M1 to M2 TAMs, their functionality and, finally, the possible ways to target M2 TAMs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreisc_2n8gyLVg90H21EOLACvtfcHk0lgiEUK_WRs_Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWqtLw%253D&md5=0407f61ea5fe47fd8a223af7cae3f347</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cellimm.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellimm.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DK.%2BK.%26aulast%3DGhosh%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DBaral%26aufirst%3DR.%26atitle%3DTumor%2520promoting%2520role%2520of%2520anti-tumor%2520macrophages%2520in%2520tumor%2520microenvironment%26jtitle%3DCell.%2520Immunol.%26date%3D2017%26volume%3D316%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.cellimm.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngambenjawong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pun, S. H.</span></span> <span> </span><span class="NLM_article-title">Progress in tumor-associated macrophage (TAM)-targeted therapeutics</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.addr.2017.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28449873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=206-221&author=C.+Ngambenjawongauthor=H.+H.+Gustafsonauthor=S.+H.+Pun&title=Progress+in+tumor-associated+macrophage+%28TAM%29-targeted+therapeutics&doi=10.1016%2Fj.addr.2017.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in tumor-associated macrophage (TAM)-targeted therapeutics</span></div><div class="casAuthors">Ngambenjawong, Chayanon; Gustafson, Heather H.; Pun, Suzie H.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-221</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As an essential innate immune population for maintaining body homeostasis and warding off foreign pathogens, macrophages display high plasticity and perform diverse supportive functions specialized to different tissue compartments.  Consequently, aberrance in macrophage functions contributes substantially to progression of several diseases including cancer, fibrosis, and diabetes.  In the context of cancer, tumor-assocd. macrophages (TAMs) in tumor microenvironment (TME) typically promote cancer cell proliferation, immunosuppression, and angiogenesis in support of tumor growth and metastasis.  Oftentimes, the abundance of TAMs in tumor is correlated with poor disease prognosis.  Hence, significant attention has been drawn towards development of cancer immunotherapies targeting these TAMs; either depleting them from tumor, blocking their pro-tumoral functions, or restoring their immunostimulatory/tumoricidal properties.  This review aims to introduce readers to various aspects in development and evaluation of TAM-targeted therapeutics in pre-clin. and clin. stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPDjatoNEOabVg90H21EOLACvtfcHk0lgiEUK_WRs_Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKqtL0%253D&md5=5986b63aee5e4a0197b62d93838b0459</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DNgambenjawong%26aufirst%3DC.%26aulast%3DGustafson%26aufirst%3DH.%2BH.%26aulast%3DPun%26aufirst%3DS.%2BH.%26atitle%3DProgress%2520in%2520tumor-associated%2520macrophage%2520%2528TAM%2529-targeted%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D114%26spage%3D206%26epage%3D221%26doi%3D10.1016%2Fj.addr.2017.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recht, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, S.</span></span> <span> </span><span class="NLM_article-title">The promise of targeting macrophages in cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3241</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1158%2F1078-0432.CCR-16-3122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28341752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1cvhtVKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3241-3250&author=J.+M.+Brownauthor=L.+Rechtauthor=S.+Strober&title=The+promise+of+targeting+macrophages+in+cancer+therapy&doi=10.1158%2F1078-0432.CCR-16-3122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Promise of Targeting Macrophages in Cancer Therapy</span></div><div class="casAuthors">Brown J Martin; Recht Lawrence; Strober Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3241-3250</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Cancer therapy has developed around the concept of killing, or stopping the growth of, the cancer cells.  Molecularly targeted therapy is the modern expression of this paradigm.  Increasingly, however, the realization that the cancer has co-opted the normal cells of the stroma for its own survival has led to the concept that the tumor microenvironment (TME) could be targeted for effective therapy.  In this review, we outline the importance of tumor-associated macrophages (TAM), a major component of the TME, in the response of tumors to cancer therapy.  We discuss the normal role of macrophages in wound healing, the major phenotypes of TAMs, and their role in blunting the efficacy of cancer treatment by radiation and anticancer drugs, both by promoting tumor angiogenesis and by suppressing antitumor immunity.  Finally, we review the many preclinical studies that have shown that the response of tumors to irradiation and anticancer drugs can be improved, sometimes markedly so, by depleting TAMs from tumors or by suppressing their polarization from an M1 to an M2 phenotype.  The data clearly support the validity of clinical testing of combining targeting TAMs with conventional therapy.  Clin Cancer Res; 23(13); 3241-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYEpxqdHjD4IvKgEt20y1XfW6udTcc2ebZ--PnkTaKdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvhtVKrsw%253D%253D&md5=8678b1d4fd911e05ba331a9d2df520fa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3122%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DRecht%26aufirst%3DL.%26aulast%3DStrober%26aufirst%3DS.%26atitle%3DThe%2520promise%2520of%2520targeting%2520macrophages%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3241%26epage%3D3250%26doi%3D10.1158%2F1078-0432.CCR-16-3122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dull, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span> <span> </span><span class="NLM_article-title">Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1038/325549a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2F325549a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=3027579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADyaL2sXhtlarsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1987&pages=549-552&author=M.+F.+Rousselauthor=T.+J.+Dullauthor=C.+W.+Rettenmierauthor=P.+Ralphauthor=A.+Ullrichauthor=C.+J.+Sherr&title=Transforming+potential+of+the+c-fms+proto-oncogene+%28CSF-1+receptor%29&doi=10.1038%2F325549a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)</span></div><div class="casAuthors">Roussel, Martine F.; Dull, Thomas J.; Rettenmier, Carl W.; Ralph, Peter; Ullrich, Axel; Sherr, Charles J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">6104</span>),
    <span class="NLM_cas:pages">549-52</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The c-fms proto-oncogene encodes a transmembrane glycoprotein that is probably identical to the receptor for the macrophage colony stimulating factors, CSF-1.  Forty C-terminal amino acids of the normal receptor are replaced by 11 unrelated residues in the feline v-fms oncogene product, deleting a C-terminal tyrosine residue (Tyr969) whose phosphorylation might neg. regulate the receptor kinase activity.  This study showed that the human c-fms gene stimulates growth of mouse NIH 3T3 cells in agar in response to human recombinant CSF-1, indicating that receptor transduction is sufficient to induce a CSF-1 responsive phenotype.  Although cells transfected with c-fms genes contg. either Tyr969 or Phe969 were not transformed, cotransfection of these genes with CSF-1 cDNA induced transformation, with c-fms (Phe969) showing significantly more activity than c-fms (Tyr969).  In the absence of CSF-1, chimeric v-fms/c-fms genes encoding the wild-type c-fms C terminus were poorly transforming, whereas chimeras bearing Phe969 were as transforming as v-fms.  Thus, the Phe969 mutation, although not in itself sufficient to induce transformation, activates the oncogenic potential of c-fms in assocn. with an endogenous ligand or in conjuction with mutation elsewhere in the c-fms that confer ligand-independent signals for growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6BaG8vXq4LVg90H21EOLACvtfcHk0lhlu2c_Tkc4nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtlarsb4%253D&md5=b54c5fd69c815498155bdf8564ec4e39</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F325549a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F325549a0%26sid%3Dliteratum%253Aachs%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26aulast%3DRalph%26aufirst%3DP.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26atitle%3DTransforming%2520potential%2520of%2520the%2520c-fms%2520proto-oncogene%2520%2528CSF-1%2520receptor%2529%26jtitle%3DNature%26date%3D1987%26volume%3D325%26spage%3D549%26epage%3D552%26doi%3D10.1038%2F325549a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeNardo, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexhepaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadhwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keil, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junaid, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirstroem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span> <span> </span><span class="NLM_article-title">Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1158/2159-8274.CD-10-0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1158%2F2159-8274.CD-10-0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=22039576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVylsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=54-67&author=D.+G.+DeNardoauthor=D.+J.+Brennanauthor=E.+Rexhepajauthor=B.+Ruffellauthor=S.+L.+Shiaoauthor=S.+F.+Maddenauthor=W.+M.+Gallagherauthor=N.+Wadhwaniauthor=S.+D.+Keilauthor=S.+A.+Junaidauthor=H.+S.+Rugoauthor=E.+S.+Hwangauthor=K.+Jirstroemauthor=B.+L.+Westauthor=L.+M.+Coussens&title=Leukocyte+complexity+predicts+breast+cancer+survival+and+functionally+regulates+response+to+chemotherapy&doi=10.1158%2F2159-8274.CD-10-0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy</span></div><div class="casAuthors">DeNardo, David G.; Brennan, Donal J.; Rexhepaj, Elton; Ruffell, Brian; Shiao, Stephen L.; Madden, Stephen F.; Gallagher, William M.; Wadhwani, Nikhil; Keil, Scott D.; Junaid, Sharfaa A.; Rugo, Hope S.; Hwang, E. Shelley; Jirstroem, Karin; West, Brian L.; Coussens, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-67</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">Immune-regulated pathways influence multiple aspects of cancer development.  In this article we demonstrate that both macrophage abundance and T-cell abundance in breast cancer represent prognostic indicators for recurrence-free and overall survival.  We provide evidence that response to chemotherapy is in part regulated by these leukocytes; cytotoxic therapies induce mammary epithelial cells to produce monocyte/macrophage recruitment factors, including colony stimulating factor 1 (CSF1) and interleukin-34, which together enhance CSF1 receptor (CSF1R)-dependent macrophage infiltration.  Blockade of macrophage recruitment with CSF1R-signaling antagonists, in combination with paclitaxel, improved survival of mammary tumor-bearing mice by slowing primary tumor development and reducing pulmonary metastasis.  These improved aspects of mammary carcinogenesis were accompanied by decreased vessel d. and appearance of antitumor immune programs fostering tumor suppression in a CD8+ T-cell-dependent manner.  These data provide a rationale for targeting macrophage recruitment/response pathways, notably C5F1R, in combination with cytotoxic therapy, and identification of a breast cancer population likely to benefit from this novel therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFqFZ3CvAgbVg90H21EOLACvtfcHk0lhlu2c_Tkc4nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVylsbo%253D&md5=098edea4f3ec31f1e31d2e9fc5569ac6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F2159-8274.CD-10-0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8274.CD-10-0028%26sid%3Dliteratum%253Aachs%26aulast%3DDeNardo%26aufirst%3DD.%2BG.%26aulast%3DBrennan%26aufirst%3DD.%2BJ.%26aulast%3DRexhepaj%26aufirst%3DE.%26aulast%3DRuffell%26aufirst%3DB.%26aulast%3DShiao%26aufirst%3DS.%2BL.%26aulast%3DMadden%26aufirst%3DS.%2BF.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26aulast%3DWadhwani%26aufirst%3DN.%26aulast%3DKeil%26aufirst%3DS.%2BD.%26aulast%3DJunaid%26aufirst%3DS.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DHwang%26aufirst%3DE.%2BS.%26aulast%3DJirstroem%26aufirst%3DK.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26atitle%3DLeukocyte%2520complexity%2520predicts%2520breast%2520cancer%2520survival%2520and%2520functionally%2520regulates%2520response%2520to%2520chemotherapy%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D54%26epage%3D67%26doi%3D10.1158%2F2159-8274.CD-10-0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyonteck, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmacher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijeiro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1038/nm.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnm.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24056773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1264-1272&author=S.+M.+Pyonteckauthor=L.+Akkariauthor=A.+J.+Schuhmacherauthor=R.+L.+Bowmanauthor=L.+Sevenichauthor=D.+F.+Quailauthor=O.+C.+Olsonauthor=M.+L.+Quickauthor=J.+T.+Huseauthor=V.+Teijeiroauthor=M.+Settyauthor=C.+S.+Leslieauthor=Y.+Oeiauthor=A.+Pedrazaauthor=J.+Zhangauthor=C.+W.+Brennanauthor=J.+C.+Suttonauthor=E.+C.+Hollandauthor=D.+Danielauthor=J.+A.+Joyce&title=CSF-1R+inhibition+alters+macrophage+polarization+and+blocks+glioma+progression&doi=10.1038%2Fnm.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span></div><div class="casAuthors">Pyonteck, Stephanie M.; Akkari, Leila; Schuhmacher, Alberto J.; Bowman, Robert L.; Sevenich, Lisa; Quail, Daniela F.; Olson, Oakley C.; Quick, Marsha L.; Huse, Jason T.; Teijeiro, Virginia; Setty, Manu; Leslie, Christina S.; Oei, Yoko; Pedraza, Alicia; Zhang, Jianan; Brennan, Cameron W.; Sutton, James C.; Holland, Eric C.; Daniel, Dylan; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) comprises several mol. subtypes, including proneural GBM.  Most therapeutic approaches targeting glioma cells have failed.  An alternative strategy is to target cells in the glioma microenvironment, such as tumor-assocd. macrophages and microglia (TAMs).  Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival.  We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors.  CSF-1R blockade addnl. slowed intracranial growth of patient-derived glioma xenografts.  Surprisingly, TAMs were not depleted in treated mice.  Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition.  Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions.  These gene signatures were assocd. with enhanced survival in patients with proneural GBM.  Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirwpRVIWUELVg90H21EOLACvtfcHk0lhlu2c_Tkc4nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N&md5=9b908e86c4a7da35a009bf322d492214</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3337%26sid%3Dliteratum%253Aachs%26aulast%3DPyonteck%26aufirst%3DS.%2BM.%26aulast%3DAkkari%26aufirst%3DL.%26aulast%3DSchuhmacher%26aufirst%3DA.%2BJ.%26aulast%3DBowman%26aufirst%3DR.%2BL.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DOlson%26aufirst%3DO.%2BC.%26aulast%3DQuick%26aufirst%3DM.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DTeijeiro%26aufirst%3DV.%26aulast%3DSetty%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DC.%2BS.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DPedraza%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26aulast%3DSutton%26aufirst%3DJ.%2BC.%26aulast%3DHolland%26aufirst%3DE.%2BC.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DCSF-1R%2520inhibition%2520alters%2520macrophage%2520polarization%2520and%2520blocks%2520glioma%2520progression%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1264%26epage%3D1272%26doi%3D10.1038%2Fnm.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span> <span> </span><span class="NLM_article-title">CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e26968</span> <span class="refDoi"> DOI: 10.4161/onci.26968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.4161%2Fonci.26968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24498562" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&author=D.+C.+Strachanauthor=B.+Ruffellauthor=Y.+Oeiauthor=M.+J.+Bissellauthor=L.+M.+Coussensauthor=N.+Pryerauthor=D.+Daniel&title=CSF1R+inhibition+delays+cervical+and+mammary+tumor+growth+in+murine+models+by+attenuating+the+turnover+of+tumor-associated+macrophages+and+enhancing+infiltration+by+CD8%28%2B%29+T+cells&doi=10.4161%2Fonci.26968"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4161%2Fonci.26968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.26968%26sid%3Dliteratum%253Aachs%26aulast%3DStrachan%26aufirst%3DD.%2BC.%26aulast%3DRuffell%26aufirst%3DB.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DBissell%26aufirst%3DM.%2BJ.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DPryer%26aufirst%3DN.%26aulast%3DDaniel%26aufirst%3DD.%26atitle%3DCSF1R%2520inhibition%2520delays%2520cervical%2520and%2520mammary%2520tumor%2520growth%2520in%2520murine%2520models%2520by%2520attenuating%2520the%2520turnover%2520of%2520tumor-associated%2520macrophages%2520and%2520enhancing%2520infiltration%2520by%2520CD8%2528%252B%2529%2520T%2520cells%26jtitle%3DOncoimmunology%26date%3D2013%26volume%3D2%26doi%3D10.4161%2Fonci.26968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegg, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruttinger, D.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">53</span> <span class="refDoi"> DOI: 10.1186/s40425-017-0257-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1186%2Fs40425-017-0257-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28716061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=M.+A.+Cannarileauthor=M.+Weisserauthor=W.+Jacobauthor=A.-M.+Jeggauthor=C.+H.+Riesauthor=D.+Ruttinger&title=Colony-stimulating+factor+1+receptor+%28CSF1R%29+inhibitors+in+cancer+therapy&doi=10.1186%2Fs40425-017-0257-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span></div><div class="casAuthors">Cannarile Michael A; Weisser Martin; Jacob Wolfgang; Jegg Anna-Maria; Ries Carola H; Ruttinger Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells.  In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development.  Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents.  The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion.  In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending.  As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment.  Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells.  We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies.  Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQzjcxKO1-OQqdek-gHSrIfW6udTcc2eYqPqq0IFE6O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D&md5=09fab249b606af3e00f545dc7e7121b4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2Fs40425-017-0257-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-017-0257-y%26sid%3Dliteratum%253Aachs%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DWeisser%26aufirst%3DM.%26aulast%3DJacob%26aufirst%3DW.%26aulast%3DJegg%26aufirst%3DA.-M.%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DRuttinger%26aufirst%3DD.%26atitle%3DColony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2017%26volume%3D5%26doi%3D10.1186%2Fs40425-017-0257-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span> </span><span class="NLM_article-title">A Study of BLZ945 Single Agent or BLZ945 in Combination
With PDR001
in Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02829723" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02829723</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+BLZ945+Single+Agent+or+BLZ945+in+Combination%0AWith+PDR001%0Ain+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02829723+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520BLZ945%2520Single%2520Agent%2520or%2520BLZ945%2520in%2520Combination%250AWith%2520PDR001%250Ain%2520Advanced%2520Solid%2520Tumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span> </span><span class="NLM_article-title">FDA Approves
First Therapy for Rare Joint Tumor</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0AFirst+Therapy+for+Rare+Joint+Tumor.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-therapy-rare-joint-tumor+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250AFirst%2520Therapy%2520for%2520Rare%2520Joint%2520Tumor%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3093</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.3093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1200%2Fjco.2011.29.15_suppl.3093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3093&author=S.+P.+Anthonyauthor=I.+Puzanovauthor=P.+S.+Linauthor=K.+B.+Nolopauthor=B.+Westauthor=D.+D.+Von+Hoff&title=Pharmacodynamic+activity+demonstrated+in+phase+I+for+PLX3397%2C+a+selective+inhibitor+of+FMS+and+Kit&doi=10.1200%2Fjco.2011.29.15_suppl.3093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.3093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.3093%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DWest%26aufirst%3DB.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26atitle%3DPharmacodynamic%2520activity%2520demonstrated%2520in%2520phase%2520I%2520for%2520PLX3397%252C%2520a%2520selective%2520inhibitor%2520of%2520FMS%2520and%2520Kit%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3093%26doi%3D10.1200%2Fjco.2011.29.15_suppl.3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">5689</span>– <span class="NLM_lpage">5694</span>, <span class="refDoi"> DOI: 10.1073/pnas.1219457110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1073%2Fpnas.1219457110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=23493555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=5689-5694&author=C.+Zhangauthor=P.+N.+Ibrahimauthor=J.+Zhangauthor=E.+A.+Burtonauthor=G.+Habetsauthor=Y.+Zhangauthor=B.+Powellauthor=B.+L.+Westauthor=B.+Matusowauthor=G.+Tsangauthor=R.+Shellooeauthor=H.+Cariasauthor=H.+Nguyenauthor=A.+Marimuthuauthor=K.+Y.+J.+Zhangauthor=A.+Ohauthor=R.+Bremerauthor=C.+R.+Hurtauthor=D.+R.+Artisauthor=G.+Wuauthor=M.+Nespiauthor=W.+Spevakauthor=P.+Linauthor=K.+Nolopauthor=P.+Hirthauthor=G.+H.+Teschauthor=G.+Bollag&title=Design+and+pharmacology+of+a+highly+specific+dual+FMS+and+KIT+kinase+inhibitor&doi=10.1073%2Fpnas.1219457110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor</span></div><div class="casAuthors">Zhang, Chao; Ibrahim, Prabha N.; Zhang, Jiazhong; Burton, Elizabeth A.; Habets, Gaston; Zhang, Ying; Powell, Ben; West, Brian L.; Matusow, Bernice; Tsang, Garson; Shellooe, Rafe; Carias, Heidi; Nguyen, Hoa; Marimuthu, Adhirai; Zhang, Kam Y. J.; Oh, Angela; Bremer, Ryan; Hurt, Clarence R.; Artis, Dean R.; Wu, Guoxian; Nespi, Marika; Spevak, Wayne; Lin, Paul; Nolop, Keith; Hirth, Peter; Tesch, Greg H.; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5689-5694, S5689/1-S5689/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inflammation and cancer, two therapeutic areas historically addressed by sep. drug discovery efforts, are now coupled in treatment approaches by a growing understanding of the dynamic mol. dialogues between immune and cancer cells.  Agents that target specific compartments of the immune system, therefore, not only bring new disease modifying modalities to inflammatory diseases, but also offer a new avenue to cancer therapy by disrupting immune components of the microenvironment that foster tumor growth, progression, immune evasion, and treatment resistance.  McDonough feline sarcoma viral (v-fms) oncogene homolog (FMS) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) are two hematopoietic cell surface receptors that regulate the development and function of macrophages and mast cells, resp.  The authors disclose a highly specific dual FMS and KIT kinase inhibitor developed from a multifaceted chem. scaffold.  As expected, this inhibitor blocks the activation of macrophages, osteoclasts, and mast cells controlled by these two receptors.  More importantly, the dual FMS and KIT inhibition profile has translated into a combination of benefits in preclin. disease models of inflammation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofECnjzEONuLVg90H21EOLACvtfcHk0lgRip-fB392wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWksLk%253D&md5=e4fbca9d41f95718a5119a08a54f5acc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1219457110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1219457110%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DHurt%26aufirst%3DC.%2BR.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTesch%26aufirst%3DG.%2BH.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDesign%2520and%2520pharmacology%2520of%2520a%2520highly%2520specific%2520dual%2520FMS%2520and%2520KIT%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D5689%26epage%3D5694%26doi%3D10.1073%2Fpnas.1219457110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">S5689/1-S5689/11.</p></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staddon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong-Starksen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1056%2FNEJMoa1411366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=26222558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=428-437&author=W.+D.+Tapauthor=Z.+A.+Wainbergauthor=S.+P.+Anthonyauthor=P.+N.+Ibrahimauthor=C.+Zhangauthor=J.+H.+Healeyauthor=B.+Chmielowskiauthor=A.+P.+Staddonauthor=A.+L.+Cohnauthor=G.+I.+Shapiroauthor=V.+L.+Keedyauthor=A.+S.+Singhauthor=I.+Puzanovauthor=E.+L.+Kwakauthor=A.+J.+Wagnerauthor=D.+D.+Von+Hoffauthor=G.+J.+Weissauthor=R.+K.+Ramanathanauthor=J.+Zhangauthor=G.+Habetsauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=G.+Visorauthor=L.+Sanftnerauthor=P.+Seversonauthor=H.+Nguyenauthor=M.+J.+Kimauthor=A.+Marimuthuauthor=G.+Tsangauthor=R.+Shellooeauthor=C.+Geeauthor=B.+L.+Westauthor=P.+Hirthauthor=K.+Nolopauthor=M.+van+de+Rijnauthor=H.+H.+Hsuauthor=C.+Peterfyauthor=P.+S.+Linauthor=S.+Tong-Starksenauthor=G.+Bollag&title=Structure-guided+blockade+of+CSF1R+kinase+in+tenosynovial+giant-cell+tumor&doi=10.1056%2FNEJMoa1411366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor</span></div><div class="casAuthors">Tap, W. D.; Wainberg, Z. A.; Anthony, S. P.; Ibrahim, P. N.; Zhang, C.; Healey, J. H.; Chmielowski, B.; Staddon, A. P.; Cohn, A. L.; Shapiro, G. I.; Keedy, V. L.; Singh, A. S.; Puzanov, I.; Kwak, E. L.; Wagner, A. J.; Von Hoff, D. D.; Weiss, G. J.; Ramanathan, R. K.; Zhang, J.; Habets, G.; Zhang, Y.; Burton, E. A.; Visor, G.; Sanftner, L.; Severson, P.; Nguyen, H.; Kim, M. J.; Marimuthu, A.; Tsang, G.; Shellooe, R.; Gee, C.; West, B. L.; Hirth, P.; Nolop, K.; van de Rijn, M.; Hsu, H. H.; Peterfy, C.; Lin, P. S.; Tong-Starksen, S.; Bollag, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-437</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors.  This observation has led to the discovery and clin. development of therapy targeting the CSF1 receptor (CSF1R).  METHODS Using x-ray co-crystallog. to guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps the kinase in the autoinhibited conformation.  We then conducted a multicenter, phase 1 trial in two parts to analyze this compd.  In the first part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (doseescalation study).  In the second part, we evaluated PLX3397 at the chosen phase 2 dose in an extension cohort of patients with tenosynovial giant-cell tumors (extension study).  Pharmacokinetic and tumor responses in the enrolled patients were assessed, and CSF1 in situ hybridization was performed to confirm the mechanism of action of PLX3397 and that the pattern of CSF1 expression was consistent with the pathol. features of tenosynovial giant-cell tumor.  RESULTS A total of 41 patients were enrolled in the dose-escalation study, and an addnl. 23 patients were enrolled in the extension study.  The chosen phase 2 dose of PLX3397 was 1000 mg per day.  In the extension study, 12 patients with tenosynovial giant-cell tumors had a partial response and 7 patients had stable disease.  Responses usually occurred within the first 4 mo of treatment, and the median duration of response exceeded 8 mo.  The most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema; adverse events rarely led to discontinuation of treatment.  CONCLUSIONS Treatment of tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor vol. in most patients. (Funded by Plexxikon; ClinicalTrials.gov no., NCT01004861.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgftPP4lKlQrVg90H21EOLACvtfcHk0lgRip-fB392wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLjN&md5=5e822a87786aca7495222e3d18f82bdb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411366%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DStaddon%26aufirst%3DA.%2BP.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DKeedy%26aufirst%3DV.%2BL.%26aulast%3DSingh%26aufirst%3DA.%2BS.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DSeverson%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DGee%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong-Starksen%26aufirst%3DS.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DStructure-guided%2520blockade%2520of%2520CSF1R%2520kinase%2520in%2520tenosynovial%2520giant-cell%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D428%26epage%3D437%26doi%3D10.1056%2FNEJMoa1411366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span> </span><span class="NLM_article-title">Phase 3 Study of Pexidartinib for Pigmented Villonodular
Synovitis
(PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) (ENLIVEN)</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02371369" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02371369</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3+Study+of+Pexidartinib+for+Pigmented+Villonodular%0ASynovitis%0A%28PVNS%29+or+Giant+Cell+Tumor+of+the+Tendon+Sheath+%28GCT-TS%29+%28ENLIVEN%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02371369+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%25203%2520Study%2520of%2520Pexidartinib%2520for%2520Pigmented%2520Villonodular%250ASynovitis%250A%2528PVNS%2529%2520or%2520Giant%2520Cell%2520Tumor%2520of%2520the%2520Tendon%2520Sheath%2520%2528GCT-TS%2529%2520%2528ENLIVEN%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Giraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradel, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerhake, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucknischke, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaluza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorr, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tourneau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruettinger, D.</span></span> <span> </span><span class="NLM_article-title">Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.ccr.2014.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24898549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=846-859&author=C.+H.+Riesauthor=M.+A.+Cannarileauthor=S.+Hovesauthor=J.+Benzauthor=K.+Warthaauthor=V.+Runzaauthor=F.+Rey-Giraudauthor=L.+P.+Pradelauthor=F.+Feuerhakeauthor=I.+Klamanauthor=T.+Jonesauthor=U.+Jucknischkeauthor=S.+Scheiblichauthor=K.+Kaluzaauthor=I.+H.+Gorrauthor=A.+Walzauthor=K.+Abirajauthor=P.+A.+Cassierauthor=A.+Sicaauthor=C.+Gomez-Rocaauthor=K.+E.+de+Visserauthor=A.+Italianoauthor=C.+Le+Tourneauauthor=J.-P.+Delordauthor=H.+Levitskyauthor=J.-Y.+Blayauthor=D.+Ruettinger&title=Targeting+tumor-associated+macrophages+with+anti-CSF-1R+antibody+reveals+a+strategy+for+cancer+therapy&doi=10.1016%2Fj.ccr.2014.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy</span></div><div class="casAuthors">Ries, Carola H.; Cannarile, Michael A.; Hoves, Sabine; Benz, Joerg; Wartha, Katharina; Runza, Valeria; Rey-Giraud, Flora; Pradel, Leon P.; Feuerhake, Friedrich; Klaman, Irina; Jones, Tobin; Jucknischke, Ute; Scheiblich, Stefan; Kaluza, Klaus; Gorr, Ingo H.; Walz, Antje; Abiraj, Keelara; Cassier, Philippe A.; Sica, Antonio; Gomez-Roca, Carlos; de Visser, Karin E.; Italiano, Antoine; Le Tourneau, Christophe; Delord, Jean-Pierre; Levitsky, Hyam; Blay, Jean-Yves; Ruettinger, Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">846-859</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Macrophage infiltration has been identified as an independent poor prognostic factor in several cancer types.  The major survival factor for these macrophages is macrophage colony-stimulating factor 1 (CSF-1).  We generated a monoclonal antibody (RG7155) that inhibits CSF-1 receptor (CSF-1R) activation.  In vitro RG7155 treatment results in cell death of CSF-1-differentiated macrophages.  In animal models, CSF-1R inhibition strongly reduces F4/80+ tumor-assocd. macrophages accompanied by an increase of the CD8+/CD4+ T cell ratio.  Administration of RG7155 to patients led to striking redns. of CSF-1R+CD163+ macrophages in tumor tissues, which translated into clin. objective responses in diffuse-type giant cell tumor (Dt-GCT) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXw3weYo79F7Vg90H21EOLACvtfcHk0ljhRTA1oTqNjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCntrw%253D&md5=023e0585a753021f10b204c6aeb72d4b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DHoves%26aufirst%3DS.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DWartha%26aufirst%3DK.%26aulast%3DRunza%26aufirst%3DV.%26aulast%3DRey-Giraud%26aufirst%3DF.%26aulast%3DPradel%26aufirst%3DL.%2BP.%26aulast%3DFeuerhake%26aufirst%3DF.%26aulast%3DKlaman%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJucknischke%26aufirst%3DU.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKaluza%26aufirst%3DK.%26aulast%3DGorr%26aufirst%3DI.%2BH.%26aulast%3DWalz%26aufirst%3DA.%26aulast%3DAbiraj%26aufirst%3DK.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DSica%26aufirst%3DA.%26aulast%3DGomez-Roca%26aufirst%3DC.%26aulast%3Dde%2BVisser%26aufirst%3DK.%2BE.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DLevitsky%26aufirst%3DH.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DRuettinger%26aufirst%3DD.%26atitle%3DTargeting%2520tumor-associated%2520macrophages%2520with%2520anti-CSF-1R%2520antibody%2520reveals%2520a%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26spage%3D846%26epage%3D859%26doi%3D10.1016%2Fj.ccr.2014.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span> </span><span class="NLM_article-title">A Study of AMG 820 in Subjects With Advanced Solid
Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT01444404" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01444404</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+AMG+820+in+Subjects+With+Advanced+Solid%0ATumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01444404+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520AMG%2520820%2520in%2520Subjects%2520With%2520Advanced%2520Solid%250ATumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span> </span><span class="NLM_article-title">A Study
of IMC-CS4 in Subjects With Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT01346358" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01346358</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+IMC-CS4+in+Subjects+With+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01346358+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%250Aof%2520IMC-CS4%2520in%2520Subjects%2520With%2520Advanced%2520Solid%2520Tumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span> </span><span class="NLM_article-title">Evaluation
of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB)
Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced
Pancreatic or Colorectal Cancers</span>. <a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=NCT02777710&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://clinicaltrials.gov/ct2/results?cond=&term=NCT02777710&cntry=&state=&city=&dist=</a> accessed July 22, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation%0Aof+Safety+and+Activity+of+an+Anti-PDL1+Antibody+%28DURVALUMAB%29%0ACombined+With+CSF-1R+TKI+%28PEXIDARTINIB%29+in+Patients+With+Metastatic%2FAdvanced%0APancreatic+or+Colorectal+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DNCT02777710%26cntry%3D%26state%3D%26city%3D%26dist%3D+accessed+July+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEvaluation%250Aof%2520Safety%2520and%2520Activity%2520of%2520an%2520Anti-PDL1%2520Antibody%2520%2528DURVALUMAB%2529%250ACombined%2520With%2520CSF-1R%2520TKI%2520%2528PEXIDARTINIB%2529%2520in%2520Patients%2520With%2520Metastatic%252FAdvanced%250APancreatic%2520or%2520Colorectal%2520Cancers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span> </span><span class="NLM_article-title">Durvalumab
in Combination With a CSF-1R Inhibitor (SNDX-6532) Following
Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT04301778?term=NCT04301778&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04301778?term=NCT04301778&draw=2&rank=1</a> (accessed July 22, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Durvalumab%0Ain+Combination+With+a+CSF-1R+Inhibitor+%28SNDX-6532%29+Following%0AChemo+or+Radio-Embolization+for+Patients+With+Intrahepatic+Cholangiocarcinoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04301778%3Fterm%3DNCT04301778%26draw%3D2%26rank%3D1+%28accessed+July+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDurvalumab%250Ain%2520Combination%2520With%2520a%2520CSF-1R%2520Inhibitor%2520%2528SNDX-6532%2529%2520Following%250AChemo%2520or%2520Radio-Embolization%2520for%2520Patients%2520With%2520Intrahepatic%2520Cholangiocarcinoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span> </span><span class="NLM_article-title">Nivolumab
and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab
(BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell
Lymphoma</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03927105?term=NCT03927105&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03927105?term=NCT03927105&draw=2&rank=1</a> (accessed July <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nivolumab%0Aand+the+Antagonistic+CSF-1R+Monoclonal+Antibody+Cabiralizumab%0A%28BMS-986227%29+in+Patients+With+Relapsed%2FRefractory+Peripheral+T+Cell%0ALymphoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03927105%3Fterm%3DNCT03927105%26draw%3D2%26rank%3D1+%28accessed+July+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNivolumab%250Aand%2520the%2520Antagonistic%2520CSF-1R%2520Monoclonal%2520Antibody%2520Cabiralizumab%250A%2528BMS-986227%2529%2520in%2520Patients%2520With%2520Relapsed%252FRefractory%2520Peripheral%2520T%2520Cell%250ALymphoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duignan, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs for colon-restricted delivery: design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0203567/1</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0203567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1371%2Fjournal.pone.0203567" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=D.+M.+Georgeauthor=R.+J.+Huntleyauthor=K.+Cusackauthor=D.+B.+Duignanauthor=M.+Hoemannauthor=J.+Loudauthor=R.+Marioauthor=T.+Melimauthor=K.+Mullenauthor=G.+Somalauthor=L.+Wangauthor=J.+J.+Edmunds&title=Prodrugs+for+colon-restricted+delivery%3A+design%2C+synthesis%2C+and+in+vivo+evaluation+of+colony+stimulating+factor+1+receptor+%28CSF1R%29+inhibitors&doi=10.1371%2Fjournal.pone.0203567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0203567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0203567%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DD.%2BM.%26aulast%3DHuntley%26aufirst%3DR.%2BJ.%26aulast%3DCusack%26aufirst%3DK.%26aulast%3DDuignan%26aufirst%3DD.%2BB.%26aulast%3DHoemann%26aufirst%3DM.%26aulast%3DLoud%26aufirst%3DJ.%26aulast%3DMario%26aufirst%3DR.%26aulast%3DMelim%26aufirst%3DT.%26aulast%3DMullen%26aufirst%3DK.%26aulast%3DSomal%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26atitle%3DProdrugs%2520for%2520colon-restricted%2520delivery%253A%2520design%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520evaluation%2520of%2520colony%2520stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0203567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Gamal, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ameen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Koumi, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamad, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalal, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.-H.</span></span> <span> </span><span class="NLM_article-title">Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5450</span>– <span class="NLM_lpage">5466</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5450-5466&author=M.+I.+El-Gamalauthor=S.+K.+Al-Ameenauthor=D.+M.+Al-Koumiauthor=M.+G.+Hamadauthor=N.+A.+Jalalauthor=C.-H.+Oh&title=Recent+advances+of+colony-stimulating+factor-1+receptor+%28CSF-1R%29+kinase+and+its+inhibitors&doi=10.1021%2Facs.jmedchem.7b00873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors</span></div><div class="casAuthors">El-Gamal, Mohammed I.; Al-Ameen, Shahad K.; Al-Koumi, Dania M.; Hamad, Mawadda G.; Jalal, Nouran A.; Oh, Chang-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5450-5466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Colony stimulation factor-1 receptor (CSF-1R), which is also known as FMS kinase, plays an important role in initiating inflammatory, cancer, and bone disorders when it is over-stimulated by its ligand, CSF-1.  Innate immunity, as well as macrophage differentiation and survival, are regulated by the stimulation of the CSF-1R.  Another ligand, interleukin-34 (IL-34), was recently reported to activate the CSF-1R receptor in a different manner.  The relationship between CSF-1R and microglia has been reviewed.  Both CSF-1 antibodies and small mol. CSF-1R kinase inhibitors have now been tested in animal models and in humans.  In this Perspective, the authors discuss the role of CSF-1 and IL-34 in producing cancer, bone disorders, and inflammation.  The authors also review the newly discovered and improved small mol. kinase inhibitors and monoclonal antibodies that have shown potent activity toward CSF-1R, reported from 2012 until 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4GIYJSVtGbVg90H21EOLACvtfcHk0liEWrt2Zjf1VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWgtg%253D%253D&md5=9fa615ecf2f532f1a2f1bac1e4c48932</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00873%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Gamal%26aufirst%3DM.%2BI.%26aulast%3DAl-Ameen%26aufirst%3DS.%2BK.%26aulast%3DAl-Koumi%26aufirst%3DD.%2BM.%26aulast%3DHamad%26aufirst%3DM.%2BG.%26aulast%3DJalal%26aufirst%3DN.%2BA.%26aulast%3DOh%26aufirst%3DC.-H.%26atitle%3DRecent%2520advances%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520kinase%2520and%2520its%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5450%26epage%3D5466%26doi%3D10.1021%2Facs.jmedchem.7b00873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span> <span> </span><span class="NLM_article-title">Comparing antibody and small-molecule therapies for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrc1913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnrc1913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=16929325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=714-727&author=K.+Imaiauthor=A.+Takaoka&title=Comparing+antibody+and+small-molecule+therapies+for+cancer&doi=10.1038%2Fnrc1913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing antibody and small-molecule therapies for cancer</span></div><div class="casAuthors">Imai, Kohzoh; Takaoka, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-mol. compds. have been approved for cancer treatment.  Both antibodies and small-mol. compds. are therefore promising tools for target-protein-based cancer therapy.  We discuss and compare the distinctive properties of these two therapeutic strategies to provide a better view for the development of new drugs and the future direction of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfUrcKvj1GLVg90H21EOLACvtfcHk0liEWrt2Zjf1VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D&md5=31cfa17a5e3ddba75b2e32632aaa0deb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1913%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26aulast%3DTakaoka%26aufirst%3DA.%26atitle%3DComparing%2520antibody%2520and%2520small-molecule%2520therapies%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D714%26epage%3D727%26doi%3D10.1038%2Fnrc1913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokieda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohzeki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serizawa, I.</span></span> <span> </span><span class="NLM_article-title">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1002/eji.200737199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1002%2Feji.200737199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=18085662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVOnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-291&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohzekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-Fms+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model&doi=10.1002%2Feji.200737199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span></div><div class="casAuthors">Ohno, Hiroaki; Uemura, Yasunori; Murooka, Hideko; Takanashi, Hiromi; Tokieda, Takemi; Ohzeki, Yumiko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrophage colony-stimulating factor (M-CSF) is important in the development of macrophages and osteoclasts.  Previous studies have also shown that CD11b+ myeloblasts and osteoclasts play key roles during inflammation and bone destruction in arthritic lesions.  In this study, we investigated whether N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl] urea (Ki20227), an inhibitor of the M-CSF receptor (c-Fms), suppressed disease progression in a type II collagen (CII)-induced arthritis (CIA) mouse model.  We found that Ki20227 inhibited M-CSF-dependent reactions, such as lipopolysaccharide-induced tumor necrosis factor-α prodn., which were enhanced by M-CSF in vitro.  Oral administration of Ki20227 in vivo prevented inflammatory cell infiltration and bone destruction, and consequently suppressed disease progression.  In addn., the no. of CD11b+, Gr-1+, and Ly-6G+ cells in the spleen decreased in the Ki20227-treated mice, and the CII-induced cytokine prodn. in splenocytes isolated from the Ki20227-treated arthritic mice was also reduced.  These observations indicate that Ki20227 might exert its therapeutic effects in the CIA mouse model by suppressing the M-CSF-dependent accumulation of both inflammatory and osteoclast cells, as well as by inhibiting inflammatory cytokine prodn.  Hence, inhibitors of the c-Fms tyrosine kinase might act as anti-inflammatory or anti-osteolytic agents against arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU2PPX9fmE17Vg90H21EOLACvtfcHk0liEWrt2Zjf1VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVOnt78%253D&md5=70f7884eda9cec53118c2fa600aaf33d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Feji.200737199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.200737199%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-Fms%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D291%26doi%3D10.1002%2Feji.200737199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illig, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballentine, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJarlais, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crysler, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donatelli, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczuk, B. E.</span></span> <span> </span><span class="NLM_article-title">Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7860</span>– <span class="NLM_lpage">7883</span>, <span class="refDoi"> DOI: 10.1021/jm200900q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200900q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7860-7883&author=C.+R.+Illigauthor=C.+L.+Mantheyauthor=M.+J.+Wallauthor=S.+K.+Meegallaauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=E.+Yurkowauthor=Z.+Zhouauthor=M.+R.+Playerauthor=B.+E.+Tomczuk&title=Optimization+of+a+potent+class+of+arylamide+colony-stimulating+factor-1+receptor+inhibitors+leading+to+anti-inflammatory+clinical+candidate+4-cyano-N-%5B2-%281-cyclohexen-1-yl%29-4-%5B1-%5B%28dimethylamino%29acetyl%5D-4-piperidinyl%5Dphenyl%5D-1H-imidazole-2-carboxamide+%28JNJ-28312141%29&doi=10.1021%2Fjm200900q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)</span></div><div class="casAuthors">Illig, Carl R.; Manthey, Carl L.; Wall, Mark J.; Meegalla, Sanath K.; Chen, Jinsheng; Wilson, Kenneth J.; Ballentine, Shelley K.; DesJarlais, Renee L.; Schubert, Carsten; Crysler, Carl S.; Chen, Yanmin; Molloy, Christopher J.; Chaikin, Margery A.; Donatelli, Robert R.; Yurkow, Edward; Zhou, Zhao; Player, Mark R.; Tomczuk, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7860-7883</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS) was optimized to improve pharmacokinetic and pharmacodynamic properties and potential toxicol. liabilities.  Early stage absorption, distribution, metab., and excretion assays were employed to ensure the incorporation of druglike properties resulting in the selection of several compds. with good activity in a pharmacodynamic screening assay in mice.  Further investigation, utilizing the type II collagen-induced arthritis model in mice, culminated in the selection of anti-inflammatory development candidate JNJ-28312141 (23, I, FMS IC50 = 0.69 nM, cell assay IC50 = 2.6 nM).  Compd. 23 also demonstrated efficacy in rat adjuvant and streptococcal cell wall-induced models of arthritis and has entered phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9cLVtgUGRbVg90H21EOLACvtfcHk0ljHhpM_JEeO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqs7bO&md5=a2d8b6a468f917dd1abbddc704f0f0ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200900q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200900q%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26atitle%3DOptimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520colony-stimulating%2520factor-1%2520receptor%2520inhibitors%2520leading%2520to%2520anti-inflammatory%2520clinical%2520candidate%25204-cyano-N-%255B2-%25281-cyclohexen-1-yl%2529-4-%255B1-%255B%2528dimethylamino%2529acetyl%255D-4-piperidinyl%255Dphenyl%255D-1H-imidazole-2-carboxamide%2520%2528JNJ-28312141%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7860%26epage%3D7883%26doi%3D10.1021%2Fjm200900q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezhuthachan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogoe, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4591</span>– <span class="NLM_lpage">4596</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2013.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=23842474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4591-4596&author=D.+A.+Scottauthor=L.+A.+Dakinauthor=K.+Dalyauthor=D.+J.+Del+Valleauthor=R.+B.+Dieboldauthor=L.+Drewauthor=J.+Ezhuthachanauthor=T.+W.+Geroauthor=C.+A.+Ogoeauthor=C.+A.+Omerauthor=S.+P.+Redmondauthor=G.+Repikauthor=K.+Thakurauthor=Q.+Yeauthor=X.+Zheng&title=Mitigation+of+cardiovascular+toxicity+in+a+series+of+CSF-1R+inhibitors%2C+and+the+identification+of+AZD7507&doi=10.1016%2Fj.bmcl.2013.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507</span></div><div class="casAuthors">Scott, David A.; Dakin, Les A.; Daly, Kevin; Del Valle, David J.; Diebold, R. Bruce; Drew, Lisa; Ezhuthachan, Jayachandran; Gero, Thomas W.; Ogoe, Claude A.; Omer, Charles A.; Redmond, Sean P.; Repik, Galina; Thakur, Kumar; Ye, Qing; Zheng, Xiaolan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4591-4596</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compd. and ion channel activity in particular.  Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacol. profiles.  Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBUarwHmu2-rVg90H21EOLACvtfcHk0ljHhpM_JEeO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltbjO&md5=7ffab262014fea03ff82233b1b45e21a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DDel%2BValle%26aufirst%3DD.%2BJ.%26aulast%3DDiebold%26aufirst%3DR.%2BB.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DOgoe%26aufirst%3DC.%2BA.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DRedmond%26aufirst%3DS.%2BP.%26aulast%3DRepik%26aufirst%3DG.%26aulast%3DThakur%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DMitigation%2520of%2520cardiovascular%2520toxicity%2520in%2520a%2520series%2520of%2520CSF-1R%2520inhibitors%252C%2520and%2520the%2520identification%2520of%2520AZD7507%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4591%26epage%3D4596%26doi%3D10.1016%2Fj.bmcl.2013.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">16078</span>– <span class="NLM_lpage">16083</span>, <span class="refDoi"> DOI: 10.1073/pnas.0502000102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.-H.+J.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580&doi=10.1073%2Fpnas.0502000102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0lhPoZDsIfiKIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.-H.%2BJ.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083%26doi%3D10.1073%2Fpnas.0502000102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikegashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.10.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2018.10.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=30442420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=115-118&author=K.+Ikegashiraauthor=T.+Ikenogamiauthor=T.+Yamasakiauthor=Y.+Haseauthor=T.+Yamaguchiauthor=K.+Inagakiauthor=S.+Doiauthor=T.+Adachiauthor=Y.+Kogaauthor=H.+Hashimoto&title=Discovery+of+a+novel+azetidine+scaffold+for+colony+stimulating+factor-1+receptor+%28CSF-1R%29+Type+II+inhibitors+by+the+use+of+docking+models&doi=10.1016%2Fj.bmcl.2018.10.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models</span></div><div class="casAuthors">Ikegashira, Kazutaka; Ikenogami, Taku; Yamasaki, Takayuki; Hase, Yasunori; Yamaguchi, Takayuki; Inagaki, Koji; Doi, Satoki; Adachi, Tsuyoshi; Koga, Yoshihisa; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by using a structure-based drug design (SBDD) based on a docking model.  The work leads to the representative compd. 4a with high CSF-1R inhibitory activity (IC50 = 9.1 nM).  The obtained crystal structure of an azetidine compd. with CSF-1R, which matched our predicted docking model, demonstrates that the azetidine compds. bind to the DFG-out conformation of the protein as a Type II inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod-KAPARMDLLVg90H21EOLACvtfcHk0lhPoZDsIfiKIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WitrnK&md5=04ea00b26cadb1d227c28d5b9ab95197</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.10.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.10.051%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DIkenogami%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520azetidine%2520scaffold%2520for%2520colony%2520stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520Type%2520II%2520inhibitors%2520by%2520the%2520use%2520of%2520docking%2520models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D115%26epage%3D118%26doi%3D10.1016%2Fj.bmcl.2018.10.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikegashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, H.</span></span> <span> </span><span class="NLM_article-title">Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2019.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=30755337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFyjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=873-877&author=K.+Ikegashiraauthor=T.+Ikenogamiauthor=T.+Yamasakiauthor=T.+Okaauthor=Y.+Haseauthor=N.+Miyagawaauthor=K.+Inagakiauthor=I.+Kawaharaauthor=Y.+Kogaauthor=H.+Hashimoto&title=Optimization+of+an+azetidine+series+as+inhibitors+of+colony+stimulating+factor-1+receptor+%28CSF-1R%29+Type+II+to+lead+to+the+clinical+candidate+JTE-952&doi=10.1016%2Fj.bmcl.2019.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952</span></div><div class="casAuthors">Ikegashira, Kazutaka; Ikenogami, Taku; Yamasaki, Takayuki; Oka, Takahiro; Hase, Yasunori; Miyagawa, Naoki; Inagaki, Koji; Kawahara, Iichiro; Koga, Yoshihisa; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">873-877</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of novel azetidine compds., which we had found as colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors, provided JTE-952 as a clin. candidate with high cellular activity (IC50 = 20 nM) and good pharmacokinetics profile.  JTE-952 was also effective against a mouse collagen-induced model of arthritis (mouse CIA-model).  Addnl., the x-ray co-crystal structure of JTE-952 with CSF-1R protein was shown to be a Type II inhibitor, and the kinase panel assay indicated that JTE-952 had high kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporHDNUrI_qLVg90H21EOLACvtfcHk0lgRDPKtITlM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFyjtb4%253D&md5=06ce87cb35a119745316b21ee777002b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DIkenogami%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DMiyagawa%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DK.%26aulast%3DKawahara%26aufirst%3DI.%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DOptimization%2520of%2520an%2520azetidine%2520series%2520as%2520inhibitors%2520of%2520colony%2520stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520Type%2520II%2520to%2520lead%2520to%2520the%2520clinical%2520candidate%2520JTE-952%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D873%26epage%3D877%26doi%3D10.1016%2Fj.bmcl.2019.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgRDPKtITlM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span> <span> </span><span class="NLM_article-title">BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2768</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1021/jm030543u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030543u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2768-2775&author=A.+C.+Pierceauthor=G.+Raoauthor=G.+W.+Bemis&title=BREED%3A+Generating+novel+inhibitors+through+hybridization+of+known+ligands.+Application+to+CDK2%2C+P38%2C+and+HIV+protease&doi=10.1021%2Fjm030543u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</span></div><div class="casAuthors">Pierce, Albert C.; Rao, Govinda; Bemis, Guy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2768-2775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target.  The method is essentially an automation of the common medicinal chem. practice of joining fragments of two known ligands to generate a new inhibitor.  The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new mols.  Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands.  In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new mol. structures were generated.  These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds.  The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques.  In an era of increasingly high-throughput structural biol., such methods for high-throughput utilization of structural information will become increasingly valuable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskNA5h73CbbVg90H21EOLACvtfcHk0lgRDPKtITlM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ajurk%253D&md5=e0bec9082fab05b694742498b3f41549</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm030543u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030543u%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DBREED%253A%2520Generating%2520novel%2520inhibitors%2520through%2520hybridization%2520of%2520known%2520ligands.%2520Application%2520to%2520CDK2%252C%2520P38%252C%2520and%2520HIV%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2768%26epage%3D2775%26doi%3D10.1021%2Fjm030543u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span> </span><span class="NLM_article-title">MolecularOperating
Environment (MOE), C. C. G. U., 1010 Sherbrook St. West, Suite 910,Montreal,
Canada, H3A 2R7</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MolecularOperating%0AEnvironment+%28MOE%29%2C+C.+C.+G.+U.%2C+1010+Sherbrook+St.+West%2C+Suite+910%2CMontreal%2C%0ACanada%2C+H3A+2R7%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DMolecularOperating%250AEnvironment%2520%2528MOE%2529%252C%2520C.%2520C.%2520G.%2520U.%252C%25201010%2520Sherbrook%2520St.%2520West%252C%2520Suite%2520910%252CMontreal%252C%250ACanada%252C%2520H3A%25202R7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span>; <span class="NLM_string-name">Hassell, A. M.</span>; <span class="NLM_string-name">Holmes, W. D.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Emmerson, H. K.</span>; <span class="NLM_string-name">Musso, D. L.</span>; <span class="NLM_string-name">Chamberlain, S. D.</span>; <span class="NLM_string-name">Peckham, G. E.</span></span> <span> </span><span class="NLM_article-title">Co-Crystal Structure of Liganded Inhibitors of Colony-Stimulating Factor 1 Receptor Kinase in Treatment of Disease</span>. <span class="NLM_patent">US20070010540</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+M.+Shewchuk&author=A.+M.+Hassell&author=W.+D.+Holmes&author=J.+M.+Veal&author=H.+K.+Emmerson&author=D.+L.+Musso&author=S.+D.+Chamberlain&author=G.+E.+Peckham&title=Co-Crystal+Structure+of+Liganded+Inhibitors+of+Colony-Stimulating+Factor+1+Receptor+Kinase+in+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26atitle%3DCo-Crystal%2520Structure%2520of%2520Liganded%2520Inhibitors%2520of%2520Colony-Stimulating%2520Factor%25201%2520Receptor%2520Kinase%2520in%2520Treatment%2520of%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative examples of small-molecule CSF1R inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Schematic showing the scaffold-hopping template and kinase hinge target interactions. (B) Molecular model of 4-pyridyl hinge-binding motif with the −C–O– linker engaging the backbone NH of Cys666 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO">3LCO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity profile of compound <b>12</b> against a panel of 468 kinases at a 1 μM test concentration. The larger the red circle, the greater the inhibition. Six kinases with the percent of control <10: CSF1R, cKIT, FLT3, AURB, PDGFRα, and PDGFRβ. See also <a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S1</a>, Supporting information.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CSF1R inhibitors deplete tumor macrophages and reduce tumor growth. IHC for F4/80 for PANC02 tumors in mice that were treated daily for 7 days with (A) vehicle, (B) 200 mg/kg BLZ945, or (C) 200 mg/kg compound <b>12</b> (<i>n</i> = 4 mice/group). (D) Pathologist-scored quantification of the F4/80 IHC signal in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> (<i>n</i> = 4 mice/group). (E) Relative CSF1R protein expression in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> as measured using ELISA (<i>n</i> = 4 mice/group). (F) Relative mRNA expression of known macrophage genes in PANC02 tumors from mice treated daily for 7 days with vehicle, 200 mg/kg BLZ945, or 200 mg/kg compound <b>12</b> (<i>n</i> = 3 mice/group) as measured using a nanostring code set. (G) Growth of MC38 tumors implanted subcutaneously in mice and treated daily with vehicle or 200 mg/kg compound <b>12</b> (<i>n</i> = 10 mice/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Model of compound <b>12</b> bound to CSF1R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO">3LCO</a>). (B) Sequence alignment of class III receptor tyrosine kinases highlighting a key difference in the xDFG motif. (C) Overlay of cKIT Cys809 (orange; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HVS">4HVS</a>) with the model of compound <b>12</b> bound to CSF1R shows a small pocket that is present in CSF1R that is filled by a cysteine side chain in other class III RTKs. (D) Overlay of GW2580 (pink) with the model of compound <b>12</b> shows a methoxy group filling this pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Selectivity profile of IACS-9439 (<b>1</b>) against a panel of 97 kinases (DiscoverX) at a 1 μM test concentration. The larger the red circle, the greater the inhibition. One kinase with the percent of control <10: CSF1R. See also <a href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf" class="ext-link">Table S3</a>, Supporting information.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. IACS-9439 (<b>1</b>) depletes tumor macrophages, promotes M1 macrophage, and inhibits tumor growth. (A) Heat map of nanostring and IHC measuring relative macrophage mRNAs or F4/80 protein levels from MC38 tumors treated daily for 10 days with vehicle or 20, 60, or 200 mg/kg of BLZ945, compound <b>12</b>, or IACS-9439 (<b>1</b>) (<i>n</i> = 3 mice/group). Note that 100 = no change (white) compared to vehicle-treated mice. (B) Relative EMR1 (F4/80) or (C) CD4 mRNA from PANC02 tumors treated daily for 10 days with 10, 25, 50, 100, or 200 mg/kg BLZ945 or IACS-9439 (<b>1</b>) (<i>n</i> = 4 mice/group). Tumor samples from CSF1Ri-treated mice were normalized to vehicle-treated mice and plotted in relation to the concentration of the compound in the plasma. Note that the vehicle was artificially set as 0.1 μM to enable curve fitting. (D) Flow cytometry depicting the percent of M1 (MHC II+) and M2 (CD206+) macrophages (CD45+, C11b+, F4/80+) in MC38 tumors from mice treated daily for 10 days with vehicle, 10, 50, or 200 mg/kg BLZ945, or IACS-9439 (<b>1</b>) (<i>n</i> = 10 mice/group). (E) Growth of MC38 tumors implanted subcutaneously in mice and treated daily with vehicle, BLZ945, or 200 mg/kg IACS-9439 (<b>1</b>) (<i>n</i> = 10 mice/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of Compounds <b>2</b>, <b>3</b>, and <b>8–20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnOH, NaH, 0 °C, dimethylformamide (DMF), 99%; (b) N<sub>2</sub>H<sub>4</sub>–H<sub>2</sub>O, Raney-Ni, rt, MeOH, 88%; (c) KSCN, CuSO<sub>4</sub>, 90 °C, MeOH, 37%; or KSCN, Br<sub>2</sub>, HOAc, 0 °C to rt, 4 h, AcOH, 12.5–78%; (d) <i>t</i>-BuONO, CuBr<sub>2</sub>, 0 °C to rt, MeCN, 30–53%; (e) amine, K<sub>2</sub>CO<sub>3</sub>, dimethyl sulfoxide (DMSO), 100 °C, 81%; or amine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, 110 °C, 78–100%; or amine, 110 °C, 79%; or amine, Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidinone (NMP), 125 °C, 66–70%; (f) TFA, 110 °C, 100%; (g) ArCH<sub>2</sub>Cl, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 42–88%; or ArCH<sub>2</sub>Cl, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 27–80%; (h) TFA, rt, quant.; (i) BBr<sub>3</sub>, 0 °C to rt, dichloromethane (DCM), 78–90%; (j) B<sub>2</sub>Pin<sub>2</sub>, KOAc, Pd(dppf)Cl<sub>2</sub>, 100 °C, 1,4-dioxane, quant.; (k) H<sub>2</sub>O<sub>2</sub>, rt, 1,4-dioxane, 60%; (l) BH<sub>3</sub>–tetrahydrofuran (THF); 60 °C, 45%; (m) 4-methoxybenzyl amine, 150 °C, 64%; and (n) SOCl<sub>2</sub>, rt, 2 h, DCM, 94%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Chemical Synthesis of Compounds <b>4</b>–<b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIBAL-H, THF, 0 °C–rt 4 h, 98%; (b) MeSNa, DMF,12 h, 71%; (c) MsCl, DIPEA, DMF. DCM, 0 °C–rt, 12 h, quant.; (d) pyridin-3-ylmethanol or pyridin-4-ylmethanol, <i>t</i>-BuOK, dimethyl acetamide (DMA), 100 °C, 2 h, quant.; (e) <i>m</i>-CPBA, DCM, 2 h, quant.; (f) cyclohexanamine, DIPEA, DMA,120 °C 2 h, 18%; (g) DPPA, 1,8-diazabicycloundec-7-ene (DBU), THF, rt, 3 h, 92%; (h) Lindlar Cat., H<sub>2</sub>, EtOH, 2 h; and (i) 3-iodopyridine or 4-iodopyridine, Cu, CsOAc, DMSO, 90 °C, 2 h, 78%.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Chemical Synthesis of Compounds <b>21</b>–<b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>3</sub>, H<sub>2</sub>O 90 °C, 3 h, 49%; (b) AIBN, NCS, CCl<sub>4</sub>, 18 h, 67%; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, rt, 4 h, DMF, 8%; (d) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, rt, 20 h, DMF, 93%; (e) 10% Pt–C, rt, 2 h, THF–MeOH, (5:1), 97%; (f) di(1<i>H</i>-imidazol-1-yl)methanethione, (1<i>S</i>,2<i>S</i>)-2-aminocyclohexan-1-ol, rt, 4 h, DCM, 96%; (g) BnMe<sub>3</sub>NBr<sub>3</sub>, BSTFA, rt, 20 min, DCM, 95%; (h) NH<sub>3</sub> (7 M, in MeOH), 120 °C, 4 h, 64%; and (i) NCS, 50 °C, 2 h, DCM, quant.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Chemical Synthesis of Compounds <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (4-(chloromethyl)pyridin-2-yl)carbamate, Cs<sub>2</sub>CO<sub>3</sub>, 80 °C, 2 h, DMF, 17%; (b) TFA, rt, 16 h, 35%; (c) TFA, 65 °C, 24 h 40 h, 24%; (d) <i>tert</i>-butyl (4-(hydroxymethyl)pyridin-2-yl)carbamate, Ph<sub>3</sub>P, DtBAD, rt, 16 h, THF, 93%; (e) TFA, rt, 3 h, DCM, 60%; (f) Ac<sub>2</sub>O, pyr, 60 °C, 1 h, DMF, 88%; and (g) (1<i>R</i>,2<i>R</i>)-2-aminocyclohexan-1-ol DIPEA, DMA, 100 °C, 12 h, 38%.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/medium/jm0c00936_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Chemical Synthesis of Compounds <b>26</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00936/20200903/images/large/jm0c00936_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00936&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBSCl, imid., DMF, 12 h, rt, 91%; (b) NH<sub>3</sub> in <i>i</i>PrOH (2 M), 120 °C, MW, 8 h, 72%; (c) phenylchloroformate, Py, DMAP (Cat.), 3 h, rt; (d) MeNH<sub>2</sub>, 12 h, rt, 51% for two steps; (e) tetra-<i>n</i>-butylammonium fluoride (TBAF), 12 h, rt, 40%; and (f) (i) 1-methyl-1<i>H</i>-pyrazol-4-amine DIPEA, 120 °C, 10 h, DMA, 46% (<b>1</b>); (ii) 1-methyl-1<i>H</i>-pyrazol-3-amine, DIPEA, 120 °C, 5 h, 2-propanol, MW, 15% (<b>27</b>); (iii) 1<i>H</i>-pyrazol-4-amine, TEA, 120 °C, 2 h, DMSO, MW, 44% (<b>28</b>); (iv) 1<i>H</i>-pyrazol-3-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 110 °C, 2 h, 14% (<b>29</b>); (v) 4-amino isoxazole hydrochloride, TEA, 120 °C, 2 h, DMSO, MW, 63% (<b>30</b>); (vi) 1-methyl-1<i>H</i>-1,2,3-triazol-4-amine, TsOH, dioxan, 110 °C, 12 h, 10% (<b>31</b>); and (vii) 1-methyl-1<i>H</i>-pyrazol-3-amine, DIPEA, 110 °C, 18 h, 5% (<b>32</b>).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i146">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savai, R.</span></span> <span> </span><span class="NLM_article-title">Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">48436</span>– <span class="NLM_lpage">48452</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.18632%2Foncotarget.17061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28467800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1crjs1Ciuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=48436-48452&author=X.+Zhengauthor=K.+Turkowskiauthor=J.+Moraauthor=B.+Bruneauthor=A.+Weigertauthor=W.+Seegerauthor=R.+Savai&title=Redirecting+tumor-associated+macrophages+to+become+tumoricidal+effectors+as+a+novel+strategy+for+cancer+therapy&doi=10.18632%2Foncotarget.17061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy</span></div><div class="casAuthors">Zheng Xiang; Turkowski Kati; Seeger Werner; Savai Rajkumar; Mora Javier; Brune Bernhard; Weigert Andreas; Seeger Werner; Savai Rajkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">48436-48452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer research in recent decades has highlighted the potential influence of the tumor microenvironment on the progression and metastasis of most known cancer types.  Within the established microenvironment, tumor-associated macrophages (TAMs) are one of the most abundant and crucial non-neoplastic cell types.  The polarization of macrophages into tumor-suppressive M1 or tumor-promoting M2 types is a fundamental event in the establishment of the tumor microenvironment.  Although ample evidence indicates that TAMs are primarily M2 polarized, the mechanisms responsible for the regulation and maintenance of M1 and M2 polarization imbalance remain unclear.  The manipulation of this critical axis through three main approaches may provide new strategies for cancer therapy - (I) specific interference with M2-like TAM survival or inhibiting their signaling cascades, (II) repression of macrophage recruitment to tumors, and (III) repolarization of tumor-promoting M2-like TAMs to a tumoricidal M1-like phenotype.  This review summarizes current strategies for cancer intervention via manipulation of macrophage polarization, with particular focus on composition of the tumor microenvironment and its influence on cancer progression and metastasis.  It is clear that additional fundamental and preclinical research is required to confirm the efficacy and practicality of this novel and promising strategy for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVn-pfX7PHl5Pq5LRczm8ffW6udTcc2eZhA2oabFBNXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjs1Ciuw%253D%253D&md5=31465e5ce142a49835f12d75963e02da</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17061%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTurkowski%26aufirst%3DK.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DBrune%26aufirst%3DB.%26aulast%3DWeigert%26aufirst%3DA.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DSavai%26aufirst%3DR.%26atitle%3DRedirecting%2520tumor-associated%2520macrophages%2520to%2520become%2520tumoricidal%2520effectors%2520as%2520a%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D48436%26epage%3D48452%26doi%3D10.18632%2Foncotarget.17061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: implications in cancer immunotherapy</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.2217%2Fimt-2016-0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28231720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=289-302&author=A.+J.+Pettyauthor=Y.+Yang&title=Tumor-associated+macrophages%3A+implications+in+cancer+immunotherapy&doi=10.2217%2Fimt-2016-0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated macrophages: implications in cancer immunotherapy</span></div><div class="casAuthors">Petty, Amy J.; Yang, Yiping</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-302</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-743X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment.  These anti-inflammatory and protumorigenic macrophages modulate the local microenvironment to facilitate tumor growth and metastasis.  In this review, we examine the origin of TAMs and the complex regulatory networks within the tumor microenvironment that facilitate the polarization of TAMs toward a protumoral phenotype.  More extensively, we evaluate the mechanisms by which TAMs mediate angiogenesis, metastasis, chemotherapeutic resistance and immune evasion.  Lastly, we will highlight novel interventional strategies targeting TAMs in preclin. studies and in early clin. trials that have significant potential in improving efficacy of current chemotherapeutic and/or immunotherapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp07UjzPBelvrVg90H21EOLACvtfcHk0lh2yM5MQVBm7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1Gls7s%253D&md5=e873b29c2f3661a8e49db1f06277adac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0135%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DTumor-associated%2520macrophages%253A%2520implications%2520in%2520cancer%2520immunotherapy%26jtitle%3DImmunotherapy%26date%3D2017%26volume%3D9%26spage%3D289%26epage%3D302%26doi%3D10.2217%2Fimt-2016-0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baral, R.</span></span> <span> </span><span class="NLM_article-title">Tumor promoting role of anti-tumor macrophages in tumor microenvironment</span>. <i>Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.cellimm.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.cellimm.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28433198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2017&pages=1-10&author=K.+K.+Goswamiauthor=T.+Ghoshauthor=S.+Ghoshauthor=M.+Sarkarauthor=A.+Boseauthor=R.+Baral&title=Tumor+promoting+role+of+anti-tumor+macrophages+in+tumor+microenvironment&doi=10.1016%2Fj.cellimm.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor promoting role of anti-tumor macrophages in tumor microenvironment</span></div><div class="casAuthors">Goswami, Kuntal Kanti; Ghosh, Tithi; Ghosh, Sarbari; Sarkar, Madhurima; Bose, Anamika; Baral, Rathindranath</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CLIMB8</span>;
        ISSN:<span class="NLM_cas:issn">0008-8749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent advances in tumor biol. demand detailed anal. of the complex interaction of tumor cells with their adjacent microenvironment (tumor stroma) to understand the various mechanisms involved in tumor growth and metastasis.  Mononuclear phagocytes or macrophages, a type of innate immune cells, defend the organism against infection and injury.  On the other hand, tumor assocd. macrophages (TAMs) constitute a significant part of the tumor-infiltrating immune cells, have been linked to the growth, angiogenesis, and metastasis of a variety of cancers, most likely through polarization of TAMs to the M2 (alternative) phenotype.  Clin. and exptl. evidences have shown that cancer tissues with high infiltration of TAMs are assocd. with poor patient prognosis and resistance to therapies, thus, targeting of TAMs in tumors is considered as a promising immunotherapeutic strategy.  Depletion of M2 TAMs or 're-education' of them as anti-tumor effectors might contribute significantly to the search of new modalities in anti-cancer treatments.  Basic questions on the factors responsible for homing of macrophages in tumors, mechanism of conversion of M1 to M2 TAMs, their functionality and, finally, the possible ways to target M2 TAMs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreisc_2n8gyLVg90H21EOLACvtfcHk0lh2yM5MQVBm7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWqtLw%253D&md5=0407f61ea5fe47fd8a223af7cae3f347</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cellimm.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellimm.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DK.%2BK.%26aulast%3DGhosh%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DBaral%26aufirst%3DR.%26atitle%3DTumor%2520promoting%2520role%2520of%2520anti-tumor%2520macrophages%2520in%2520tumor%2520microenvironment%26jtitle%3DCell.%2520Immunol.%26date%3D2017%26volume%3D316%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.cellimm.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngambenjawong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pun, S. H.</span></span> <span> </span><span class="NLM_article-title">Progress in tumor-associated macrophage (TAM)-targeted therapeutics</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.addr.2017.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28449873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=206-221&author=C.+Ngambenjawongauthor=H.+H.+Gustafsonauthor=S.+H.+Pun&title=Progress+in+tumor-associated+macrophage+%28TAM%29-targeted+therapeutics&doi=10.1016%2Fj.addr.2017.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in tumor-associated macrophage (TAM)-targeted therapeutics</span></div><div class="casAuthors">Ngambenjawong, Chayanon; Gustafson, Heather H.; Pun, Suzie H.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-221</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As an essential innate immune population for maintaining body homeostasis and warding off foreign pathogens, macrophages display high plasticity and perform diverse supportive functions specialized to different tissue compartments.  Consequently, aberrance in macrophage functions contributes substantially to progression of several diseases including cancer, fibrosis, and diabetes.  In the context of cancer, tumor-assocd. macrophages (TAMs) in tumor microenvironment (TME) typically promote cancer cell proliferation, immunosuppression, and angiogenesis in support of tumor growth and metastasis.  Oftentimes, the abundance of TAMs in tumor is correlated with poor disease prognosis.  Hence, significant attention has been drawn towards development of cancer immunotherapies targeting these TAMs; either depleting them from tumor, blocking their pro-tumoral functions, or restoring their immunostimulatory/tumoricidal properties.  This review aims to introduce readers to various aspects in development and evaluation of TAM-targeted therapeutics in pre-clin. and clin. stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPDjatoNEOabVg90H21EOLACvtfcHk0lh2yM5MQVBm7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKqtL0%253D&md5=5986b63aee5e4a0197b62d93838b0459</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DNgambenjawong%26aufirst%3DC.%26aulast%3DGustafson%26aufirst%3DH.%2BH.%26aulast%3DPun%26aufirst%3DS.%2BH.%26atitle%3DProgress%2520in%2520tumor-associated%2520macrophage%2520%2528TAM%2529-targeted%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D114%26spage%3D206%26epage%3D221%26doi%3D10.1016%2Fj.addr.2017.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recht, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, S.</span></span> <span> </span><span class="NLM_article-title">The promise of targeting macrophages in cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3241</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1158%2F1078-0432.CCR-16-3122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28341752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1cvhtVKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3241-3250&author=J.+M.+Brownauthor=L.+Rechtauthor=S.+Strober&title=The+promise+of+targeting+macrophages+in+cancer+therapy&doi=10.1158%2F1078-0432.CCR-16-3122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Promise of Targeting Macrophages in Cancer Therapy</span></div><div class="casAuthors">Brown J Martin; Recht Lawrence; Strober Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3241-3250</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Cancer therapy has developed around the concept of killing, or stopping the growth of, the cancer cells.  Molecularly targeted therapy is the modern expression of this paradigm.  Increasingly, however, the realization that the cancer has co-opted the normal cells of the stroma for its own survival has led to the concept that the tumor microenvironment (TME) could be targeted for effective therapy.  In this review, we outline the importance of tumor-associated macrophages (TAM), a major component of the TME, in the response of tumors to cancer therapy.  We discuss the normal role of macrophages in wound healing, the major phenotypes of TAMs, and their role in blunting the efficacy of cancer treatment by radiation and anticancer drugs, both by promoting tumor angiogenesis and by suppressing antitumor immunity.  Finally, we review the many preclinical studies that have shown that the response of tumors to irradiation and anticancer drugs can be improved, sometimes markedly so, by depleting TAMs from tumors or by suppressing their polarization from an M1 to an M2 phenotype.  The data clearly support the validity of clinical testing of combining targeting TAMs with conventional therapy.  Clin Cancer Res; 23(13); 3241-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYEpxqdHjD4IvKgEt20y1XfW6udTcc2eZNApzPtpF-5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvhtVKrsw%253D%253D&md5=8678b1d4fd911e05ba331a9d2df520fa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3122%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DRecht%26aufirst%3DL.%26aulast%3DStrober%26aufirst%3DS.%26atitle%3DThe%2520promise%2520of%2520targeting%2520macrophages%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3241%26epage%3D3250%26doi%3D10.1158%2F1078-0432.CCR-16-3122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dull, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span> <span> </span><span class="NLM_article-title">Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1038/325549a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2F325549a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=3027579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADyaL2sXhtlarsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1987&pages=549-552&author=M.+F.+Rousselauthor=T.+J.+Dullauthor=C.+W.+Rettenmierauthor=P.+Ralphauthor=A.+Ullrichauthor=C.+J.+Sherr&title=Transforming+potential+of+the+c-fms+proto-oncogene+%28CSF-1+receptor%29&doi=10.1038%2F325549a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)</span></div><div class="casAuthors">Roussel, Martine F.; Dull, Thomas J.; Rettenmier, Carl W.; Ralph, Peter; Ullrich, Axel; Sherr, Charles J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">6104</span>),
    <span class="NLM_cas:pages">549-52</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The c-fms proto-oncogene encodes a transmembrane glycoprotein that is probably identical to the receptor for the macrophage colony stimulating factors, CSF-1.  Forty C-terminal amino acids of the normal receptor are replaced by 11 unrelated residues in the feline v-fms oncogene product, deleting a C-terminal tyrosine residue (Tyr969) whose phosphorylation might neg. regulate the receptor kinase activity.  This study showed that the human c-fms gene stimulates growth of mouse NIH 3T3 cells in agar in response to human recombinant CSF-1, indicating that receptor transduction is sufficient to induce a CSF-1 responsive phenotype.  Although cells transfected with c-fms genes contg. either Tyr969 or Phe969 were not transformed, cotransfection of these genes with CSF-1 cDNA induced transformation, with c-fms (Phe969) showing significantly more activity than c-fms (Tyr969).  In the absence of CSF-1, chimeric v-fms/c-fms genes encoding the wild-type c-fms C terminus were poorly transforming, whereas chimeras bearing Phe969 were as transforming as v-fms.  Thus, the Phe969 mutation, although not in itself sufficient to induce transformation, activates the oncogenic potential of c-fms in assocn. with an endogenous ligand or in conjuction with mutation elsewhere in the c-fms that confer ligand-independent signals for growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6BaG8vXq4LVg90H21EOLACvtfcHk0lhAl_gJaalYKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtlarsb4%253D&md5=b54c5fd69c815498155bdf8564ec4e39</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F325549a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F325549a0%26sid%3Dliteratum%253Aachs%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26aulast%3DRalph%26aufirst%3DP.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26atitle%3DTransforming%2520potential%2520of%2520the%2520c-fms%2520proto-oncogene%2520%2528CSF-1%2520receptor%2529%26jtitle%3DNature%26date%3D1987%26volume%3D325%26spage%3D549%26epage%3D552%26doi%3D10.1038%2F325549a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeNardo, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexhepaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadhwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keil, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junaid, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirstroem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span> <span> </span><span class="NLM_article-title">Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1158/2159-8274.CD-10-0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1158%2F2159-8274.CD-10-0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=22039576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVylsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=54-67&author=D.+G.+DeNardoauthor=D.+J.+Brennanauthor=E.+Rexhepajauthor=B.+Ruffellauthor=S.+L.+Shiaoauthor=S.+F.+Maddenauthor=W.+M.+Gallagherauthor=N.+Wadhwaniauthor=S.+D.+Keilauthor=S.+A.+Junaidauthor=H.+S.+Rugoauthor=E.+S.+Hwangauthor=K.+Jirstroemauthor=B.+L.+Westauthor=L.+M.+Coussens&title=Leukocyte+complexity+predicts+breast+cancer+survival+and+functionally+regulates+response+to+chemotherapy&doi=10.1158%2F2159-8274.CD-10-0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy</span></div><div class="casAuthors">DeNardo, David G.; Brennan, Donal J.; Rexhepaj, Elton; Ruffell, Brian; Shiao, Stephen L.; Madden, Stephen F.; Gallagher, William M.; Wadhwani, Nikhil; Keil, Scott D.; Junaid, Sharfaa A.; Rugo, Hope S.; Hwang, E. Shelley; Jirstroem, Karin; West, Brian L.; Coussens, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-67</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">Immune-regulated pathways influence multiple aspects of cancer development.  In this article we demonstrate that both macrophage abundance and T-cell abundance in breast cancer represent prognostic indicators for recurrence-free and overall survival.  We provide evidence that response to chemotherapy is in part regulated by these leukocytes; cytotoxic therapies induce mammary epithelial cells to produce monocyte/macrophage recruitment factors, including colony stimulating factor 1 (CSF1) and interleukin-34, which together enhance CSF1 receptor (CSF1R)-dependent macrophage infiltration.  Blockade of macrophage recruitment with CSF1R-signaling antagonists, in combination with paclitaxel, improved survival of mammary tumor-bearing mice by slowing primary tumor development and reducing pulmonary metastasis.  These improved aspects of mammary carcinogenesis were accompanied by decreased vessel d. and appearance of antitumor immune programs fostering tumor suppression in a CD8+ T-cell-dependent manner.  These data provide a rationale for targeting macrophage recruitment/response pathways, notably C5F1R, in combination with cytotoxic therapy, and identification of a breast cancer population likely to benefit from this novel therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFqFZ3CvAgbVg90H21EOLACvtfcHk0lhAl_gJaalYKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVylsbo%253D&md5=098edea4f3ec31f1e31d2e9fc5569ac6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F2159-8274.CD-10-0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8274.CD-10-0028%26sid%3Dliteratum%253Aachs%26aulast%3DDeNardo%26aufirst%3DD.%2BG.%26aulast%3DBrennan%26aufirst%3DD.%2BJ.%26aulast%3DRexhepaj%26aufirst%3DE.%26aulast%3DRuffell%26aufirst%3DB.%26aulast%3DShiao%26aufirst%3DS.%2BL.%26aulast%3DMadden%26aufirst%3DS.%2BF.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26aulast%3DWadhwani%26aufirst%3DN.%26aulast%3DKeil%26aufirst%3DS.%2BD.%26aulast%3DJunaid%26aufirst%3DS.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DHwang%26aufirst%3DE.%2BS.%26aulast%3DJirstroem%26aufirst%3DK.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26atitle%3DLeukocyte%2520complexity%2520predicts%2520breast%2520cancer%2520survival%2520and%2520functionally%2520regulates%2520response%2520to%2520chemotherapy%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D54%26epage%3D67%26doi%3D10.1158%2F2159-8274.CD-10-0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyonteck, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmacher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijeiro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1038/nm.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnm.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24056773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1264-1272&author=S.+M.+Pyonteckauthor=L.+Akkariauthor=A.+J.+Schuhmacherauthor=R.+L.+Bowmanauthor=L.+Sevenichauthor=D.+F.+Quailauthor=O.+C.+Olsonauthor=M.+L.+Quickauthor=J.+T.+Huseauthor=V.+Teijeiroauthor=M.+Settyauthor=C.+S.+Leslieauthor=Y.+Oeiauthor=A.+Pedrazaauthor=J.+Zhangauthor=C.+W.+Brennanauthor=J.+C.+Suttonauthor=E.+C.+Hollandauthor=D.+Danielauthor=J.+A.+Joyce&title=CSF-1R+inhibition+alters+macrophage+polarization+and+blocks+glioma+progression&doi=10.1038%2Fnm.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span></div><div class="casAuthors">Pyonteck, Stephanie M.; Akkari, Leila; Schuhmacher, Alberto J.; Bowman, Robert L.; Sevenich, Lisa; Quail, Daniela F.; Olson, Oakley C.; Quick, Marsha L.; Huse, Jason T.; Teijeiro, Virginia; Setty, Manu; Leslie, Christina S.; Oei, Yoko; Pedraza, Alicia; Zhang, Jianan; Brennan, Cameron W.; Sutton, James C.; Holland, Eric C.; Daniel, Dylan; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) comprises several mol. subtypes, including proneural GBM.  Most therapeutic approaches targeting glioma cells have failed.  An alternative strategy is to target cells in the glioma microenvironment, such as tumor-assocd. macrophages and microglia (TAMs).  Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival.  We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors.  CSF-1R blockade addnl. slowed intracranial growth of patient-derived glioma xenografts.  Surprisingly, TAMs were not depleted in treated mice.  Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition.  Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions.  These gene signatures were assocd. with enhanced survival in patients with proneural GBM.  Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirwpRVIWUELVg90H21EOLACvtfcHk0liielbE89wNvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N&md5=9b908e86c4a7da35a009bf322d492214</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3337%26sid%3Dliteratum%253Aachs%26aulast%3DPyonteck%26aufirst%3DS.%2BM.%26aulast%3DAkkari%26aufirst%3DL.%26aulast%3DSchuhmacher%26aufirst%3DA.%2BJ.%26aulast%3DBowman%26aufirst%3DR.%2BL.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DOlson%26aufirst%3DO.%2BC.%26aulast%3DQuick%26aufirst%3DM.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DTeijeiro%26aufirst%3DV.%26aulast%3DSetty%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DC.%2BS.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DPedraza%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26aulast%3DSutton%26aufirst%3DJ.%2BC.%26aulast%3DHolland%26aufirst%3DE.%2BC.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DCSF-1R%2520inhibition%2520alters%2520macrophage%2520polarization%2520and%2520blocks%2520glioma%2520progression%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1264%26epage%3D1272%26doi%3D10.1038%2Fnm.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span> <span> </span><span class="NLM_article-title">CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e26968</span> <span class="refDoi"> DOI: 10.4161/onci.26968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.4161%2Fonci.26968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24498562" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&author=D.+C.+Strachanauthor=B.+Ruffellauthor=Y.+Oeiauthor=M.+J.+Bissellauthor=L.+M.+Coussensauthor=N.+Pryerauthor=D.+Daniel&title=CSF1R+inhibition+delays+cervical+and+mammary+tumor+growth+in+murine+models+by+attenuating+the+turnover+of+tumor-associated+macrophages+and+enhancing+infiltration+by+CD8%28%2B%29+T+cells&doi=10.4161%2Fonci.26968"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4161%2Fonci.26968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.26968%26sid%3Dliteratum%253Aachs%26aulast%3DStrachan%26aufirst%3DD.%2BC.%26aulast%3DRuffell%26aufirst%3DB.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DBissell%26aufirst%3DM.%2BJ.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DPryer%26aufirst%3DN.%26aulast%3DDaniel%26aufirst%3DD.%26atitle%3DCSF1R%2520inhibition%2520delays%2520cervical%2520and%2520mammary%2520tumor%2520growth%2520in%2520murine%2520models%2520by%2520attenuating%2520the%2520turnover%2520of%2520tumor-associated%2520macrophages%2520and%2520enhancing%2520infiltration%2520by%2520CD8%2528%252B%2529%2520T%2520cells%26jtitle%3DOncoimmunology%26date%3D2013%26volume%3D2%26doi%3D10.4161%2Fonci.26968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegg, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruttinger, D.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">53</span> <span class="refDoi"> DOI: 10.1186/s40425-017-0257-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1186%2Fs40425-017-0257-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=28716061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=M.+A.+Cannarileauthor=M.+Weisserauthor=W.+Jacobauthor=A.-M.+Jeggauthor=C.+H.+Riesauthor=D.+Ruttinger&title=Colony-stimulating+factor+1+receptor+%28CSF1R%29+inhibitors+in+cancer+therapy&doi=10.1186%2Fs40425-017-0257-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span></div><div class="casAuthors">Cannarile Michael A; Weisser Martin; Jacob Wolfgang; Jegg Anna-Maria; Ries Carola H; Ruttinger Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells.  In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development.  Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents.  The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion.  In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending.  As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment.  Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells.  We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies.  Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQzjcxKO1-OQqdek-gHSrIfW6udTcc2eabS47dsZb55rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D&md5=09fab249b606af3e00f545dc7e7121b4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2Fs40425-017-0257-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-017-0257-y%26sid%3Dliteratum%253Aachs%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DWeisser%26aufirst%3DM.%26aulast%3DJacob%26aufirst%3DW.%26aulast%3DJegg%26aufirst%3DA.-M.%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DRuttinger%26aufirst%3DD.%26atitle%3DColony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2017%26volume%3D5%26doi%3D10.1186%2Fs40425-017-0257-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span> </span><span class="NLM_article-title">A Study of BLZ945 Single Agent or BLZ945 in Combination
With PDR001
in Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02829723" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02829723</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+BLZ945+Single+Agent+or+BLZ945+in+Combination%0AWith+PDR001%0Ain+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02829723+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520BLZ945%2520Single%2520Agent%2520or%2520BLZ945%2520in%2520Combination%250AWith%2520PDR001%250Ain%2520Advanced%2520Solid%2520Tumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span> </span><span class="NLM_article-title">FDA Approves
First Therapy for Rare Joint Tumor</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0AFirst+Therapy+for+Rare+Joint+Tumor.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-therapy-rare-joint-tumor+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250AFirst%2520Therapy%2520for%2520Rare%2520Joint%2520Tumor%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3093</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.3093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1200%2Fjco.2011.29.15_suppl.3093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3093&author=S.+P.+Anthonyauthor=I.+Puzanovauthor=P.+S.+Linauthor=K.+B.+Nolopauthor=B.+Westauthor=D.+D.+Von+Hoff&title=Pharmacodynamic+activity+demonstrated+in+phase+I+for+PLX3397%2C+a+selective+inhibitor+of+FMS+and+Kit&doi=10.1200%2Fjco.2011.29.15_suppl.3093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.3093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.3093%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DWest%26aufirst%3DB.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26atitle%3DPharmacodynamic%2520activity%2520demonstrated%2520in%2520phase%2520I%2520for%2520PLX3397%252C%2520a%2520selective%2520inhibitor%2520of%2520FMS%2520and%2520Kit%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3093%26doi%3D10.1200%2Fjco.2011.29.15_suppl.3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">5689</span>– <span class="NLM_lpage">5694</span>, <span class="refDoi"> DOI: 10.1073/pnas.1219457110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1073%2Fpnas.1219457110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=23493555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=5689-5694&author=C.+Zhangauthor=P.+N.+Ibrahimauthor=J.+Zhangauthor=E.+A.+Burtonauthor=G.+Habetsauthor=Y.+Zhangauthor=B.+Powellauthor=B.+L.+Westauthor=B.+Matusowauthor=G.+Tsangauthor=R.+Shellooeauthor=H.+Cariasauthor=H.+Nguyenauthor=A.+Marimuthuauthor=K.+Y.+J.+Zhangauthor=A.+Ohauthor=R.+Bremerauthor=C.+R.+Hurtauthor=D.+R.+Artisauthor=G.+Wuauthor=M.+Nespiauthor=W.+Spevakauthor=P.+Linauthor=K.+Nolopauthor=P.+Hirthauthor=G.+H.+Teschauthor=G.+Bollag&title=Design+and+pharmacology+of+a+highly+specific+dual+FMS+and+KIT+kinase+inhibitor&doi=10.1073%2Fpnas.1219457110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor</span></div><div class="casAuthors">Zhang, Chao; Ibrahim, Prabha N.; Zhang, Jiazhong; Burton, Elizabeth A.; Habets, Gaston; Zhang, Ying; Powell, Ben; West, Brian L.; Matusow, Bernice; Tsang, Garson; Shellooe, Rafe; Carias, Heidi; Nguyen, Hoa; Marimuthu, Adhirai; Zhang, Kam Y. J.; Oh, Angela; Bremer, Ryan; Hurt, Clarence R.; Artis, Dean R.; Wu, Guoxian; Nespi, Marika; Spevak, Wayne; Lin, Paul; Nolop, Keith; Hirth, Peter; Tesch, Greg H.; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5689-5694, S5689/1-S5689/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Inflammation and cancer, two therapeutic areas historically addressed by sep. drug discovery efforts, are now coupled in treatment approaches by a growing understanding of the dynamic mol. dialogues between immune and cancer cells.  Agents that target specific compartments of the immune system, therefore, not only bring new disease modifying modalities to inflammatory diseases, but also offer a new avenue to cancer therapy by disrupting immune components of the microenvironment that foster tumor growth, progression, immune evasion, and treatment resistance.  McDonough feline sarcoma viral (v-fms) oncogene homolog (FMS) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) are two hematopoietic cell surface receptors that regulate the development and function of macrophages and mast cells, resp.  The authors disclose a highly specific dual FMS and KIT kinase inhibitor developed from a multifaceted chem. scaffold.  As expected, this inhibitor blocks the activation of macrophages, osteoclasts, and mast cells controlled by these two receptors.  More importantly, the dual FMS and KIT inhibition profile has translated into a combination of benefits in preclin. disease models of inflammation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofECnjzEONuLVg90H21EOLACvtfcHk0lgf3cj22TFNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWksLk%253D&md5=e4fbca9d41f95718a5119a08a54f5acc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1219457110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1219457110%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DHurt%26aufirst%3DC.%2BR.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTesch%26aufirst%3DG.%2BH.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDesign%2520and%2520pharmacology%2520of%2520a%2520highly%2520specific%2520dual%2520FMS%2520and%2520KIT%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D5689%26epage%3D5694%26doi%3D10.1073%2Fpnas.1219457110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">S5689/1-S5689/11.</p></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staddon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong-Starksen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1056%2FNEJMoa1411366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=26222558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=428-437&author=W.+D.+Tapauthor=Z.+A.+Wainbergauthor=S.+P.+Anthonyauthor=P.+N.+Ibrahimauthor=C.+Zhangauthor=J.+H.+Healeyauthor=B.+Chmielowskiauthor=A.+P.+Staddonauthor=A.+L.+Cohnauthor=G.+I.+Shapiroauthor=V.+L.+Keedyauthor=A.+S.+Singhauthor=I.+Puzanovauthor=E.+L.+Kwakauthor=A.+J.+Wagnerauthor=D.+D.+Von+Hoffauthor=G.+J.+Weissauthor=R.+K.+Ramanathanauthor=J.+Zhangauthor=G.+Habetsauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=G.+Visorauthor=L.+Sanftnerauthor=P.+Seversonauthor=H.+Nguyenauthor=M.+J.+Kimauthor=A.+Marimuthuauthor=G.+Tsangauthor=R.+Shellooeauthor=C.+Geeauthor=B.+L.+Westauthor=P.+Hirthauthor=K.+Nolopauthor=M.+van+de+Rijnauthor=H.+H.+Hsuauthor=C.+Peterfyauthor=P.+S.+Linauthor=S.+Tong-Starksenauthor=G.+Bollag&title=Structure-guided+blockade+of+CSF1R+kinase+in+tenosynovial+giant-cell+tumor&doi=10.1056%2FNEJMoa1411366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor</span></div><div class="casAuthors">Tap, W. D.; Wainberg, Z. A.; Anthony, S. P.; Ibrahim, P. N.; Zhang, C.; Healey, J. H.; Chmielowski, B.; Staddon, A. P.; Cohn, A. L.; Shapiro, G. I.; Keedy, V. L.; Singh, A. S.; Puzanov, I.; Kwak, E. L.; Wagner, A. J.; Von Hoff, D. D.; Weiss, G. J.; Ramanathan, R. K.; Zhang, J.; Habets, G.; Zhang, Y.; Burton, E. A.; Visor, G.; Sanftner, L.; Severson, P.; Nguyen, H.; Kim, M. J.; Marimuthu, A.; Tsang, G.; Shellooe, R.; Gee, C.; West, B. L.; Hirth, P.; Nolop, K.; van de Rijn, M.; Hsu, H. H.; Peterfy, C.; Lin, P. S.; Tong-Starksen, S.; Bollag, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-437</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors.  This observation has led to the discovery and clin. development of therapy targeting the CSF1 receptor (CSF1R).  METHODS Using x-ray co-crystallog. to guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps the kinase in the autoinhibited conformation.  We then conducted a multicenter, phase 1 trial in two parts to analyze this compd.  In the first part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (doseescalation study).  In the second part, we evaluated PLX3397 at the chosen phase 2 dose in an extension cohort of patients with tenosynovial giant-cell tumors (extension study).  Pharmacokinetic and tumor responses in the enrolled patients were assessed, and CSF1 in situ hybridization was performed to confirm the mechanism of action of PLX3397 and that the pattern of CSF1 expression was consistent with the pathol. features of tenosynovial giant-cell tumor.  RESULTS A total of 41 patients were enrolled in the dose-escalation study, and an addnl. 23 patients were enrolled in the extension study.  The chosen phase 2 dose of PLX3397 was 1000 mg per day.  In the extension study, 12 patients with tenosynovial giant-cell tumors had a partial response and 7 patients had stable disease.  Responses usually occurred within the first 4 mo of treatment, and the median duration of response exceeded 8 mo.  The most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema; adverse events rarely led to discontinuation of treatment.  CONCLUSIONS Treatment of tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor vol. in most patients. (Funded by Plexxikon; ClinicalTrials.gov no., NCT01004861.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgftPP4lKlQrVg90H21EOLACvtfcHk0liBep-HS16tLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLjN&md5=5e822a87786aca7495222e3d18f82bdb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411366%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DStaddon%26aufirst%3DA.%2BP.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DKeedy%26aufirst%3DV.%2BL.%26aulast%3DSingh%26aufirst%3DA.%2BS.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DSeverson%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DGee%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong-Starksen%26aufirst%3DS.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DStructure-guided%2520blockade%2520of%2520CSF1R%2520kinase%2520in%2520tenosynovial%2520giant-cell%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D428%26epage%3D437%26doi%3D10.1056%2FNEJMoa1411366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span> </span><span class="NLM_article-title">Phase 3 Study of Pexidartinib for Pigmented Villonodular
Synovitis
(PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) (ENLIVEN)</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02371369" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02371369</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3+Study+of+Pexidartinib+for+Pigmented+Villonodular%0ASynovitis%0A%28PVNS%29+or+Giant+Cell+Tumor+of+the+Tendon+Sheath+%28GCT-TS%29+%28ENLIVEN%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02371369+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%25203%2520Study%2520of%2520Pexidartinib%2520for%2520Pigmented%2520Villonodular%250ASynovitis%250A%2528PVNS%2529%2520or%2520Giant%2520Cell%2520Tumor%2520of%2520the%2520Tendon%2520Sheath%2520%2528GCT-TS%2529%2520%2528ENLIVEN%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Giraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradel, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerhake, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucknischke, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaluza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorr, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tourneau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruettinger, D.</span></span> <span> </span><span class="NLM_article-title">Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.ccr.2014.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=24898549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=846-859&author=C.+H.+Riesauthor=M.+A.+Cannarileauthor=S.+Hovesauthor=J.+Benzauthor=K.+Warthaauthor=V.+Runzaauthor=F.+Rey-Giraudauthor=L.+P.+Pradelauthor=F.+Feuerhakeauthor=I.+Klamanauthor=T.+Jonesauthor=U.+Jucknischkeauthor=S.+Scheiblichauthor=K.+Kaluzaauthor=I.+H.+Gorrauthor=A.+Walzauthor=K.+Abirajauthor=P.+A.+Cassierauthor=A.+Sicaauthor=C.+Gomez-Rocaauthor=K.+E.+de+Visserauthor=A.+Italianoauthor=C.+Le+Tourneauauthor=J.-P.+Delordauthor=H.+Levitskyauthor=J.-Y.+Blayauthor=D.+Ruettinger&title=Targeting+tumor-associated+macrophages+with+anti-CSF-1R+antibody+reveals+a+strategy+for+cancer+therapy&doi=10.1016%2Fj.ccr.2014.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy</span></div><div class="casAuthors">Ries, Carola H.; Cannarile, Michael A.; Hoves, Sabine; Benz, Joerg; Wartha, Katharina; Runza, Valeria; Rey-Giraud, Flora; Pradel, Leon P.; Feuerhake, Friedrich; Klaman, Irina; Jones, Tobin; Jucknischke, Ute; Scheiblich, Stefan; Kaluza, Klaus; Gorr, Ingo H.; Walz, Antje; Abiraj, Keelara; Cassier, Philippe A.; Sica, Antonio; Gomez-Roca, Carlos; de Visser, Karin E.; Italiano, Antoine; Le Tourneau, Christophe; Delord, Jean-Pierre; Levitsky, Hyam; Blay, Jean-Yves; Ruettinger, Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">846-859</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Macrophage infiltration has been identified as an independent poor prognostic factor in several cancer types.  The major survival factor for these macrophages is macrophage colony-stimulating factor 1 (CSF-1).  We generated a monoclonal antibody (RG7155) that inhibits CSF-1 receptor (CSF-1R) activation.  In vitro RG7155 treatment results in cell death of CSF-1-differentiated macrophages.  In animal models, CSF-1R inhibition strongly reduces F4/80+ tumor-assocd. macrophages accompanied by an increase of the CD8+/CD4+ T cell ratio.  Administration of RG7155 to patients led to striking redns. of CSF-1R+CD163+ macrophages in tumor tissues, which translated into clin. objective responses in diffuse-type giant cell tumor (Dt-GCT) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXw3weYo79F7Vg90H21EOLACvtfcHk0liBep-HS16tLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCntrw%253D&md5=023e0585a753021f10b204c6aeb72d4b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DHoves%26aufirst%3DS.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DWartha%26aufirst%3DK.%26aulast%3DRunza%26aufirst%3DV.%26aulast%3DRey-Giraud%26aufirst%3DF.%26aulast%3DPradel%26aufirst%3DL.%2BP.%26aulast%3DFeuerhake%26aufirst%3DF.%26aulast%3DKlaman%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJucknischke%26aufirst%3DU.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKaluza%26aufirst%3DK.%26aulast%3DGorr%26aufirst%3DI.%2BH.%26aulast%3DWalz%26aufirst%3DA.%26aulast%3DAbiraj%26aufirst%3DK.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DSica%26aufirst%3DA.%26aulast%3DGomez-Roca%26aufirst%3DC.%26aulast%3Dde%2BVisser%26aufirst%3DK.%2BE.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DLevitsky%26aufirst%3DH.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DRuettinger%26aufirst%3DD.%26atitle%3DTargeting%2520tumor-associated%2520macrophages%2520with%2520anti-CSF-1R%2520antibody%2520reveals%2520a%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26spage%3D846%26epage%3D859%26doi%3D10.1016%2Fj.ccr.2014.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span> </span><span class="NLM_article-title">A Study of AMG 820 in Subjects With Advanced Solid
Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT01444404" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01444404</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+AMG+820+in+Subjects+With+Advanced+Solid%0ATumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01444404+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520AMG%2520820%2520in%2520Subjects%2520With%2520Advanced%2520Solid%250ATumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span> </span><span class="NLM_article-title">A Study
of IMC-CS4 in Subjects With Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT01346358" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01346358</a> (accessed July 15, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+IMC-CS4+in+Subjects+With+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01346358+%28accessed+July+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%250Aof%2520IMC-CS4%2520in%2520Subjects%2520With%2520Advanced%2520Solid%2520Tumors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span> </span><span class="NLM_article-title">Evaluation
of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB)
Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced
Pancreatic or Colorectal Cancers</span>. <a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=NCT02777710&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://clinicaltrials.gov/ct2/results?cond=&term=NCT02777710&cntry=&state=&city=&dist=</a> accessed July 22, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation%0Aof+Safety+and+Activity+of+an+Anti-PDL1+Antibody+%28DURVALUMAB%29%0ACombined+With+CSF-1R+TKI+%28PEXIDARTINIB%29+in+Patients+With+Metastatic%2FAdvanced%0APancreatic+or+Colorectal+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DNCT02777710%26cntry%3D%26state%3D%26city%3D%26dist%3D+accessed+July+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEvaluation%250Aof%2520Safety%2520and%2520Activity%2520of%2520an%2520Anti-PDL1%2520Antibody%2520%2528DURVALUMAB%2529%250ACombined%2520With%2520CSF-1R%2520TKI%2520%2528PEXIDARTINIB%2529%2520in%2520Patients%2520With%2520Metastatic%252FAdvanced%250APancreatic%2520or%2520Colorectal%2520Cancers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span> </span><span class="NLM_article-title">Durvalumab
in Combination With a CSF-1R Inhibitor (SNDX-6532) Following
Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT04301778?term=NCT04301778&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04301778?term=NCT04301778&draw=2&rank=1</a> (accessed July 22, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Durvalumab%0Ain+Combination+With+a+CSF-1R+Inhibitor+%28SNDX-6532%29+Following%0AChemo+or+Radio-Embolization+for+Patients+With+Intrahepatic+Cholangiocarcinoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04301778%3Fterm%3DNCT04301778%26draw%3D2%26rank%3D1+%28accessed+July+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDurvalumab%250Ain%2520Combination%2520With%2520a%2520CSF-1R%2520Inhibitor%2520%2528SNDX-6532%2529%2520Following%250AChemo%2520or%2520Radio-Embolization%2520for%2520Patients%2520With%2520Intrahepatic%2520Cholangiocarcinoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span> </span><span class="NLM_article-title">Nivolumab
and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab
(BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell
Lymphoma</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03927105?term=NCT03927105&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03927105?term=NCT03927105&draw=2&rank=1</a> (accessed July <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nivolumab%0Aand+the+Antagonistic+CSF-1R+Monoclonal+Antibody+Cabiralizumab%0A%28BMS-986227%29+in+Patients+With+Relapsed%2FRefractory+Peripheral+T+Cell%0ALymphoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03927105%3Fterm%3DNCT03927105%26draw%3D2%26rank%3D1+%28accessed+July+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNivolumab%250Aand%2520the%2520Antagonistic%2520CSF-1R%2520Monoclonal%2520Antibody%2520Cabiralizumab%250A%2528BMS-986227%2529%2520in%2520Patients%2520With%2520Relapsed%252FRefractory%2520Peripheral%2520T%2520Cell%250ALymphoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duignan, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs for colon-restricted delivery: design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0203567/1</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0203567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1371%2Fjournal.pone.0203567" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=D.+M.+Georgeauthor=R.+J.+Huntleyauthor=K.+Cusackauthor=D.+B.+Duignanauthor=M.+Hoemannauthor=J.+Loudauthor=R.+Marioauthor=T.+Melimauthor=K.+Mullenauthor=G.+Somalauthor=L.+Wangauthor=J.+J.+Edmunds&title=Prodrugs+for+colon-restricted+delivery%3A+design%2C+synthesis%2C+and+in+vivo+evaluation+of+colony+stimulating+factor+1+receptor+%28CSF1R%29+inhibitors&doi=10.1371%2Fjournal.pone.0203567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0203567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0203567%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DD.%2BM.%26aulast%3DHuntley%26aufirst%3DR.%2BJ.%26aulast%3DCusack%26aufirst%3DK.%26aulast%3DDuignan%26aufirst%3DD.%2BB.%26aulast%3DHoemann%26aufirst%3DM.%26aulast%3DLoud%26aufirst%3DJ.%26aulast%3DMario%26aufirst%3DR.%26aulast%3DMelim%26aufirst%3DT.%26aulast%3DMullen%26aufirst%3DK.%26aulast%3DSomal%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26atitle%3DProdrugs%2520for%2520colon-restricted%2520delivery%253A%2520design%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520evaluation%2520of%2520colony%2520stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0203567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Gamal, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ameen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Koumi, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamad, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalal, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.-H.</span></span> <span> </span><span class="NLM_article-title">Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5450</span>– <span class="NLM_lpage">5466</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00873</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00873" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5450-5466&author=M.+I.+El-Gamalauthor=S.+K.+Al-Ameenauthor=D.+M.+Al-Koumiauthor=M.+G.+Hamadauthor=N.+A.+Jalalauthor=C.-H.+Oh&title=Recent+advances+of+colony-stimulating+factor-1+receptor+%28CSF-1R%29+kinase+and+its+inhibitors&doi=10.1021%2Facs.jmedchem.7b00873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors</span></div><div class="casAuthors">El-Gamal, Mohammed I.; Al-Ameen, Shahad K.; Al-Koumi, Dania M.; Hamad, Mawadda G.; Jalal, Nouran A.; Oh, Chang-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5450-5466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Colony stimulation factor-1 receptor (CSF-1R), which is also known as FMS kinase, plays an important role in initiating inflammatory, cancer, and bone disorders when it is over-stimulated by its ligand, CSF-1.  Innate immunity, as well as macrophage differentiation and survival, are regulated by the stimulation of the CSF-1R.  Another ligand, interleukin-34 (IL-34), was recently reported to activate the CSF-1R receptor in a different manner.  The relationship between CSF-1R and microglia has been reviewed.  Both CSF-1 antibodies and small mol. CSF-1R kinase inhibitors have now been tested in animal models and in humans.  In this Perspective, the authors discuss the role of CSF-1 and IL-34 in producing cancer, bone disorders, and inflammation.  The authors also review the newly discovered and improved small mol. kinase inhibitors and monoclonal antibodies that have shown potent activity toward CSF-1R, reported from 2012 until 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4GIYJSVtGbVg90H21EOLACvtfcHk0lg0sRIA_I0BVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWgtg%253D%253D&md5=9fa615ecf2f532f1a2f1bac1e4c48932</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00873%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Gamal%26aufirst%3DM.%2BI.%26aulast%3DAl-Ameen%26aufirst%3DS.%2BK.%26aulast%3DAl-Koumi%26aufirst%3DD.%2BM.%26aulast%3DHamad%26aufirst%3DM.%2BG.%26aulast%3DJalal%26aufirst%3DN.%2BA.%26aulast%3DOh%26aufirst%3DC.-H.%26atitle%3DRecent%2520advances%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520kinase%2520and%2520its%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5450%26epage%3D5466%26doi%3D10.1021%2Facs.jmedchem.7b00873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span> <span> </span><span class="NLM_article-title">Comparing antibody and small-molecule therapies for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrc1913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnrc1913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=16929325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=714-727&author=K.+Imaiauthor=A.+Takaoka&title=Comparing+antibody+and+small-molecule+therapies+for+cancer&doi=10.1038%2Fnrc1913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing antibody and small-molecule therapies for cancer</span></div><div class="casAuthors">Imai, Kohzoh; Takaoka, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-mol. compds. have been approved for cancer treatment.  Both antibodies and small-mol. compds. are therefore promising tools for target-protein-based cancer therapy.  We discuss and compare the distinctive properties of these two therapeutic strategies to provide a better view for the development of new drugs and the future direction of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfUrcKvj1GLVg90H21EOLACvtfcHk0lg8AfoPegZtTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D&md5=31cfa17a5e3ddba75b2e32632aaa0deb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1913%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26aulast%3DTakaoka%26aufirst%3DA.%26atitle%3DComparing%2520antibody%2520and%2520small-molecule%2520therapies%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D714%26epage%3D727%26doi%3D10.1038%2Fnrc1913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokieda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohzeki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serizawa, I.</span></span> <span> </span><span class="NLM_article-title">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1002/eji.200737199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1002%2Feji.200737199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=18085662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVOnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-291&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohzekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-Fms+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model&doi=10.1002%2Feji.200737199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span></div><div class="casAuthors">Ohno, Hiroaki; Uemura, Yasunori; Murooka, Hideko; Takanashi, Hiromi; Tokieda, Takemi; Ohzeki, Yumiko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrophage colony-stimulating factor (M-CSF) is important in the development of macrophages and osteoclasts.  Previous studies have also shown that CD11b+ myeloblasts and osteoclasts play key roles during inflammation and bone destruction in arthritic lesions.  In this study, we investigated whether N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl] urea (Ki20227), an inhibitor of the M-CSF receptor (c-Fms), suppressed disease progression in a type II collagen (CII)-induced arthritis (CIA) mouse model.  We found that Ki20227 inhibited M-CSF-dependent reactions, such as lipopolysaccharide-induced tumor necrosis factor-α prodn., which were enhanced by M-CSF in vitro.  Oral administration of Ki20227 in vivo prevented inflammatory cell infiltration and bone destruction, and consequently suppressed disease progression.  In addn., the no. of CD11b+, Gr-1+, and Ly-6G+ cells in the spleen decreased in the Ki20227-treated mice, and the CII-induced cytokine prodn. in splenocytes isolated from the Ki20227-treated arthritic mice was also reduced.  These observations indicate that Ki20227 might exert its therapeutic effects in the CIA mouse model by suppressing the M-CSF-dependent accumulation of both inflammatory and osteoclast cells, as well as by inhibiting inflammatory cytokine prodn.  Hence, inhibitors of the c-Fms tyrosine kinase might act as anti-inflammatory or anti-osteolytic agents against arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU2PPX9fmE17Vg90H21EOLACvtfcHk0lg8AfoPegZtTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVOnt78%253D&md5=70f7884eda9cec53118c2fa600aaf33d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Feji.200737199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.200737199%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-Fms%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D291%26doi%3D10.1002%2Feji.200737199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illig, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballentine, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJarlais, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crysler, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donatelli, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczuk, B. E.</span></span> <span> </span><span class="NLM_article-title">Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7860</span>– <span class="NLM_lpage">7883</span>, <span class="refDoi"> DOI: 10.1021/jm200900q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200900q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7860-7883&author=C.+R.+Illigauthor=C.+L.+Mantheyauthor=M.+J.+Wallauthor=S.+K.+Meegallaauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=E.+Yurkowauthor=Z.+Zhouauthor=M.+R.+Playerauthor=B.+E.+Tomczuk&title=Optimization+of+a+potent+class+of+arylamide+colony-stimulating+factor-1+receptor+inhibitors+leading+to+anti-inflammatory+clinical+candidate+4-cyano-N-%5B2-%281-cyclohexen-1-yl%29-4-%5B1-%5B%28dimethylamino%29acetyl%5D-4-piperidinyl%5Dphenyl%5D-1H-imidazole-2-carboxamide+%28JNJ-28312141%29&doi=10.1021%2Fjm200900q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)</span></div><div class="casAuthors">Illig, Carl R.; Manthey, Carl L.; Wall, Mark J.; Meegalla, Sanath K.; Chen, Jinsheng; Wilson, Kenneth J.; Ballentine, Shelley K.; DesJarlais, Renee L.; Schubert, Carsten; Crysler, Carl S.; Chen, Yanmin; Molloy, Christopher J.; Chaikin, Margery A.; Donatelli, Robert R.; Yurkow, Edward; Zhou, Zhao; Player, Mark R.; Tomczuk, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7860-7883</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS) was optimized to improve pharmacokinetic and pharmacodynamic properties and potential toxicol. liabilities.  Early stage absorption, distribution, metab., and excretion assays were employed to ensure the incorporation of druglike properties resulting in the selection of several compds. with good activity in a pharmacodynamic screening assay in mice.  Further investigation, utilizing the type II collagen-induced arthritis model in mice, culminated in the selection of anti-inflammatory development candidate JNJ-28312141 (23, I, FMS IC50 = 0.69 nM, cell assay IC50 = 2.6 nM).  Compd. 23 also demonstrated efficacy in rat adjuvant and streptococcal cell wall-induced models of arthritis and has entered phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9cLVtgUGRbVg90H21EOLACvtfcHk0lg8AfoPegZtTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqs7bO&md5=a2d8b6a468f917dd1abbddc704f0f0ec</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200900q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200900q%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26atitle%3DOptimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520colony-stimulating%2520factor-1%2520receptor%2520inhibitors%2520leading%2520to%2520anti-inflammatory%2520clinical%2520candidate%25204-cyano-N-%255B2-%25281-cyclohexen-1-yl%2529-4-%255B1-%255B%2528dimethylamino%2529acetyl%255D-4-piperidinyl%255Dphenyl%255D-1H-imidazole-2-carboxamide%2520%2528JNJ-28312141%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7860%26epage%3D7883%26doi%3D10.1021%2Fjm200900q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezhuthachan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogoe, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4591</span>– <span class="NLM_lpage">4596</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2013.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=23842474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4591-4596&author=D.+A.+Scottauthor=L.+A.+Dakinauthor=K.+Dalyauthor=D.+J.+Del+Valleauthor=R.+B.+Dieboldauthor=L.+Drewauthor=J.+Ezhuthachanauthor=T.+W.+Geroauthor=C.+A.+Ogoeauthor=C.+A.+Omerauthor=S.+P.+Redmondauthor=G.+Repikauthor=K.+Thakurauthor=Q.+Yeauthor=X.+Zheng&title=Mitigation+of+cardiovascular+toxicity+in+a+series+of+CSF-1R+inhibitors%2C+and+the+identification+of+AZD7507&doi=10.1016%2Fj.bmcl.2013.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507</span></div><div class="casAuthors">Scott, David A.; Dakin, Les A.; Daly, Kevin; Del Valle, David J.; Diebold, R. Bruce; Drew, Lisa; Ezhuthachan, Jayachandran; Gero, Thomas W.; Ogoe, Claude A.; Omer, Charles A.; Redmond, Sean P.; Repik, Galina; Thakur, Kumar; Ye, Qing; Zheng, Xiaolan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4591-4596</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compd. and ion channel activity in particular.  Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacol. profiles.  Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBUarwHmu2-rVg90H21EOLACvtfcHk0lhIgEuaGid9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltbjO&md5=7ffab262014fea03ff82233b1b45e21a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DDel%2BValle%26aufirst%3DD.%2BJ.%26aulast%3DDiebold%26aufirst%3DR.%2BB.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DEzhuthachan%26aufirst%3DJ.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DOgoe%26aufirst%3DC.%2BA.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DRedmond%26aufirst%3DS.%2BP.%26aulast%3DRepik%26aufirst%3DG.%26aulast%3DThakur%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DMitigation%2520of%2520cardiovascular%2520toxicity%2520in%2520a%2520series%2520of%2520CSF-1R%2520inhibitors%252C%2520and%2520the%2520identification%2520of%2520AZD7507%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4591%26epage%3D4596%26doi%3D10.1016%2Fj.bmcl.2013.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">16078</span>– <span class="NLM_lpage">16083</span>, <span class="refDoi"> DOI: 10.1073/pnas.0502000102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1073%2Fpnas.0502000102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=16249345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=16078-16083&author=J.+G.+Conwayauthor=B.+McDonaldauthor=J.+Parhamauthor=B.+Keithauthor=D.+W.+Rusnakauthor=E.+Shawauthor=M.+Jansenauthor=P.+Linauthor=A.+Payneauthor=R.+M.+Crosbyauthor=J.+H.+Johnsonauthor=L.+Frickauthor=M.-H.+J.+Linauthor=S.+Depeeauthor=S.+Tadepalliauthor=B.+Vottaauthor=I.+Jamesauthor=K.+Fullerauthor=T.+J.+Chambersauthor=F.+C.+Kullauthor=S.+D.+Chamberlainauthor=J.+T.+Hutchins&title=Inhibition+of+colony-stimulating-factor-1+signaling+in+vivo+with+the+orally+bioavailable+cFMS+kinase+inhibitor+GW2580&doi=10.1073%2Fpnas.0502000102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580</span></div><div class="casAuthors">Conway, James G.; McDonald, Brad; Parham, Janet; Keith, Barry; Rusnak, David W.; Shaw, Eva; Jansen, Marilyn; Lin, Peiyuan; Payne, Alan; Crosby, Renae M.; Johnson, Jennifer H.; Frick, Lloyd; Lin, Min-Hwa Jasmine; Depee, Scott; Tadepalli, Sarva; Votta, Bart; James, Ian; Fuller, Karen; Chambers, Timothy J.; Kull, Frederick C.; Chamberlain, Stanley D.; Hutchins, Jeff T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16078-16083</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases.  To help investigate the role of cFMS kinase in disease, the authors identified GW2580, an orally bioavailable inhibitor of cFMS kinase.  GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases.  GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degrdn. in cultures of human osteoclasts, rat calvaria, and rat fetal long bone.  In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines.  GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 prodn. in freshly isolated human monocytes and mouse macrophages.  After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 prodn. in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.  Unexpectedly, GW2580 inhibited LPS-induced TNF prodn. in mice, in contrast to effects on monocytes and macrophages in vitro.  In conclusion, GW2580's selective inhibition of monocyte growth and bone degrdn. is consistent with cFMS kinase inhibition.  The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5EGN2P59OrVg90H21EOLACvtfcHk0lhIgEuaGid9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrzM&md5=6a5afc80faa9acec528fdbf766ad05bd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502000102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502000102%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DJ.%2BG.%26aulast%3DMcDonald%26aufirst%3DB.%26aulast%3DParham%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShaw%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPayne%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DFrick%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DM.-H.%2BJ.%26aulast%3DDepee%26aufirst%3DS.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DFuller%26aufirst%3DK.%26aulast%3DChambers%26aufirst%3DT.%2BJ.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26atitle%3DInhibition%2520of%2520colony-stimulating-factor-1%2520signaling%2520in%2520vivo%2520with%2520the%2520orally%2520bioavailable%2520cFMS%2520kinase%2520inhibitor%2520GW2580%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D16078%26epage%3D16083%26doi%3D10.1073%2Fpnas.0502000102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikegashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.10.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2018.10.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=30442420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=115-118&author=K.+Ikegashiraauthor=T.+Ikenogamiauthor=T.+Yamasakiauthor=Y.+Haseauthor=T.+Yamaguchiauthor=K.+Inagakiauthor=S.+Doiauthor=T.+Adachiauthor=Y.+Kogaauthor=H.+Hashimoto&title=Discovery+of+a+novel+azetidine+scaffold+for+colony+stimulating+factor-1+receptor+%28CSF-1R%29+Type+II+inhibitors+by+the+use+of+docking+models&doi=10.1016%2Fj.bmcl.2018.10.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models</span></div><div class="casAuthors">Ikegashira, Kazutaka; Ikenogami, Taku; Yamasaki, Takayuki; Hase, Yasunori; Yamaguchi, Takayuki; Inagaki, Koji; Doi, Satoki; Adachi, Tsuyoshi; Koga, Yoshihisa; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by using a structure-based drug design (SBDD) based on a docking model.  The work leads to the representative compd. 4a with high CSF-1R inhibitory activity (IC50 = 9.1 nM).  The obtained crystal structure of an azetidine compd. with CSF-1R, which matched our predicted docking model, demonstrates that the azetidine compds. bind to the DFG-out conformation of the protein as a Type II inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod-KAPARMDLLVg90H21EOLACvtfcHk0lhmVzG2mmxt2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WitrnK&md5=04ea00b26cadb1d227c28d5b9ab95197</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.10.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.10.051%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DIkenogami%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520azetidine%2520scaffold%2520for%2520colony%2520stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520Type%2520II%2520inhibitors%2520by%2520the%2520use%2520of%2520docking%2520models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D115%26epage%3D118%26doi%3D10.1016%2Fj.bmcl.2018.10.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikegashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenogami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, H.</span></span> <span> </span><span class="NLM_article-title">Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1016%2Fj.bmcl.2019.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=30755337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFyjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=873-877&author=K.+Ikegashiraauthor=T.+Ikenogamiauthor=T.+Yamasakiauthor=T.+Okaauthor=Y.+Haseauthor=N.+Miyagawaauthor=K.+Inagakiauthor=I.+Kawaharaauthor=Y.+Kogaauthor=H.+Hashimoto&title=Optimization+of+an+azetidine+series+as+inhibitors+of+colony+stimulating+factor-1+receptor+%28CSF-1R%29+Type+II+to+lead+to+the+clinical+candidate+JTE-952&doi=10.1016%2Fj.bmcl.2019.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952</span></div><div class="casAuthors">Ikegashira, Kazutaka; Ikenogami, Taku; Yamasaki, Takayuki; Oka, Takahiro; Hase, Yasunori; Miyagawa, Naoki; Inagaki, Koji; Kawahara, Iichiro; Koga, Yoshihisa; Hashimoto, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">873-877</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of novel azetidine compds., which we had found as colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors, provided JTE-952 as a clin. candidate with high cellular activity (IC50 = 20 nM) and good pharmacokinetics profile.  JTE-952 was also effective against a mouse collagen-induced model of arthritis (mouse CIA-model).  Addnl., the x-ray co-crystal structure of JTE-952 with CSF-1R protein was shown to be a Type II inhibitor, and the kinase panel assay indicated that JTE-952 had high kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporHDNUrI_qLVg90H21EOLACvtfcHk0lhmVzG2mmxt2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFyjtb4%253D&md5=06ce87cb35a119745316b21ee777002b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DIkegashira%26aufirst%3DK.%26aulast%3DIkenogami%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DMiyagawa%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DK.%26aulast%3DKawahara%26aufirst%3DI.%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DOptimization%2520of%2520an%2520azetidine%2520series%2520as%2520inhibitors%2520of%2520colony%2520stimulating%2520factor-1%2520receptor%2520%2528CSF-1R%2529%2520Type%2520II%2520to%2520lead%2520to%2520the%2520clinical%2520candidate%2520JTE-952%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D873%26epage%3D877%26doi%3D10.1016%2Fj.bmcl.2019.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhmVzG2mmxt2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span> <span> </span><span class="NLM_article-title">BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2768</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1021/jm030543u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030543u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2768-2775&author=A.+C.+Pierceauthor=G.+Raoauthor=G.+W.+Bemis&title=BREED%3A+Generating+novel+inhibitors+through+hybridization+of+known+ligands.+Application+to+CDK2%2C+P38%2C+and+HIV+protease&doi=10.1021%2Fjm030543u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease</span></div><div class="casAuthors">Pierce, Albert C.; Rao, Govinda; Bemis, Guy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2768-2775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target.  The method is essentially an automation of the common medicinal chem. practice of joining fragments of two known ligands to generate a new inhibitor.  The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new mols.  Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands.  In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new mol. structures were generated.  These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds.  The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques.  In an era of increasingly high-throughput structural biol., such methods for high-throughput utilization of structural information will become increasingly valuable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskNA5h73CbbVg90H21EOLACvtfcHk0lg4L69ezf8CTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ajurk%253D&md5=e0bec9082fab05b694742498b3f41549</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm030543u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030543u%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DBREED%253A%2520Generating%2520novel%2520inhibitors%2520through%2520hybridization%2520of%2520known%2520ligands.%2520Application%2520to%2520CDK2%252C%2520P38%252C%2520and%2520HIV%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2768%26epage%3D2775%26doi%3D10.1021%2Fjm030543u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span> </span><span class="NLM_article-title">MolecularOperating
Environment (MOE), C. C. G. U., 1010 Sherbrook St. West, Suite 910,Montreal,
Canada, H3A 2R7</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MolecularOperating%0AEnvironment+%28MOE%29%2C+C.+C.+G.+U.%2C+1010+Sherbrook+St.+West%2C+Suite+910%2CMontreal%2C%0ACanada%2C+H3A+2R7%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DMolecularOperating%250AEnvironment%2520%2528MOE%2529%252C%2520C.%2520C.%2520G.%2520U.%252C%25201010%2520Sherbrook%2520St.%2520West%252C%2520Suite%2520910%252CMontreal%252C%250ACanada%252C%2520H3A%25202R7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span>; <span class="NLM_string-name">Hassell, A. M.</span>; <span class="NLM_string-name">Holmes, W. D.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Emmerson, H. K.</span>; <span class="NLM_string-name">Musso, D. L.</span>; <span class="NLM_string-name">Chamberlain, S. D.</span>; <span class="NLM_string-name">Peckham, G. E.</span></span> <span> </span><span class="NLM_article-title">Co-Crystal Structure of Liganded Inhibitors of Colony-Stimulating Factor 1 Receptor Kinase in Treatment of Disease</span>. <span class="NLM_patent">US20070010540</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+M.+Shewchuk&author=A.+M.+Hassell&author=W.+D.+Holmes&author=J.+M.+Veal&author=H.+K.+Emmerson&author=D.+L.+Musso&author=S.+D.+Chamberlain&author=G.+E.+Peckham&title=Co-Crystal+Structure+of+Liganded+Inhibitors+of+Colony-Stimulating+Factor+1+Receptor+Kinase+in+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26atitle%3DCo-Crystal%2520Structure%2520of%2520Liganded%2520Inhibitors%2520of%2520Colony-Stimulating%2520Factor%25201%2520Receptor%2520Kinase%2520in%2520Treatment%2520of%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H','PDB','4R7H'); return false;">PDB: 4R7H</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LCO','PDB','3LCO'); return false;">PDB: 3LCO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HVS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HVS','PDB','4HVS'); return false;">PDB: 4HVS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i142"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00936">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01578"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00936?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00936</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay conditions, materials and methods, kinase profiling data for compound <b>12</b> (Table S1) and for IACS-9439 (<b>1</b>) (Table S3) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf">PDF</a>)</p></li><li><p class="inline">CSF1R compound <b>3</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_002.pdb">PDB</a>)</p></li><li><p class="inline">CSF1R compound <b>12</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_001.pdf">jm0c00936_si_001.pdf (312.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_002.pdb">jm0c00936_si_002.pdb (371.31 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_003.pdb">jm0c00936_si_003.pdb (371.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00936/suppl_file/jm0c00936_si_004.csv">jm0c00936_si_004.csv (4.3 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00936&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00936%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00936" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679930e71edd3d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
